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Abstract 
An interesting insight has been developed into the roles of a paralogous pair of transcriptional 
regulators MmfR and MmyR in the regulation of methylenomycin antibiotic biosynthesis in 
Streptomyces coelicolor. Research involved the development and use of a luciferase reporter 
assay, optimised for use in GC high bacteria. MmfR belongs to the TetR-family of 
transcriptional repressor proteins and works as a single component system, binding to DNA at 
one of three methylenomycin auto-regulatory response element (MARE) operators. Here it 
represses transcription of five different operons until a conformational change is brought 
about by specific binding to one of five small signalling molecules; the methylenomycin 
furans (MMFs). 
This investigation revealed that the five different MmfR-regulated operons have promoters of 
differing strengths, which is also contributed to by a variation in the strength of MmfR 
binding to the three MARE operator sites. Each of the five naturally produced MMF ligands 
were also shown to have a different efficacy for deactivating and displacing MmfR. An in 
silico analysis of the MmfR primary and tertiary structures, followed by in vivo mutagenesis, 
revealed the presence of two tyrosine residues implicated in ligand binding. 
The paralogue MmyR was shown to vary in activity from that of MmfR. It showed weaker, 
but significant binding to only two out of the three MARE operator sites, binding with 
different affinities to each, and no significant removal of repression was seen in the presence 
of the MMF ligands. 
The MmfR/MMF/MARE operator system shows promise as something that can be developed 
into a novel inducible expression system for use in GC high bacteria. However, whether this 
system can be adapted to be efficient in multiple hosts is yet to be seen, with affinity for the 
MARE operators from exogenous regulatory proteins predicted. 
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1 Introduction 
1.1 Streptomyces and their Natural Products 
Streptomyces are Gram-positive actinomycetes found naturally in the soil. In fact, the earthy 
smell associated with soil comes from geosmin, a natural product produced by 
streptomycetes.(1) They breach the gap between bacteria and fungi with their complex 
mycelial life cycles (Figure 1.1). The life cycle starts with a spore, then, with the right 
nutrients present, this spore will germinate and form vegetative hyphae that branch into the 
surrounding growth media forming fungi-like mycelia. Upon nutrient depletion, non-
branching sporogenic aerial hyphae will also form.(2) These aerial hyphae septate to form 
largely dormant unigenomic spores that can then start the cycle again. It is during this spore 
formation stage that grey spore pigments are synthesised, as well as a range of other natural 
products.(3) A natural product is any substance or chemical produced by a living organism 
and is often used synonymously with the term ‘secondary metabolite’.(4, 5) The natural 
products produced by streptomycetes total over 70 per cent of commercially available 
antibiotics,(6) a number of these can be seen highlighted in Figure 1.2; a timeline of antibiotic 
discovery and their bacterial origins. It is clear therefore that streptomycetes are of huge 
importance in natural product research. 
 
 
Figure 1.1. Schematic representation of the streptomycete life cycle 
This image was taken directly from the paper by Seipke et al. from 2012 (7) 
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Figure 1.2. Key dates when antibiotics were discovered 
Antibiotics produced by streptomycetes are highlighted in red.(8-14) 
 
The natural products made by Streptomyces include antifungals such as nystatin,(15) as well 
as anti-bacterials like chloramphenicol,(11) neomycin,(10) and streptomycin (9) (highlighted 
in Figure 1.2).(8) Streptomycetes also produce a range of other useful natural products such 
the anti-parasitic ivermectin (16) as well as anti-tumour drugs, (17) immunosuppressive 
agents (18) and agrochemicals such as fungicides.(19) These natural products are often 
produced as a defence mechanism to fight other bacteria competing for resources. At sub-
lethal levels however, antibiotics may be able to function as signalling molecules, benefiting 
otherwise susceptible bacteria and helping to maintain homeostasis in microbial 
communities.(20) 
There is a need for new antibiotics, with resistance developing to new antibiotics within tens 
of years of clinical introduction, if not sooner.(21) Alexander Fleming famously warned of 
the inevitable risk of antibiotic resistance as early as 1945 in his Nobel Prize speech, with the 
widespread use of penicillin only coming about two years before and the first sulphonamide 
only having been commercially available since the 1930s.(22) Over-prescription and incorrect 
usage of antibiotics selects for resistant strains and has contributed to resistance being 
developed at an accelerated rate compared to that which would occur in the wild without this 
human interference. Interest into natural product antibiotic research declined due to the 
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frequent rediscovery of existing antibiotics and the development of a number of synthetic 
methods such as the screening of large libraries of synthetic compounds.(23-25) These 
synthetic methods proved to be largely unsuccessful and new strategies have again been 
developed for natural product discovery. The potential for discovering novel natural 
compounds is increasing again with the ‘genomic age’.(26) 
Importance of Genome Mining in Natural Product Research 
Despite Streptomyces already being the main source of commercially available antibiotics, 
there is still potential for the discovery of many more, with prospective natural products lying 
undiscovered in currently ‘silent’ and cryptic gene clusters. These are being further 
investigated by genome mining.(6) 
Entire genomes are scanned for sequences corresponding to hypothetical antibiotic regulatory 
or biosynthetic enzymes, based on sequence identity to clusters already studied 
experimentally. These ‘silent’ or cryptic gene clusters uncovered by genome mining often 
need very specific environmental conditions or inducer molecules for natural product 
biosynthesis to be switched on, often not present in standard laboratory conditions. For this 
reason, there are many hypothetical natural product gene clusters for which we know very 
little about the end product.(27) If the regulation of these clusters could be better understood 
then they could be genetically manipulated or put into a heterologous expression host (28) 
and the metabolites isolated. An example of a natural product that has been discovered by 
genome mining is coelichelin, a Streptomces coelicolor iron chelator.(26, 29, 30) 
As of 3rd August 2016, as many as 252 different streptomycetale strains had their complete 
genomes sequenced and listed on NCBI out of 8629 genomes available on this site.(31) Many 
more full genomic sequences are expected every year as genome sequencing becomes more 
economical.(27) The Streptomyces genus is therefore one of the most sequenced of non-
pathogenic bacteria, but the true extent of the implications of such widespread analysis on the 
production of useful metabolites is not yet realised with many biosynthetic investigations still 
on-going. 
 
1.2 Regulation of Natural Product Biosynthesis in 
Streptomyces 
1.2.1 An Introduction to Microbial Hormones 
It is important for bacteria to regulate the production of antibiotics, not only to conserve 
cellular resources but also to prevent the antibiotic having a potentially toxic or lethal effect 
on the producer strain. A variety of different regulatory mechanisms are utilised to control the 
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production of any natural products. Streptomycete regulatory systems include transcriptional 
activators and repressors, the use of rare codons, sigma factors, riboswitches and receptor 
ligand responses as well as the use of microbial hormones.(32) Natural product biosynthesis 
may also be influenced by environmental factors such as pH and nutrient deprivation as well 
as being effected by cell density via quorum sensing (see below). In this report, it is the 
regulation by microbial hormones and their cognate receptors that is of particular interest. 
A hormone is described as being a ‘regulatory substance produced in an organism and 
transported in tissue fluids such as blood or sap to stimulate specific cells or tissues into 
action.’(33) When applying this to the microbial level, a hormone could be described as a 
diffusible master switch for morphological differentiation and secondary metabolism.(34) The 
ability of bacteria to signal to one another using nanomolar concentrations of small molecules 
is well known.(35) This signalling is often influenced by a phenomenon called ‘quorum 
sensing’, where gene expression is regulated in response to population density and the 
accumulation of auto-inducing microbial hormones.(36) The higher the density of cells in an 
area, the greater the accumulation of signalling molecule that they produce. Once this 
signalling molecule reaches a threshold concentration, transcription of associated genes will 
be switched on. This is co-ordinated in the entire local population and has even been known 
to occur between species. In response to high population density therefore, streptomycetes 
will produce microbial hormones to signal for antibiotic production to kill competition for 
resources, as well as signalling to turn on the next stages in their complex sporogenic life 
cycle (Figure 1.1). 
1.2.2 The Gamma-Butyrolactones 
Examples of these microbial hormones in Gram-positive bacteria include the well-known 
gamma butryrolactones (GBLs). These are small signalling molecules involved in quorum 
sensing and the activation of antibiotic biosynthesis and cover a variety of similar small 
molecules (see Figure 1.3). GBL hormonal regulatory systems are found across a wide range 
of Streptomyces species and are formed of two parts; the enzymes for GBL synthesis as well 
as least one cognate receptor.(37) Examples of these receptor-ligand systems includes A 
factor and its receptor ArpA in Streptomyces griseus,(34) SCB1 and ScbR in S. 
coelicolor,(38) VB and BarA in Streptomyces virginiae (39, 40) and IM-2 and FarA in 
Streptomyces lavendulae (41, 42) (see Figure 1.3 for chemical structures of these microbial 
hormones). In the absence of their ligand, ArpA, ScbR, BarA and FarA will normally be 
bound to DNA at an operator site, repressing the production of an associated natural product. 
The production and detection of a threshold level of their hormone ligand will cause a 
conformational change and the release of the repressor from a promoter site, thereby allowing 
the expression of natural product biosynthetic genes. 
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1.2.3 TetR Family Transcriptional Repressors 
The cognate receptors for microbial hormones are often members of the TetR family of 
transcriptional repressors. This widespread family of transcriptional repressors includes 
hundreds of thousands of proteins found across a variety of genera of bacteria and 
archaea.(32, 43) TFRs (TetR family repressors) work as single component systems. Unlike 
two-component systems, such as kinase signalling pathways, the sensory and DNA binding 
components of these systems are located on the same polypeptide.(43) A single protein 
therefore receives the hormonal signal and transduces the message into a change in gene 
expression. These repressors are almost exclusively alpha helical and have an N-terminal 
DNA binding domain and C-terminal ligand binding domain. An N-terminal DNA binding 
domain has previously been associated with being a repressor whereas a C-terminal binding 
domain is often thought to relate to being an activator (note however that there are well 
documented exceptions to this rule).(43) TFR proteins are homodimeric meaning that for each 
dimer there are two identical ligand-binding pockets and two identical DNA-binding 
domains, usually binding to a palindromic operator sequence. A number of TFRs have had 
their 3D structure determined by X-ray crystallography including TetR,(44) QacR, CprB, 
SimR (45) and EthR (46) which has broadened our understanding of their functionality. 
The common motif that connects the proteins in this family is the conserved helix-turn-helix 
DNA binding domain.(32) Outside of this sequence of 47 amino acids, there is no clear 
conservation in amino acid sequence however and the TetR family has been shown to bind to 
a large range of different ligands. 
The TetR family of repressors are particularly common in microbes that have to adapt to 
changes in environment, for example soil dwelling bacteria such as Streptomyces or 
extremophiles and plant and animal pathogens. Regulation by this family of proteins is not 
limited to the biosynthesis of antibiotics with regulation of efflux pumps, responses to 
osmotic stress and the control of differentiation having been shown, amongst other 
targets.(32) The gene target for many TFRs is not known however. There are often repeated 
operator motifs, but these can be hard to predict.(43) 
The complexity of regulation varies within the TetR family. An example of simple regulation 
is that of the repression of tetA by TetR, which is then released by tetracycline, thereby 
regulating tetracycline resistance in Escherichia coli.(47) However, in other systems it can be 
more complicated with modulation by other regulators and cross-interactions with other 
networks including the regulation of pathway specific activators and the repression of 
multiple bidirectional operators.(32) One consensus between TFRs appears to be that they are 
self-regulatory. For example, TetR controls the repression not only of tetA but also of tetR, 
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the gene for its own production. However, as with any class of proteins, there are exceptions 
to the rule and not all TFRs will function in the manner just described. 
Pseudoreceptors 
GBL systems often have been found to contain two TetR family receptors, for example ScbR 
and ScbR2.(38, 48) ScbR2 appears to have a distinct role compared to the ScbR, the latter of 
which binds the S. coelicolor butyrolactone SCB1. This second type of protein is often 
thought of as a ‘pseudoreceptor’, sharing similar structures and sequence identity with the 
‘real’ cognate GBL receptors but showing differences in ligand binding specificity as well as 
the range of DNA targets it will bind to.(49)  
ScbR2 is the best studied of these pseudoreceptors.(50) ScbR and ScbR2, which share 33% 
identity over ~85% of their sequences, are involved in the regulation of antibiotics 
actinorhodin and undecylprodigiosin.(51) ScbR2 has been indicated to bind these and other 
end product antibiotics in vitro and in vivo as opposed to SCB1, thereby releasing its 
repression and influencing antibiotic production.(49, 52) ScbR has also been shown to be 
expressed at a different time to ScbR, further validating the evidence that it has a different 
role.(50)  
The ligand binding domains of the GBL receptors and pseudoreceptors are not conserved. It is 
thought that a range of both endogenous and exogenous non-GBL ligands may bind these 
second repressors meaning that they may have a cross-species regulatory function.(52) It is 
also hypothesised that in some systems, the second receptor may only become ‘activated’ as a 
repressor in the presence of a cognate ligand, potentially the end product antibiotic.(50) In 
this way, this second repressor is thought switch off antibiotic production once enough has 
been produced. Alternatively, they may be able to directly or indirectly activate transcription 
of some genes as well as controlling the repression of others, although the mechanistics of 
this are not established.(50) The differences in ligand binding capacity between the true 
receptor and pseudoreceptor are poorly understood in many TetR systems and many 
inferences remain as hypotheses that are yet to be experimentally proven.  
As well as differences in ligand binding, the DNA binding sequences for the pseudoreceptors 
have often been predicted to outnumber those for its paralogue and are also sometimes 
thought to be found in otherwise unrelated endogenous gene clusters, further indicating that 
these systems are cross-regulatory.(50) 
Having a second ‘pseudoreceptor’ adds an extra level of complexity and control over gene 
expression and understanding the role of these paralogous pseudoreceptors in the co-
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ordination of antibiotic biosynthesis is key to exploiting ‘cryptic’ natural product gene 
clusters and increasing the yield of commercially available antibiotics.(49) 
1.2.4 Other Microbial Hormones 
As well as these gamma-butyrolactones, other groups of microbial hormones include 
butenolides such as avenolide (53) and furans such as the methylenomycin furans,(54) which 
have also been shown to work with equivalent ligand-TetR family receptor/repressor systems. 
Examples of these hormones are shown in Figure 1.3. 
The small methylenomycin furans (MMFs) from Streptomyces coelicolor A3(2) belong to a 
group of 2-alkyl-4-hydroxymethylfuran-3-carboxylic acids (AHFCAs) that are structurally 
distinct from the GBL family.(35, 54) Five known furan hormones are believed to alter the 
action of TetR family member MmfR (and possibly its paralogue MmyR) by inducing a 
conformational change and releasing the repression of the methylenomycin antibiotic 
biosynthetic cluster.(55) MmfR is an orthologue of the previously mentioned ArpA receptor 
which binds the GBL; A-factor. It is these methylenomycin furans (MMFs) from model 
actinomycete Streptomyces coelicolor A3(2) that is of particular interest in this project. 
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Figure 1.3. Chemical structures of microbial hormones from Streptomyces species 
VB-A – S. virginiae GBL, IM-2 – S. lavenduelae GBL, A factor – S. griseus GBL, Avenolide – S. 
avermitilis butenolide, MMF1 – S. coelicolor furan, SCB1 – S. coelicolor GBL. 
 
1.3 Streptomyces coelicolor – A Model Organism 
1.3.1 S. coelicolor Genetics 
S. coelicolor (56) was initially chosen as a model organism as it produces red and blue 
pigments, a phenotype that is easy to observe and track in mutant strains.(57, 58) The name 
coelicolor comes from the Latin term coelus meaning ‘sky’ colour, referring to these blue 
pigments that this species produces.(59) 
More than 10 years ago the entire Streptomyces coelicolor A3(2) genome was sequenced, 
allowing a greater understanding of the biosynthesis of crucial metabolites.(6) These soil 
living bacteria have a large 8 667 507 base pair single linear chromosome, the largest known 
bacterial genome at the time of discovery. The genome also includes two plasmids; the linear 
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SCP1 (356 023 bp) (60) and the circular SCP2 (31 317 bp), (61) which were also sequenced 
in 2004 and 2003 respectively. Of the large single chromosome, over 12% of protein coding 
genes are thought to be regulatory,(6) with roles in regulating morphological and metabolic 
changes as well as programming antibiotic synthesis via the use of microbial hormones.(32) 
S. coelicolor is known to produce at least five known antibiotics, including 
methylenomycin,(62) but the availability of the entire genome sequences has allowed the 
identification of a number of analogous pathways with unknown natural products, many of 
which are currently under further investigation.  
1.3.2 Methylenomycin 
Figure 1.4 shows the chemical structures of the methylenomycin antibiotic and its precursor 
from Streptomyces coelicolor A3(2). Methylenomycin A is a cyclopentanone antibiotic that 
acts upon both Gram-positive and Gram-negative bacteria, working optimally in low pH 
conditions.(63) It appears to be particularly active against the Gram-negative Proteus, also 
commonly found in soil as well as in faeces and manure.(64) Streptomyces violaceoruber is 
also known to produce methylenomycin, with 99% nucleotide identity shown in the 
biosynthetic cluster (65) but this strain has not been studied in this project. 
Figure 1.4. Chemical structures of the antibiotic methylenomycin A and its precursor, 
methylenomycin C from S. coelicolor A3(2) and S. violaceoruber 
 
Despite being discovered in the 1970s (14) the exact mechanism of methylenomycin 
antibacterial action is as yet unclear and it has shown little promise clinically with high levels 
of toxicity to animal cells shown. In the past, this antibiotic was of particular interest as all 19 
kb (54) of the 21 biosynthetic, regulatory and resistance genes are found in a cluster on the 
SCP1 plasmid of S. coelicolor (and pSV1 in S. violaceoruber) (66), (67), (68) (see Figure 
1.5). Although extra chromosomal giant plasmids are often associated with secondary 
metabolism,(69) methylenomycin is one of very few known antibiotics where the whole 
biosynthetic cluster is entirely plasmid based. Being plasmid based meant that the genes were 
easily transmissible between streptomycetes and it was relatively simple to produce knockout 
strains.(70) This was particularly important at a time before technologies for creating 
knockouts had advanced to the level they have today. For studying methylenomycin 
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production, the SCP1-free S. coelicolor strain M145 could be used to study sections of the 
biosynthetic pathway without background interactions from the wild type system. 
MmfR/MMF regulation of methylenomycin biosynthesis is analogous to a number of other 
antibiotic regulatory systems in other Streptomyces strains including S. venezuelae and S. 
avermitilis (see Section 1.4.3 on page 16). By further investigating this cluster that already 
has extensive research done on it and is partially understood, it might also be possible to shed 
some light on the regulation some of these other potentially harder to study biosynthetic 
clusters on which we have much less information. 
Methylenomycin Biosynthetic Cluster 
The 21 genes of the methylenomycin cluster include mmfR and mmyR, coding for the TetR 
family transcriptional repressors MmfR and its paralogue MmyR, and the mmfLHP operon, 
which is responsible for making the enzymes used in the production of the cognate furan 
ligands for MmfR; the MMF microbial hormones. The cluster also contains mmyJ and mmr, 
both involved in methylenomycin resistance as well as mmyB, which produces a pathway 
specific activator. There is also a selection of methylenomycin biosynthetic genes which 
come together in operons; mmyTOC, mmyBQEDXCAPK and mmmYF.(71) The assembly of 
these genes on the SCP1 plasmid are shown below in Figure 1.5 with different colours 
denoting different types of product. Biosynthetic genes are all shown in red, repressors in 
peach, genes associated with resistance in purple, MMF biosynthetic genes in blue and the 
MmyB activator is in green. 
 
Figure 1.5. Organisation of the methylenomycin biosynthetic gene cluster from the SCP1 
plasmid of S. coelicolor A3(2)1 
Proposed functional attributions are mmfR and mmyR – transcriptional repressors, 
mmfLHP – methylenomycin furan biosynthetic genes, mmyJ and mmr – methylenomycin 
resistance, mmyB – transcriptional activator, all others – methylenomycin biosynthesis, 
based on the work of Chater and Bruton (65) 
1.4 Regulation of Methylenomycin Biosynthesis  
1.4.1 MmfR – A TetR Family Transcriptional Repressor 
MmfR is a TetR family member and like them, is a homodimeric protein with a C-terminal 
DNA binding region and a N-terminal ligand-binding domain. As yet unpublished, the crystal 
                                                      
1 This diagram is to scale and represents the appropriate sizes of the individual genes, it was created 
using the SnapGene Viewer software (72. Biotech G. SnapGene Viewer. In: Glick B, editor. 3.0.3 ed. 
Chicago, IL2004-2016.) 
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structure of MmfR has been determined, both with and without MMF2 to a resolution of 
1.5Å. This reveals the molecular interactions between MmfR and MMF2 and opens up the 
potential for more bioinformatical analyses to be carried out on the protein (73) with a higher 
chance of accuracy for predictions of MmfR binding to the other four MMFs. 
Figure 1.6 shows two representations of the 3D structure of this repressor protein in its apo 
form, based on the crystal structure obtained. The cartoon model on the right hand side shows 
the location of the ligand binding pocket as well as the TetR HTH DNA binding domain, 
labelled as B and A respectively. Each monomer in this homodimer contains one ligand 
binding pocket and a DNA binding domain meaning that each complete dimer will bind two 
MMF molecules. Work is currently being carried out to achieve a crystal structure of MmfR 
bound to DNA to complete the picture of its different conformations. 
Figure 1.6. Representatives from the crystal structure of the TetR family homodimer 
MmfR from the methylenomycin biosynthetic cluster of S. coelicolor in its apo form 
Left) Filled surface model. Right) Cylindrical cartoon model; where A) indicates the location of the N-
terminal DNA binding domain in each monomer and B) the location of the C-terminal ligand-binding 
pockets. 
(Adapted from the work of Dean Rea et al.) (73) 
 
Methylenomycin Furans – Microbial Hormones 
In Figure 1.7, the chemical structure of the five structurally similar methylenomycin furan 
signalling molecules that are thought to bind MmfR can be found. These molecules are based 
around a furan group; a five membered ring made of four carbons and one oxygen atom. Each 
MMF also has a carboxylic acid group and a hydroxyl group attached to this furan group as 
well as a variable region with a branched or unbranched alkyl chain of differing length.(54) 
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Figure 1.7. Chemical structures of the known S. coelicolor methylenomycin furans 
(Based on the work by Corre et al.) (54) 
 
Previous research by Nicolas Malet has implied that it is the alkyl chain of these small 
molecules that allows the MMFs to fit the MmfR binding pocket completely and initiate the 
conformational change.(55) Work with synthetic analogues also indicated that an alkyl chain 
with a length of between three and five carbons is optimal triggering MmfR release. The 
hydrophobicity of this alkyl tail also means that the MMFs with longer chains are less soluble 
in water. The implications of the different properties of the five ligands in vivo are not known. 
 
Research carried out by Peter Harrison (73) revealed that the different MMFs vary in their 
binding kinetics to MmfR. In particular, his work consistently indicated that MMF1 with its 
branched alkyl chain was best at causing MmfR release. Findings on the other four MMFs 
were less distinct. It is not yet clear why there are five different methylenomycin furans and 
what impact the choice of these ligands will have on transcription. More in vivo work is 
needed before conclusions can be made about the five molecules. 
Methylenomycin Furan Biosynthesis 
Of MmfLHP, the enzymes responsible for the biosynthesis of MMF1-5, MmfL has shown 
25% amino acid identity and 43% similarity over 83% of its sequence to AfsA, a butenolide 
synthase used in the production of the GBL signalling molecule A-factor.(71, 74) MmfL also 
appears to be the most critical of the three in the MmfLHP operon with MMF production 
ceasing in mmfL knockouts and low level MMF production detected when mmfL was present 
but mmfH and mmfP were absent (see the genes highlighted in blue in Figure 1.5).(54, 71) On 
the other hand, the production of a mmfP or mmfH knockout did not result in the termination 
of MMF production but just lower levels produced, the indication of which being that MmfP-
like and MmfH-like proteins are present in S. coelicolor that can partially takes over their 
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roles.(54) The proposed functions of the three enzymes are that mmfL codes for a butenolide 
synthase, mmfH for a flavin dependent dehydrogenase and mmfP for a phosphatase.(75) It 
also appears likely that precursors to the steps catalysed by MmfLHP may be intermediates 
common also to the biosynthetic pathways of the GBLs.(54, 74)  
Transcriptional Regulation by MmfR 
MmfR is proposed to bind to three different intergenic locations within the methylenomycin 
cluster, thereby blocking five different promoters and regulating the expression of the five 
associated operons. These intergenic protein-binding regions are known as methylenomycin 
auto-regulatory response elements or MAREs. A diagram of the location of these operator 
sites within the methylenomycin biosynthetic cluster can be found below in Figure 1.8, with 
the MARE operators denoted with bold vertical black lines. (Please note that this diagram is 
not to scale and is purely a representation to show the assembly of the gene cluster. This 
diagram is a reduced form the one shown earlier in Figure 1.5 and has had a section of the 
biosynthetic cluster removed so to only focus on the areas surrounding the MARE operators.) 
 
 
Figure 1.8. Proposed regulation of the methylenomycin gene cluster from the SCP1 
plasmid of S. coelicolor by the TetR family member; MmfR 
The blue lines represents the proposed location of MmfR binding operator sites and red 
arrows indicate the operons regulated by these operators and the direction of transcription. 
Proposed functional attributions are mmfR and mmyR – transcriptional repressors, 
mmfLHP – methylenomycin furan biosynthetic genes, mmyT and mmyQ – methylenomycin 
biosynthetic genes, mmyB – transcriptional activator, based on the work of Chater and 
Bruton (65) 
 
The five operons directly regulated by MmfR are mmyR, mmfLHP, mmfR, mmyBQEDXCAPK 
and mmyYF. It has been shown experimentally that there is a lag in the expression of these 
different operons with the transcripts for the biosynthetic genes being detected last.(71) 
MmfR regulation of mmfR and mmfL means that the system is auto-regulatory with both 
negative and positive control mechanisms (Figure 1.8) where MmfR repression influences 
both its own synthesis as well as the synthesis of the MMFs which will then cause its release 
from the MARE operator. 
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The MARE operator sequences at each of the intergenic regions are as follows; 
mmfLR   5’ ATAATACCTTCC CGCAGGTATATT 3’ 
  3’ TATTATGGAAGG GCGTCCATATAA 5’ 
 
mmyR   5’ AACATACCTTCC CGAGGGTATGTT 3’ 
  3’ TTGTATGGAAGG GCTCCCATACAA 5’ 
 
mmyBY  5’ AAAAAACCTTCG GGAAGGTTTGAC 3’ 
  3’ TTTTTTGGAAGC CCTTCCAAACTG 5’ 
 
Conserved nucleotides between the three sites have been highlighted in yellow. The MARE 
operator sequences are 24 base pairs in length, 12 bp for each monomer, but are not a perfect 
palindrome despite MmfR being homodimeric. The three different intergenic MARE operator 
sequences do also vary quite considerably with only 13 out of the 24 bases remaining constant 
between the three sites, indicating possible different affinities of MmfR at each site. 
There are also different -35/-10 sequences for each of the five promoters regulated by MmfR 
(Table 3.1) in this cluster. These different promoters may therefore have different strengths, 
adding yet another layer of control to this biosynthetic cluster. The variation in promoter 
strength between the five operons is yet to be shown experimentally however. 
MmfR also has a paralogue, MmyR, which has been shown to also be involved in the 
regulation of methylenomycin biosynthesis. 
1.4.2 MmyR and its Role in Transcriptional Regulation 
Much less is known of the transcriptional regulation by MmyR. This TetR family member 
shares 35% identity with MmfR (over 54% of its sequence, covering the N terminal regions) 
(48) but research has suggested that it has a different mechanism of action. 
MmyR has been found to not be soluble when purification has been attempted with existing 
expression systems in E. coli. It has therefore not been possible to purify MmyR for 
crystallography or other in vitro analyses. For this reason, there is a lack of evidence as to 
whether MmyR will also bind the MMF molecules although genomic manipulations and the 
creation of knockout mutants have indicated that MmyR is not sensitive to the MMFs and will 
not transduce their signal.(71) The lack of an accurate crystal structure also limits the 
bioinformatical analysis that can be done on this homologue e.g. a docking analysis is a lot 
less likely to be reliable. 
MmyR can likely be regarded of as one of the pseudo-receptors mentioned in Section 1.2. 
These pseudo-receptors appear to share high levels of identity with their matching ‘real 
receptor’ but show differences in DNA and ligand binding properties, often binding a larger 
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range of DNA targets as well as sometimes acting only as a repressor in a ligand bound 
form.(50) Work by Choi et al. in 2004 into GBL receptors in non-streptomycete 
actinomycetes found that these pseudo-receptors often have a basic pI, usually around nine or 
ten. The real receptors on the other hand have a pI of around five or six.(76) Table 1.1 
contains details on the molecular weight and predicted isoelectric point of MmfR, MmyR and 
analogues ScbR and ArpA, as calculated using the software ProtParam.(77) MmfR has a 
predicted pI of 6.0 compared to 5.7 for ArpA and 6.4 for ScbR thus indicating that it is a ‘true 
receptor’, something which matches experimental findings.(71) MmyR on the other hand has 
a pI of 7.8 further indicating that it is unlikely to function as MmfR does or have the same 
operator/ligand binding properties. This does need to be proven experimentally however as 
this correlation between mode of action and predicted pI does not cover all cases and should 
be seen as no more than an indication of potential mechanism of action. Whether MmyR will 
bind to alternative ligands than the MMFs or different operators to the three MARE operators 
is yet to be seen.  
Table 1.1. Properties of TetR family member monomers MmfR, MmyR, ScbR and 
ArpA 
The predicted pI of these proteins comes from the ProtParam software, according to the 
standard parameters set by this software.(77)  
Protein Amino acid length 
Molecular weight 
(daltons) Theoretical pI 
MmfR 214 24052 5.99 
MmyR 203 21883 7.78 
ScbR 215 23861 6.38 
ArpA 287 32107 5.67 
 
Despite the unclear ligand/operator binding properties of MmyR, knockout strains for mmyR 
produce a phenotype overexpressing methylenomycin (65, 78) indicating a key role in 
regulation and repression. There is no experimental evidence that MmyR will bind the three 
MARE operators as yet however. An mmfR knockout on the other hand reveals a phenotype 
similar to that of the wild type strain despite the repression and release of MmfR by the 
MMFs having been shown experimentally.(54, 55, 71) It is clear therefore that regulation by 
the MmfR-MmfLHP-MmyR network is a complex one.(79) One hypothesis is that MmyR 
plays a secondary role, stopping the positive feedback loop once enough methylenomycin has 
been produced rather than allowing its initial production.(54) MmfR on the other hand is the 
preliminary repressor, only repressing the mmy biosynthetic genes in the absence of the auto-
inducing MMFs. More findings to support this hypothesis have been found in this project and 
will be discussed later. The regulation of natural product biosynthesis via MmfR/MmyR is 
something that is thought to be homologous in mechanism to the repression found in a 
number of other Streptomyces strains, this will now be discussed. 
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1.4.3 Analogous Systems to MmfR/MmfLHP/MmyR 
The analogous pathways in other strains of Streptomyces with similar control mechanisms to 
that found in the regulation of methylenomycin also include two distinct repressor proteins as 
well as analogues of the mmfLHP cluster. For example, SgnR and GbnR are MmfR and 
MmyR analogues respectively, found in S. venezuelae.(80) SAV_2270 and SAV_2268 from 
S. avermitilis and SHJG_7318 and SHJG_7322 from Streptomyces hygroscopicus are also 
close homologues of MmfR and MmyR.(81, 82) A schematic comparison of some of these 
clusters is represented in Figure 1.9 with the associated percentage identities at the amino acid 
level displayed. 
 
Figure 1.9. Organisation of mmfR/mmfLHP/mmyR-like clusters found in S. venezuelae 
and S. avermitilis and their associated amino acid percentage identities compared to the 
S. coelicolor cluster 
Orthologues are represented in matching colours and approximate gene sizes shown by the size of the 
arrows. This figure was taken directly from the 2016 paper by Niu et al. (35). 
 
A sequence analysis with MEME (Table 7.3) shows that all of the transcriptional repressor 
homologues have a highly conserved helix-turn-helix DNA binding domains consistent with 
being TetR family members.(83) 
These homologous transcriptional repressors not only show similarity in amino acid sequence 
but a comparison with the MARE operator sequence has revealed predicted intergenic auto-
regulatory response elements (AREs) where these homologous TetR family members are 
believed to bind in their own systems.(84) This conserved 24 bp protein binding DNA 
sequence from the four homologous strains just mentioned is shown in Figure 1.10. As yet 
however, there is no experimental data confirming TFR binding to this predicted motif. 
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Figure 1.10. Predicted motif of the intergenic auto-regulatory response element (ARE) 
sequences from S. coelicolor, S. venezuelae, S. avermitilis and S. hygroscopicus 
Schematic generated by the MEME suite (83) courtesy of Vincent Poon (84) 
 
The role of the pseudo-receptor appears to be conserved throughout the different strains 
where knockouts reveal a phenotype of natural product overproduction. For example the 
recent creation of a gbnR knockout in S. venezuelae resulted in the overproduction and 
discovery of novel natural products; the gaburedins (a family of γ-aminobutyrate (GABA)-
derived ureas).(75) These gaburedins bear very little structural or mechanistic resemblance to 
methylenomycin A the implications of which are that these homologous regulatory clusters 
are used to control the production of a range of unrelated natural products. Homology does 
not extent to the BGC (biosynthetic gene cluster). The BGC target in S. avermitilis and S. 
hygroscopicus are as yet unknown. 
Figure 1.9 also shows that, in addition to similarities between TetR receptors in these 
MmfR/MmfLHP/MmyR-like clusters, there are high levels of identity between MmfLHP and 
their orthologues giving the indication that these other strain may also produce AHFCA-like 
signalling molecules rather than GBLs.(54, 81) The AHFCAs may therefore be a novel and 
distinct class of microbial hormones found across multiple species. 
1.4.4 Other Methylenomycin Control Mechanisms 
In addition to the interaction of furan microbial hormones and the MmfR transcriptional 
repressor, methylenomycin production is also known to be regulated by pathway specific 
activators as well the use of rare codon and low alanine levels.(63) There is also activation of 
methylenomycin production upon a rapid drop in pH, an artefact that is little understood.(63) 
These factors all come together to produce a complex regulatory network, influencing the 
biosynthesis of methylenomycin. 
Transcriptional Activators 
Methylenomycin production is believed to be dependent on the presence of the pathway 
specific transcriptional activator; MmyB.(71, 85) The gene for this activator is the first found 
in the largest operon of methylenomycin biosynthetic genes; mmyBQEDXCAPK, one of the 
operons directly regulated by MmfR (and possibly MmyR). Research has indicated that 
MmyB binds to pseudo-palindromic B-boxes in the methylenomycin cluster and will activate 
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transcription of its own operon, mmyTOG, mmyY and mmyF.(71) It is hypothesised that 
maybe the main role of the MmfR/MMF/MARE operator regulatory system is to de-repress 
production of MmyB rather than direct the activation of biosynthetic genes via the removal of 
repression at the MARE operator. MmfR therefore may only indirectly influence 
methylenomycin biosynthesis. Knockout mmyB strains will not produce methylenomycin, 
even when MmfR/MmyR repression was removed by the MMFs.(71) MmyB does not appear 
to regulate the production of the MMFs but like MmfR, is potentially self-regulatory leading 
to a self reinforcing model of the activation of methylenomycin biosynthesis.(71) 
A bioinformatical analysis of MmyB shows similarities with Xre (Xenobiotic Response 
Element) family members, a family of common transcriptional regulators which, like TetR 
family members, have a HTH DNA binding domain.(85, 86) Members of this family will 
bind to DNA in homodimeric and heterodimeric forms and includes the lambda-
bacteriophage Cro protein. 
TTA Codon 
The gene for mmyB also contains the rare TTA codon thereby adding an extra level of 
translational regulation to the system.(87) The synthesis of tRNA for this codon (BldA) only 
occurs at the later stages in the complex Streptomyces life cycle.(88) Bld expression depends 
on the presence of the sigma factor BldN,(89) which itself is regulated by BldG and BldH 
both involved in preparing the cell for the production of aerial mycelium.(90) The TTA codon 
can also be found in mmfL, one of the genes to make an MMF biosynthetic enzyme. This use 
of the rare TTA codon is also found in a number of other antibiotic BGCs including those for 
achtinorhodin and prodiginine.(71) 
 
Hypothetical Regulatory Mechanisms 
Sigma Factors 
A number of other sigma factors may also be involved in the transcriptional regulation of this 
system. Promoter specificity of a polymerase can be influenced by sigma factors that interact 
with it and recruit the core RNA polymerase enzyme.(90) Alternative sigma factors are used 
to control gene expression. It is also possible to have anti-sigma factors and anti-anti-sigma 
factors, which exert yet more layers of control. E. coli only has seven sigma factors whereas 
S. coelicolor is believed to have at least 65,(90) showing the much more extensive control 
mechanisms found in streptomycetes. There is therefore potential that sigma factors are 
involved in the regulation of methylenomycin biosynthesis, however the specific sigma 
factors involved and the extent to which they have control is as yet unknown. 
Riboswitches 
It is also possible that the methylenomycin BGC is also regulated by riboswitches. 
Riboswitches are sections of mRNA molecules that can directly regulate themselves in the 
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presence of small effector molecules (possibly the MMFs).(91) Riboswitches are particularly 
common in bacteria but, as with sigma factors, the experimental evidence for their 
involvement in regulation of translation of the methylenomycin BGC is currently lacking. 
 
1.5 Introduction to Research Aims 
Research questions 
Do all five methylenomycin cluster promoters, controlled by MmfR, have the same 
strength? 
Does MmfR bind in the same way to all three MARE operator sequences? 
Is MmfR release by the MMFs the same at all three MARE operators? 
Does MmfR respond to all five furan compounds? 
Do all five MMFs have the same efficacy? 
What are the key residues in ligand binding? 
How does MmyR binding to the MARE operator and the MMFs vary from that of MmfR? 
Are there any other ligands that MmyR may bind to? 
Could MmfR, MMFs and MARE operators be used as a multi-host efficient novel inducible 
expression system for GC rich bacteria? Would this allow the purification of recombinant 
proteins? 
 
Hypothesis 
The promoters that are predicted to be controlled by MmfR have different -35/-10 
sequences so it is possible that they will have varying strengths. 
In vivo, MmfR will bind to DNA at the MARE operator and be released upon the addition 
of a MMF compound. 
The three MARE operators have different semi-palindromic sequences and so are 
likely to show differential binding to MmfR. 
MmfR will respond to all of the MMFs but due to the differing length of alkyl 
chain between the five molecules there are likely to be differences in the binding 
potential of each. 
MmyR is only produced after methylenomycin biosynthesis. It will bind to the 
methylenomycin cluster operators but not be released by the MMFs, thereby repressing 
biosynthesis when methylenomycin has been produced to conserve cell resources and to 
protect the bacterium from the potentially lethal effects of excess methylenomycin. 
Alternatively, an unknown ligand may ‘activate’ MmyR as a repressor. 
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1.5.1 How Will These Research Questions Be Answered? 
MmfR and MmyR functionality 
To assess the binding abilities of MmfR and MmyR to the MARE operator and MMFs a 
newly optimised luxCDABE (92) reporter system was developed for use in S. coelicolor (see 
Section 1.5.2 for more details). Vectors were created to contain luxCDABE under the control 
of different methylenomycin cluster intergenic regions (including the MARE operators), 
allowing the investigation of promoter strength as well as the effect of different operator sites. 
Vectors were also created that contained mmfR or mmyR to allow the study of TetR regulation 
over this BGC. MMFs could then be added to this system and their effects on 
bioluminescence measured. This luciferase assay as well as a bioinformatical analysis of 
amino acid sequences of MmfR, MmyR and their homologues fulfilled the investigative 
demands the first six research questions in this project. 
When investigating the ligand binding pocket of MmfR an in silico analysis of its crystal 
structure (73) as well as a comparison of primary structures with known homologues was 
done. This information was then used to perform site directed mutagenesis on these key 
ligand-binding residues and, using the luciferase assay, to study the effects this had on the 
release of MmfR from the MARE operators as well as whether MmfR function can be 
returned by a higher concentration of MMFs. 
A comparison could then be made between MmfR and MmyR activity in methylenomycin 
regulation and the information brought together to explain how MmfR/MmyR act together to 
regulate methylenomycin biosynthesis. 
Developing a Novel Inducible Expression System 
The production of a heterologous expression super host was investigated by adding the 
luxCDABE/mmfR system to the genetically streamlined Streptomyces albus host (93) to 
establish whether it would be suitable to use for the inducible expression system. This then 
lead onto an investigation of other alternative streptomycete hosts as well as a literature 
review of current expression systems. 
Following on from this, MmfR/MMF/MARE operator interactions were optimised so they 
could be adapted for use as a novel inducible expression system. Vectors were designed for 
the overexpression of a gene of choice to be trialled in this system and a protocol developed 
for the collection of recombinant proteins from S. coelicolor. An explanation of why a novel 
inducible expression system is needed can be found in Section 1.5.3. 
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1.5.2 Choice of Reporter System Used 
There are a number of reporter systems available and it was necessary to choose a suitable 
one for answering the research questions in this project. Unfortunately a number of reporter 
systems are not suitable for use in GC rich bacteria such as Streptomyces. The lacZ system for 
example, is a usually easy and sensitive reporter system and is widely used. Unfortunately, 
streptomycetes have an enzyme that has beta-galactosidase activity and therefore interferes 
with lacZ expression making it an unsuitable reporter system.(51) Efforts to produce 
Streptomyces knockout of this beta-galactosidase enzyme have often been unsuccessful and 
results in poorly growing colonies.  
A beta-glucorinidase system (94) has been used to study the regulation of virginiamycin 
biosynthesis by BarA and its cognate ligand VB from S. virginiae (Section 1.2.2) in tobacco 
plant cells in 2006.(95) This system was then later developed for use in actinomycetes, 
showing promise as a viable reporter system for these bacteria.(96) This is a colorimetric 
assay however and therefore limited in the quantitative results that can be obtained. It was 
therefore decided that it would be best to utilise a reporter system that produces more 
quantitative results such as fluorescence or bioluminescence. 
The gpf system has been trialled in Streptomyces with a degree of success. Streptomycetes 
will auto-fluoresce in blue light, limiting the range of colours that can be used to study 
different components of a system but otherwise appears to be fairly successful in these Gram-
positive bacteria. The disadvantage of the technique however, is that it tends to photo-bleach 
rapidly, limiting the genes it can be used to study as well as posing problems if multiple 
readings need to be taken.(92) 
A luxAB system from Vibrio harveyii has shown also a lot of potential for use in 
streptomycetes. The downside of this system is that luxAB only produce the enzyme 
luciferase and therefore there is the need to add a substrate to produce luminescence. This 
substrate may not pass through all bacterial cell walls with the same efficiency and may 
disrupt cell growth if overlaid onto a solid culture.(92) For this reason, the full luxCDABE 
system, which was optimised for GC high bacteria by Justin Nodwell and his team in Canada, 
(92) was used to investigate MmfR, MmyR, the MMFs and MARE operators further. LuxA 
and LuxB together form the heterodimeric luciferase protein whereas LuxC, D and E are the 
enzymes needed to form tetradecanal, the fatty aldehyde substrate of luciferase.(97) All other 
biochemicals required by this reaction are found naturally in bacterial cells allowing a self 
generated bioluminescent response with no need for external manipulations.(98) A diagram of 
the luxCDABE operon can be found in Figure 1.11. 
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Figure 1.11. Arrangement of open reading frames in the luxCDABE reporter system and 
the assigned functions of individual components of this operon 
This image was taken directly from the 2009 paper by Lin et al., (99) 
 
1.5.3 Why Do We Need A Novel Inducible Expression System? 
Currently, there are a number of commercially available inducible expression systems. 
Famous examples of these are the vectors regulating gene expression via the lac operon, 
inducible upon the addition of IPTG. IPTG is a lactose mimic that is not enzymatically 
broken down like lactose and so remains at a constant level, this will bind to the lac repressor 
(LacI) and cause its release from DNA thereby allowing the expression of a gene of 
interest.(100)  
Specificity of suitable expression hosts is little understood with each protein requiring a 
slightly different set of optimal expression conditions.(101) Many current systems are largely 
based in the Gram-negative Escherichia coli due to its fast growth, ease of culturing and well 
understood uses as a ‘cell factory’.(102) It is possible to optimise current expression systems 
to some extent to improve the expression of heterologous genes. For example genomic GC 
content varies widely across bacteria, ranging from anything between under 20% GC content 
to over 70% and so codon usage is also a key factor when designing recombinant genes.(103) 
There are a number of proteins that still cannot be efficiently over produced and purified 
using existing methods however. This can be due to a variety of complications such as 
physiological conditions not being suitable for the correct folding of the protein, low 
expression levels or because the host cannot carry out the required post-translational 
modifications.(101) Alternative expression systems have been developed to those in E. coli 
including systems based in yeast, other bacteria and fungi as well as those for mammalian 
cells.(104) These hosts will all provide slightly different conditions for protein expression, 
which may prove optimal for some proteins, but again these systems again cannot express all 
genes. There is no universal heterologous expression host. There is hope that the 
MmfR/MMF/MARE operator system, analogous to LacI/IPTG/lac operator can be used to 
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provide an alternative expression system for the overexpression of recombinant genes in the 
Gram-positive Streptomyces species. This system would hopefully be useful in the production 
of proteins currently not possible in existing systems. 
One benefit of using streptomycetes as an expression host is their high innate protein 
secretion capacity.(101, 105) This has the advantage of an increased chance of the protein 
folding properly (106) as well as a reduced requirement for expensive purification techniques. 
This is therefore something that would be beneficial to include in the expression system being 
designed in this project. 
In recent years there have been a number of systems developed for heterologous expression in 
streptomycetes that have shown promise. For example, the work by Noda et al. in 2015 
showed great success with the production of streptavidin from a streptomycete host.(107) 
Streptavidin is originally from Streptomyces avidinii so seems logical therefore that it is 
expressed better in these GC high bacteria as conditions are likely to be closer to the native 
conditions needed for streptavidin production. The work by Noda et al. resulted in the 
production of a much more thermostable streptavidin product compared to those produced by 
E. coli systems, thereby expanding the potential applications of streptavidin-biotin 
interactions. Not all streptomycete expression systems produce a high protein yield however 
and much optimisation is needed. An example of the type of optimisation done includes the 
work by Wilkinson et al. who investigated improving expression systems in actinomycetes 
based on optimising promoters. This lead to 100 times more product than when using than 
using wild type promoters.(108) Despite these successes however, there a still many instances 
where a heterologous protein cannot be purified from streptomycetes and so novel inducible 
expression systems are still very much in demand and it is for this reason that an additional 
inducible expression system is being developed in this project. 
 
1.6 Outline of Thesis Structure 
Chapter two specifies all of the stock solutions and protocols used to obtain results for this 
thesis as well as specifics on the source of all consumables used. Included in this section are 
details on primers used as well as lists of vectors and strains created. Further information on 
how these techniques developed based on experimental findings can also be found throughout 
the following research chapters. 
Chapter three presents the optimisation of the luxCDABE reporter gene system for GC high 
bacteria for use in studying the interactions between MmfR (and paralogue MmyR) with the 
MMFs and the binding to the MARE operator. The chapter gives details on the assembly of 
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vectors for this method and how these come together to create an arrangement that can be 
adapted to study different aspects of the regulation of methylenomycin biosynthesis. In 
addition, results from the investigation into the strength of different promoters in the 
methylenomycin biosynthetic cluster are reported within this chapter. 
Chapter four further expands on this luxCDABE reporter system specifically looking at MmfR 
as a transcriptional repressor. This chapter is divided into two main sections, the first looking 
at MmfR/MARE operator interactions and how binding varies at the three operators. The 
second is an investigation into MmfR/MMF interactions and includes details on all five 
methylenomycin furan ligands and their binding potentials to MmfR as well as an 
investigation into the MmfR ligand binding pocket and the production of mutants that were 
then also tested using the luciferase assay. 
Chapter five follows on from the investigation into MmfR, this time looking at its paralogue 
MmyR. Again both interactions with the MARE operator and the MMF ligands were 
investigated. Due to the functionality of MmyR being different to MmfR, this chapter then 
goes in a slightly different direction, investigating other possible ligands for this second 
repressor rather than studying key residues in ligand binding. 
Chapter six further explores the self-regulatory mechanism of MmfR, also using the luciferase 
assay. Investigations were carried out into the differences in MmfR repression and release 
when it is under the control of its own promoter. This chapter also briefly examines the 
potential of MmyR auto-regulation. This chapter is concluded with a proposed mechanism, 
combining the function of MmfR/MmyR in the regulation on methylenomycin biosynthesis, 
based on all of the investigative findings up until this point. 
Chapter seven is the final investigative chapter and summarises all of the findings of chapter 
three and four to develop a novel expression system for use in GC rich bacteria, utilising 
MmfR/MMF/MARE operator interactions to induce transcription. This chapter first looks at 
the potential of creating an optimised streptomycete expression host followed by details on 
the creation of vectors for this novel expression system as well as preliminary trials into using 
it with S. coelicolor as a heterologous expression host. 
Chapter eight and nine then discuss and conclude all of the findings from the previous five 
chapters as well as commenting on the implications of this work in wider research and 
explaining the possible future work that could be carried out. 
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2 Materials and Methods 
2.1 Materials and Equipment 
Table 2.1. Consumables used 
Supplier Material 
Agilent Technologies QuikChange Lightening SDM kit (109) 
Biotium GelRed™ nucleic acid dye 
Cell projects Ltd 2 mm short electroporation cuvettes 
Corre group, University of Warwick, 
Coventry, UK 
pCC4 – a pOSV566 derivative with apramycin resistance 
instead of ampicillin 
Corning 12-well plates - transparent, sterile flat bottomed tissue 
culture plates 
Day-Impex Ltd Virkon® disinfectant 
Expedeon InstantBlue™ Coomassie® stain 
GE Healthcare Ni Sepharose 6 Fast Flow 
Invitrogen One Shot® TOP10 Chemical Transformation kit 
Champion™ pET Directional TOPO® Expression Kits 
(110) 
Hygromycin B and UltraPure™ agarose 
Justin Nodwell et al., McMaster 
University, Canada 
Luciferase gene constructs,(92) in particular L1, 11NY 
and sp105 vectors shown in Table 2.5 
Merck-Millipore Amicon Ultra 15 Centrifugal Filter Unit MWCO 10 kDa 
Amicon Ultra 0.5 Centrifugal Filter Unit MWCO 10 kDa 
0.22 µm syringe filter 
MP Biomedicals FastDNA® SPIN Kit for Soil (111) and Lithium Chloride 
National Diagnostics ProtoGel 30% acrylamide 
New England Biolabs (UK) NEB 5-alpha Competent Escherichia coli 
Phusion high fidelity DNA polymerase 
High fidelity restriction enzymes with cut smart buffer 
Shrimp alkaline phosphatase 
ColorPlus™ Prestained Protein Ladder, Broad Range (10-
230 kDa) 
Pernodet Group, University of Paris-
Sud, France 
pOSV566 vector 
Roche Diagnostics Expand High Fidelity PCR System 
Sarstedt Petri dishes and universal tubes 
Scientific Laboratory Supplies Ltd. D-mannitol 
Sigma Aldrich Primers, agarose for electrophoresis, dialysis tubing 
Antibiotics; apramycin, ampicillin, kanamycin and 
chloramphenicol 
SIGMAFAST™ protease inhibitor cocktail tablets, 
EDTA-free for use in purification of histidine-tagged 
proteins 
Protease inhibitor cocktail, for use in tissue culture media, 
DMSO solution 
Thermo Fisher Scientific - Fermentas FastRuler™ DNA ladders 
GeneJET™ Plasmid Miniprep kit (112) 
GeneJET™ Gel extraction kit (113) 
Phusion High Fidelity DNA polymerase 
Restriction enzymes and buffers 
Routine PCR Taq DNA polymerase kit 
T4 DNA ligase and PEG (114) 
Wedge shaped spreaders and small cell scrapers 
VWR International Bacteriological agar 
Trichloroacetic acid for synthesis 
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Table 2.2. Equipment used 
Supplier 
Equipment 
Name Type 
Beckman Coulter Centrifuge Avanti j-25 
Bio-Rad Laboratories Ltd Horizontal electrophoresis system Wide Mini-Sub cell GT cell 
Cole-Parmer Water bath 2 litre StableTemp 
Eppendorf Microcentrifuge 
PCR machine 
PCR machine 
5424 R 
Mastercycler Nexus 
Mastercycler epgradient 
Fisher Scientific pH meter 
NanoDrop 
Acument basic AB15 
NanoDrop 2000 
Spectrophotometer 
Grant Water bath JB1 
Hettich Centrifuge Rotina 46R 
INFORS HT Incubator shaker Multitron 
New Brunswick Scientific Incubator shaker C24 
Photek Photon counting CCD camera 
Imaging software 
HRPCS4 
Photek IFS32 
StarLab Heat block Mini Dry Bath Incubator 
 
Table 2.3. Software used 
Software Distributor Reference 
ChemDraw Pro 15.0 Perkin Elmer  
Clone Manager Basic 9 Sci-Ed Software  
Clustal Omega v.1.2.1 Conway Institute UCD Dublin (48) 
Excel for Mac 2011 Microsoft Corporation  
GraphPad Prism 6 and 7 GraphPad Software (115) 
Image32 Photek  
Ligplot+ v.4.5.3 European Bioinformatics Institute (116) 
MEME v.4.10.0 National Centre for Research Resources (83) 
MacPyMOL v.1.3 Schrodinger (117) 
SnapGene Viewer v.3.0.3 GSL Biotech (72) 
SwissDock Swiss Institute of Bioinformatics (118) 
UCSF Chimera v.1.8.1 Resource for Biocomputing, 
Visualization and Informatics (119) 
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Table 2.4. Primers used 
Name Sequence 5’ to 3’ 
Screening primers  
T7 forward TAATACGACTCACTATAGGG 
T7 reverse/terminator GCTAGTTATTGCTCAGCGG 
 Luciferase screening forward AAGCCACTGAGCGGGAGCTTG 
 Luciferase screening reverse GACGCTGTTGTCGCCGAAGTTG 
gbnB insert screening forward CACGATCCAAAGGAGGATGACG 
gbnB insert screening reverse CACCTGCAGCCGGGCGGCC 
  
Primers for cloning intergenic regions into the lux vectors 
   mmfRp forward GGCTGCCTTCCTTCGTGTG 
   mmfRp reverse AGGGGCGCTACATCTCCCG 
   mmyRp forward CACGATATCATCCTGCCGCGCGGTAGCC 
   mmyRp reverse GTGGGATCCCAACGCCCGAGTCCTCTCAAG 
   mmyBp forward CCGGATATCGGTGAACTCCTTCGGCGAGTG 
   mmyBp reverse GTGGGATCCGGCGCCTCACAGTGTCAAACCTTC 
   mmfLp forward CACGGATCCGGCTGCCTTCCTTCGTGTG 
   mmfLp reverse GTGGATATCAGGGGCGCTACATCTCCCG 
   mmyYp forward CCGGGATCCGGTGAACTCCTTCGGCGAGTG 
   mmyYp reverse GTGGATATCGGCGCCTCACAGTGTCAAACCTTC 
   ermE* forward CACGGTACCAGCTTGCATGCCGGTC 
   ermE* reverse CACGATATCGCTGACGCCGTTGGATAC 
  
SDM primers 
   Y85F 1 CAGCGCGCGAAGTGCTCCTCCACCACG 
   Y85F 2 CGTGGTGGAGGAGCACTTCGCGCGCTG 
   Y144F 1 TCCAGTCCACGAAGGGCAGGGGCAG 
   Y144F 2 CTGCCCCTGCCCTTCGTGGACTGGA 
   Y85A 1 GGGCCAGCGCGCGGCGTGCTCCTCCACC 
   Y85A 2 GGTGGAGGAGCACGCCGCGCGCTGGCCC 
   Y144A 1 GGTCCAGTCCACGGCGGGCAGGGGCAGC 
   Y144A 2 GCTGCCCCTGCCCGCCGTGGACTGGACC 
  
Other primers 
mmfR forward (HindIII restriction, to 
clone from pCC2) CACAAGCTTAAAGGAGGGCAGCCATGACGAGCG 
mmfR reverse (NotI restriction, to 
clone from pCC2) CACGCGGCCGCGCGGACGCTCCCCGTC 
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Table 2.5. Vectors used in luciferase reporter gene assay 
Vector name Genes contained Resistance conferred Promoter Reference 
pCC4 - AprR and HygR 
ermEp* 
(120) 
pKMS01 pCC4 with mmfR1  AprR and HygR This project 
pKMS03 pCC4 with mmyR  AprR and HygR This project 
pOSV556 - AmpR and HygR (120) 
pKMS85 pOSV556 with Y85F mmfR mutant Amp
R and HygR This project 
pKMS144 pOSV556 with Y144F mmfR mutant Amp
R and HygR This project 
L1 luxCDABE, intergenic region for mmfL/mmfR Apr
R 
mmfLp 
(92) 
11NY luxCDABE, mmfR and intergenic region for mmfL/mmfR Apr
R (92) 
sp105 luxCDABE, mmyR and intergenic region for mmfL/mmfR Apr
R (92) 
L1F luxCDABE, reversed intergenic region for mmfL/mmfR Apr
R mmfRp This project 
L2 luxCDABE, intergenic region for mmfP/mmyR Apr
R mmyRp This project 
L3 luxCDABE, intergenic region for mmyY/mmyB Apr
R mmyBp This project 
L3F luxCDABE, reversed intergenic region for mmyY/mmyB Apr
R mmyYp This project 
L4 luxCDABE and intergenic region containing ermEp* Apr
R ermEp* This project 
 
Table 2.6. Other vectors used in this research project 
Vector name Extra details Size of vector 
Resistance 
conferred Reference 
pET151 lacZ, AmpR 5 760 bp AmpR (121) 
pET151:mmfR lacZ, mmfR, AmpR  AmpR This work 
pUZ8002 RP4 derivative ~ 60 000 bp KanR (51), (122) 
pKMS05 L1 vector with Streptococcus mutans gbnB and luxCDABE 13 047 bp Apr
R This work 
pKMS06 L1 vector with Salmonella enterica gbnB and luxCDABE 13 080 bp Apr
R This work 
pCC4 
AprR and HygR, int_pSAM2 
(containing attP for genomic 
integration), OriT, Ter, ermEp* (for 
more details see Figure 3.7) 
8 663 bp AprR and HygR (120) 
pOSV556 
AmpR and HygR, int_pSAM2 
(containing attP for genomic 
integration), OriT, Ter, ermEp* 
9 009 bp AmpR and HygR (120) 
 
 
                                                      
1 pKMS01 mmfR is sometimes referred to as wild type or WT mmfR when being compared to 
the mutants presents in pKMS85 and pKMS144 
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Table 2.7. Parent strains used in investigation 
Strain Genotype Reference 
Streptomyces coelicolor M145 SCP1- SCP2- (51) 
Streptomyces coelicolor M1152 SCP1- SCP2- Δact Δred Δcpk Δcda rpoB[C1298T]) (123) 
Streptomyces albus J1704 Wild type – GenBank: CP004370 (124) 
Escherichia coli TOP10 
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
Δ lacX74 recA1 araD139 Δ(araleu)7697 galU 
galK rpsL (StrR) endA1 nupG 
(110) 
Escherichia coli 
ET12567/pUZ8002 
F- dam-13::Tn9 dcm-6 hsdM hsdR zjj-202::Tn10 
recF143 galK2 galT22 ara-14 lacY1 xyl-5 leuB6 
thi-1 tonA31 rpsL136 hisG4 tsx-78 mtl-1 glnV44, 
pUZ8002 (KanR) 
(125), (122) 
 
Table 2.8. Strains created using various vectors to be used in the luminescence assay 
The parent strain used for all of these was S. coelicolor M145 and vector 2 always uses the 
ermEp* promoter. ‘Inducible’ refers to the possibility of the strain repression being released 
by the MMFs, this had not been proven experimentally for all vectors at the time of creation 
however. 
Name given to 
strain Vector 1 Vector 2 Type of sample 
Promoter in 
lux vector 
L1 L1 - Positive control 
mmfLp 
11NY 11NY - MmfR, inducible 
sp105 sp105 - MmyR, inducible 
L1+pCC4 L1 pCC4 Positive control 
L1+mmfR L1 pKMS01 MmfR, inducible 
L1+mmyR L1 pKMS03 MmyR, inducible 
L1+Y85F L1 pKMS85 MmfR mutant, inducible 
L1+Y144F L1 pKMS144 MmfR mutant, inducible 
L1F+pCC4 L1F pCC4 Positive control 
mmfRp L1F+mmfR L1F pKMS01 MmfR, inducible 
L1F+mmyR L1F pKMS03 MmyR, inducible 
L2+pCC4 L2 pCC4 Positive control 
mmyRp L2+mmfR L2 pKMS01 MmfR, inducible 
L2+mmyR L2 pKMS03 MmyR, inducible 
L3+pCC4 L3 pCC4 Positive control 
mmyBp L3+mmfR L3 pKMS01 MmfR, inducible 
L3+mmyR L3 pKMS03 MmyR, inducible 
L3F+pCC4 L3F pCC4 Positive control 
mmyYp L3F+mmfR L3F pKMS01 MmfR, inducible 
L3F+mmyR L3F pKMS03 MmyR, inducible 
L4+pCC4 L4 pCC4 Positive control ermEp* 
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2.2 Stock Solutions 
2.2.1 Media Stock Solutions 
 
LB medium 
10 g tryptone 
5 g yeast extract 
10 g NaCl 
Make up to 1 L with distilled water 
adjust the pH to 7.0 
Autoclave 
 
SOB media (126) 
20 g tryptone 
5 g yeast extract 
0.5 g NaCl 
Make up to 1 L with distilled water, 
adjust to pH 7.5 and autoclave 
Add filter sterilised MgSO4 to a final 
concentration of 20 mM 
 
LB agar 
10 g tryptone 
5 g yeast extract 
10 g NaCl 
15 g agar 
Make up to 1 L with distilled water 
adjust the pH to 7.0 
Autoclave 
 
SOC medium 
20 g tryptone 
5 g yeast extract 
0.5 g NaCl 
Make up to 1 L with distilled water, 
adjust to pH 7.5 and autoclave 
Add filter sterilised MgSO4 and glucose 
each to a final concentration of 20 mM 
 
SFM (soya flour mannitol) 
8 g bacto-agar 
8 g soya flour 
8 g mannitol 
Make up to 400 mL with tap water and 
mix together before autoclaving 
 
TSB medium 
17 g enzymatic digest of casein 
3 g enzymatic digest of soya bean meal 
5 g NaCl 
2.5 g dipotassium phosphate 
2.5 g glucose 
Make up to 1 L with distilled water 
adjust the pH to 7.3 (+/-0.2) 
 
2XYT broth 
16 g tryptone 
10 g yeast extract 
5 g NaCl 
Make up to 1 L with distilled water 
adjust the pH to 7.0 
Mix and autoclave 
 
Antibiotics were used at the following 
final concentrations: 
50 µg/ml apramycin 
100 µg/ml ampicillin 
25 µg/ml chloramphenicol 
50 µg/ml kanamycin 
50 µg/ml hygromycin 
25 µg/ml nalidixic acid 
 
Autoclaving was done at 121 °C for 20 minutes and then media was stored at room 
temperature. Once antibiotics were added the media would be used immediately or stored in 
the fridge until required. 
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2.2.2 DNA Gel Electrophoresis 
 
50X TAE buffer 
2 M Tris acetate, pH ~8.3 
50 mM EDTA 
In distilled water 
Filter sterilised 
1% gel – for one gel 
1 g agarose 
In 100 mL 1X TAE buffer (40 mM Tris acetate 
and 1 mM EDTA) 
Heat in the microwave at full power for 90 
seconds or until the agarose has dissolved 
Allow to cool slightly and add 5 µL GelRed™ 
 
2.2.3 Phenol Chloroform Extraction Buffers 
 
Buffer I 
50 mM Tris-HCl, pH 8 
10 mM EDTA 
 
Buffer II 
200 mM NaOH 
1% SDS 
Buffer III 
3 M potassium acetate, pH 5.5 
 
Buffers were stored at 4 °C until needed. 
 
2.2.4 Protein Purification Buffers and Solutions 
 
Protein purification buffer 
20 mM Tris-HCl pH 8 
100 mM NaCl 
10% glycerol 
 
Improved protein purification buffer for 
Ni Sepharose purification 
20 mM sodium phosphate (Na2HPO4 and 
NaH2PO4) 
500 mM NaCl 
pH 7.4 
 
Elution buffer 
20 mM Tris-HCl pH 8 
100 mM NaCl 
10% glycerol 
200 mM imidazole 
 
Improved elution buffer for Ni 
Sepharose purification 
20 mM sodium phosphate (Na2HPO4 and 
NaH2PO4) 
500 mM NaCl 
500 mM imidazole 
pH 7.4 
 
Buffers were all stored at 4 °C until 
needed. 
 
Protease inhibitors were used at the 
following final concentrations: 
1 mM EDTA and 1:500 protease 
inhibitor cocktail for tissue culture from 
Sigma-Aldrich for culture plates. 
 
One tablet of SIGMAFAST protease 
inhibitor cocktail in 100 mL ‘improved 
protein purification buffer’. 
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2.2.5 SDS-PAGE Reagents and Buffers 
 
4% SDS-PAGE stacking gel 
4% ProtoGel acrylamide 
125 mM Tris-HCl pH 6.8 
0.1% SDS 
0.05% APS 
0.01% TEMED 
 
12% SDS-PAGE resolving gel 
12% ProtoGel acrylamide 
375 mM Tris-HCl pH 8.8 
0.1% SDS 
0.1% APS 
0.01% TEMED 
 
SDS-PAGE loading dye (2x) 
125 mM Tris-HCl pH 6.8 
20% glycerol 
4% beta-mercaptoethanol 
0.2% bromophenol blue 
4% SDS 
 
SDS-PAGE running buffer (10x) 
250 mM Tris-HCl pH 8.8 
2 M glycine 
1% SDS 
 
Buffers were all stored at 4 °C until 
needed. 
 
2.3 Protocols 
2.3.1 Bacterial Cultures 
Escherichia coli 
Unless otherwise specified, E. coli cultures were grown at 37 °C using LB agar for solid 
cultures and LB media, shaking at 200 rpm for liquid cultures. Appropriate antibiotics were 
also added to the cultures at concentrations specified in Section 2.2.1. 
Streptomyces Species 
Unless otherwise specified, Streptomyces cultures were grown at 30 °C using SFM for solid 
cultures and 2xYT media, shaking at 200 rpm in baffled flasks for liquid cultures. Again, 
appropriate antibiotics were also added to the cultures at concentrations specified in Section 
2.2.1. 
2.3.2 Vector Creation 
Much of the investigative work during this project was done in vivo using new strains created 
to contain different reporter systems and genes of interest. These new strains were achieved 
via the transfer of vectors containing genes of interest into a host strain. 
 
In the case of E. coli, vectors were inserted via chemical or electro transformation (Sections 
2.3.3 and 2.3.6). Streptomyces species on the other hand require DNA to be transferred from a 
non-methylating E. coli strain via intergeneric conjugation (Section 2.3.7). The vectors for 
Streptomyces were designed so that DNA integrated into the host genome rather than having 
an extra chromosomal plasmid, as is done in E. coli. 
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Plasmid vectors were created by placing inserts into an existing plasmid backbone via the 
homologous recombination of sticky ends created by the restriction digest of the vector and 
insert. The inserts were either a PCR product or a synthetically produced gene from the 
GeneArt service by Thermo Fisher. 
 
PCR Protocol 
PCR was used to amplify the gene of interest and to add restriction sites to the 3’ and 5’ ends. 
Primer sequences can be found in Table 2.4 on page 27. The PCR reaction protocol used was 
as follows: 
5 µL 10X HF buffer 
1 µL10 mM dNTPs 
0.5 µL 100 µM forward primer 
0.5 µL 100 µM reverse primer 
0.5 µL template 
1.5 µL DMSO 
0.5 µL NEB high fidelity Phusion® DNA polymerase 
Up to 50 µL with water 
 
Table 2.9. PCR cycle times 
These cycle times are for use with the NEB high fidelity DNA polymerase. Steps two, three 
and four are all repeated 35 times before moving onto step five, the final extension. 
Stage Temperature: Length of time: 
1. Initial denaturation 95°C 2 minutes 
2. Denaturation 95°C 1 minute 
3. Annealing 45-72°C 1 minute 
4. Elongation 72°C 1 minute 
5. Final extension 72°C 15 minutes 
6. Hold 4°C - 
 
If this reaction did not produce a PCR product then the protocol was optimised by increasing 
the volume of DMSO to 2.5 µL, varying the annealing temperature or diluting the template 
1:3, 1:5 and 1:10 until a product was successfully obtained. 
Unless otherwise specified, this PCR protocol was used throughout the rest of the project. 
Gel Electrophoresis 
The size of PCR products as well as restriction digests and other DNA products were checked 
compared to a standard DNA ladder on a 1% agarose gel. This was made using the stock 
solutions specified in Section 2.2.2 using a 1% agarose gel in 1X TAE (40 mM Tris-acetate; 1 
mM EDTA). As a standard, gels were run at 100 V for 40 minutes before being observed 
under UV light. 
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Restriction Digest and Gel Extraction of DNA 
Two restriction endonucleases were selected that each cut once each within a chosen area in 
the backbone vector (either pCC4, pOSV556 or L1). These same restriction sites were also 
added to each end of the gene inserts allowing the ligation of the two parts of the vector. 
Details on the restriction enzymes used can be found in the table below. 
 
Table 2.10. Restriction sites used to create vectors for this investigation 
Vector name Genes contained Restriction sites used Insert type 
pKMS01 pCC4 with mmfR  HindIII and NotI PCR product 
pKMS03 pCC4 with mmyR  HindIII and StuI PCR product 
pKMS85 pOSV556 with Y85F mmfR mutant 
HindIII and 
NotI 
PCR product (created 
using Agilent 
QuikChange SDM kit) 
pKMS144 pOSV556 with Y144F mmfR mutant 
HindIII and 
NotI 
PCR product (created 
using Agilent 
QuikChange SDM kit) 
L1F luxCDABE, reversed intergenic region for mmfL/mmfR 
EcoRV and 
BamHI PCR product 
L2 luxCDABE, intergenic region for mmfP/mmyR 
EcoRV and 
BamHI PCR product 
L3 luxCDABE, intergenic region for mmyY/mmyB 
EcoRV and 
BamHI PCR product 
L3F luxCDABE, reversed intergenic region for mmyY/mmyB 
EcoRV and 
BamHI PCR product 
L4 luxCDABE and intergenic region for ermEp* 
EcoRV and 
KpnI PCR product 
pKMS05 L1 vector with Streptococcus mutans gbnB and luxCDABE 
BamHI and 
NotI Synthetic gene 
pKMS06 L1 vector with Salmonella enterica gbnB and luxCDABE 
BamHI and 
NotI Synthetic gene 
 
The concentration of DNA available for digestion was calculated using a NanoDrop and 
digestions carried out as specified in the protocols provided with the enzymes used. Where 
possible, NEB high fidelity enzymes were used. These enzymes have been optimised to work 
in the universal CutSmart buffer, allowing double digestion reactions and thereby increasing 
the yield of DNA that could be purified from a gel extraction as well as saving time. 
 
Example Protocol for EcoRV and BamHI 
2.5 µL 10x cut smart buffer 
5 units NEB high fidelity restriction enzyme 
0.5 µg DNA 
Up to 25 µL with water 
Incubate at 37 °C for an hour 
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Gel Extraction of DNA 
After digestion, the digestion products were then separated via gel electrophoresis on a 1% 
agarose gel as just described. The appropriate bands were then cut out and DNA was 
extracted using the Thermo Scientific GeneJET Gel Extraction Kit. The protocol provided 
with the kit was followed exactly until the final elution step, where 50 µl of 65 °C water was 
used instead of the elution buffer and samples were incubated for 10 minutes at room 
temperature before a final centrifugation was carried out at the highest speed for two minutes 
to collect the purified DNA. 
 
Ligation 
Ligation of the digested insert to the digested vector was carried out using a T4 ligase and 
50% PEG according to the protocol provided by Thermo Scientific.(114) PEG was used as 
some of the restriction enzymes used e.g. EcoRV, were blunt cutters. The polyethylene glycol 
helps to increase the ligation efficiency of blunt ended DNA. The vector was trialled at a ratio 
of molecular weights of 1:2, 1:3 or 1:5 compared to the insert for each of the reactions to 
increase the chances of successful ligation. 
Reaction mix: 
45 ng vector 
X ng insert 
2 µL 10x ligation buffer 
2 µL PEG (50%) 
1 µL T4 DNA ligase (5 units) 
Up to 20 µL with water 
 
After incubation at room temperature for an hour and then in the fridge overnight, 5 µL of the 
ligation products were used to transform 50 µL chemically competent TOP10 cells or 1-2 µL 
to transform electro-competent ET12567 cells. 
2.3.3 Chemical Transformation into TOP10 Cells 
Preparation of Chemically Competent TOP10 Cells 
For the creation of chemically competent TOP10 cells for transformation, 10 mL sterile LB 
was inoculated from a single TOP10 colony and grown overnight at 37 °C shaking. In the 
morning this starter culture was used to inoculate 500 mL sterile LB and was again grown at 
37 °C shaking, until the OD600 was between 0.35 and 0.40 (around three hours). The cells 
were then immediately placed on ice, transferring the culture to 50 mL falcon tubes. All steps 
from here on were kept at 4 °C and cell pellets were re-suspended as gently as possible. The 
cultures were allowed to chill for 20-30 minutes before centrifuging at 4000 rpm for 15 
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minutes at 4 °C. The supernatant was then decanted and the pellet re-suspended in ice cold 
sterile 100 mM MgCl2, mixing gently. (Cells could be combined in fewer tubes once re-
suspended to reduce workload). Samples were then centrifuged at 3000 rpm for 15 minutes at 
4 °C and the supernatant again decanted before ice cold sterile 100 mM CaCl2 was added. 
This was then chilled on ice for 20 minutes before centrifuging at 3000 rpm and decanting the 
supernatant as before. The pellet was then re-suspended in ice cold sterile 85 mM CaCl2 with 
15% glycerol before centrifuging at 2100 rpm for 15 minutes at 4 °C. After pouring away the 
supernatant, the cells were re-suspended in a total of 1 mL 85 mM CaCl2 with 15% glycerol 
and 50 µl aliquotted into pre-chilled cryovials. This was then either used immediately or flash 
frozen in dry ice and stored at -80 °C. 
Transformation Protocol 
Transformation into competent E. coli TOP10 cells was done following a protocol from the 
‘Invitrogen – Champion™ pET Directional TOPO® expression kits’ manual (page 20 from 
the One Shot® TOP10 Chemical Transformation Protocol).(110) Two changes were made to 
this protocol, firstly 2 µl of vector (instead of 3 µl) was added to 25 µl of competent E.coli 
DH5α (step 1) and LB (lysogeny broth) medium was used instead of S.O.C. medium (step 5). 
Transformed cultures were grown over night at 37 °C before single colonies were picked and 
stocks made with 50% glycerol for long-term storage at -80 °C. 
2.3.4 Plasmid Purification 
GeneJET™  Plasmid Miniprep kit  
Extraction and purification of cloned plasmids was needed to screen for the correct insert and 
successful vector synthesis. This was done using a GeneJET™ Plasmid Miniprep kit and 
associated protocol.(113) Changes to this protocol are as follows; 100 µl water at 70 °C was 
used instead of the elution buffer in the final step followed by incubation at room temperature 
for 15 minutes before the sample was centrifuged for two minutes to collect the purified 
DNA. 
Phenol Chloroform Purification of Cosmid DNA 
If plasmid DNA was not successfully recovered using the GeneJET™ Plasmid Miniprep kit, 
particularly a problem for larger pieces of DNA, then vectors could alternatively be extracted 
using a phenol chloroform protocol (see Section 2.2.3 for details on buffers and solutions). E. 
coli containing the plasmid of interest were grown at 37 °C overnight in a 10 mL culture with 
appropriate antibiotics. These cells were then pelleted by centrifugation at 2000 rpm for 15 
minutes. The supernatant was poured away and the cell pellet re-suspended in 100 µL of 
solution I (50 mM Tris-HCl, pH 8 and 10 mM EDTA) before being transferred into a 
microcentrifuge tube. 
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A volume of 200 µL of solution II (200 mM NaOH and 1% SDS) was then added the to the 
re-suspended cells and the tubes inverted ten times. Next, 150 µL of solution III (3 M 
potassium acetate, pH 5.5) was added and the tubes inverted ten times to mix the solutions. 
Samples were then centrifuged at full speed in a microcentrifuge for five minutes to pellet the 
cell matter. Immediately, 400 µL phenol-chloroform was added to the extracted supernatant 
and samples vortexed for two minutes. 
The samples were then centrifuged at full speed for five minutes to separate the mixture into 
two phases, the vector DNA should be in the upper phase. The upper phase was then 
transferred into a fresh microcentrifuge tube and 600 µL ice cold 2-propanol was added. This 
were then left on ice for 15 minutes before samples were spun at full speed for five minutes to 
pellet the vector DNA. The supernatant was then removed and the pellet washed with 200 µL 
ice cold ethanol before centrifuging again as before. After the supernatant was removed, the 
tube was left open and the pelleted DNA was left to dry at room temperature for ten minutes 
before the pellet was re-suspended in 50 µL water (or 10 mM Tris-HCl, pH 8 for longer term 
storage). 
2.3.5 Vector Screening and Sequencing 
Newly synthesised vectors were screened both using a PCR reaction as well as a restriction 
digest compared to a control reaction. Sequencing was also carried out on the clones that 
showed most promise in the screening, as a final check for the correct product. 
PCR Screening 
For the PCR screen, primers were designed to bind either side of inserts, ideally producing 
products of different sizes if the gene of interest was present or absent (alternatively primers 
were designed so one bound within the insert and one outside). The screening PCR reaction 
was done following the protocol from the NEB HF Phusion® DNA polymerase described 
previously unless there were a large number of samples in which case a standard Taq 
polymerase was used, as it is less costly. The protocol for the Taq polymerase follows. 
Reaction mix: 
10 µL 5X Taq buffer (NH4SO4) 
2 µL10 mM dNTPs 
1 µL 100 µM forward primer 
1 µL 100 µM reverse primer 
0.5 µL template 
1.5 µL DMSO 
0.5 µL Taq DNA polymerase 
Up to 50 µL with water 
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Table 2.11. PCR cycle times 
These cycles times are for use with the Taq polymerase. Steps two, three and four are all 
repeated 30 times before moving onto step five, the final extension. 
Stage Temperature: Length of time: 
1. Initial denaturation 95°C 2 minutes 
2. Denaturation 95°C 45 seconds 
3. Annealing 45-72°C 45 seconds 
4. Elongation 72°C 1 minute 
5. Final extension 72°C 15 minutes 
6. Hold 4°C - 
 
Again, if this PCR reaction did not produce a product then the protocol was optimised by 
increasing the volume of DMSO to 2.5 µL, varying the annealing temperature or diluting the 
template 1:3, 1:5 and 1:10 until a product for the control reaction was successfully obtained. 
Restriction Digest Screening 
A restriction digest was also run to check for expected product sizes from a successfully 
created vector. Restriction endonucleases were selected to give different product sizes for a 
control compared to the desired ligated vector and the products of these reactions analysed by 
gel electrophoresis. The digestion protocol described previously in Section 2.3.2 was again 
used, this time scaled down to be done with only around 10 µL purified DNA and no 
subsequent gel extraction. 
Sequencing 
Sequencing was done using the GATC LIGHTrun™ sequencing service, usually using the 
primers that had been used for the PCR screening step. Sequencing results could then be 
analysed for correct insertion orientation as well as mistakes that may have occurred during 
the PCR synthesis of the insert. 
2.3.6 Electro-Transformation of Vectors into ET12567/pUZ8002 
TOP10 cells were used to clone plasmids and for the creation of plasmid stocks, much of the 
work in this project however was done in vivo in S. coelicolor. S. coelicolor does not accept 
methylated DNA and so could not be directly transformed with plasmid vectors. Instead, the 
purified vectors were first transformed into a non-methylating strain of Escherichia coli; 
ET12567/pUZ8002. The transformants were then used to transfer the DNA vectors to 
Streptomyces coelicolor via intergeneric conjugation. 
Preparation of Electro-Competent ET12567/pUZ8002 
ET12567 cells with pUZ8002 were streaked out on an LB plate with kanamycin and 
chloramphenicol and grown overnight at 37 °C to produce single colonies. One of these 
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colonies was then picked and grown in 10 mL LB media with kanamycin and 
chloramphenicol overnight at 37 °C shaking. Of this starter culture, 200 μl was used to 
inoculate 10 mL fresh media with the same antibiotics. This was the grown at 37 °C until the 
OD600 was between 0.4 and 0.6 (around four hours). This cell culture was then spun at 2000 
rpm at 4 °C for 10 minutes and the supernatant removed before the cells were re-suspended in 
10 ml of ice cold 10% glycerol. Cells were then spun down again (keeping them at 4 °C) and 
re-suspended in 5 mL of ice-cold 10% glycerol. After a final centrifugation and removal of 
the supernatant, cells were re-suspended in the residual liquid. These cells were now 
competent and either kept on ice and used immediately or stored at -80 °C for later use. 
Electroporation Technique 
Taking care too keep the whole reaction on ice, 80 μl electro-competent ET12567 cells and 2 
μl vector were added to a 2 mm electroporation cuvette. The cells were then electroporated at 
2.5 kV before 1 mL ice-cold LB was immediately added. The transformants were then 
transferred into a microcentrifuge tube and left for an hour at 37 °C shaking. The culture was 
then plated out on LB agar with kanamycin and chloramphenicol to select for the de-
methylating pUZ8002 vector and an appropriate antibiotic to select for the vector being 
transformed. This was then grown overnight at 37 °C. Single colonies were picked and stocks 
made with 50% glycerol for long-term storage at -80 °C or immediate use in the intergeneric 
conjugation protocol. 
2.3.7 Intergeneric Conjugation to Introduce Vectors into Streptomyces 
coelicolor M145 
Unless otherwise noted, Streptomyces coelicolor M145 was used as the host strain for this 
assay. The transfer of vectors into this strain was carried out using the protocol specified in 
‘Practical Streptomyces Genetics’.(51) 
Single colonies of ET12567 cells with pUZ8002 containing the relevant vector were picked 
and grown overnight at 37 °C shaking in LB with the appropriate antibiotics. The next 
morning 200 μl of this starter culture was used to inoculate 10 mL fresh media (with the same 
antibiotics) and this was grown at 37 °C shaking until the OD600 was between 0.4 and 0.6 
(around four hours). This was then centrifuged for ten minutes at 2000 rpm to pellet the cells. 
The pellet was then re-suspended in 10 mL LB and centrifuged again before the washing step 
was repeated to remove any remaining antibiotics. The cell pellet was then re-suspended in 
the residual LB to give a total volume of 1 mL. 
A volume of 10 μl Streptomyces spore stock was added to 500 μl 2xYT media and the cells 
heat-shocked at 50 °C for ten minutes before being mixed with 500 μl of the prepared 
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ET12567 cells. This mixture was then serially diluted and the two strains were grown 
overnight together on SFM media on four different plates containing dilutions of between 10-1 
and 10-4. The next morning the plates were overlaid with nalidixic acid to kill the E. coli and 
apramycin or hygromycin to select for Streptomyces colonies contain the luciferase constructs 
or pCC4 vectors. This was then left to grow for three to four days, when single colonies could 
be collected and used to inoculate fresh plates. 
Intergeneric conjugation into S. albus required a lower heat shock temperature of 40 °C 
compared to the 50 °C specified in Practical Streptomyces genetics (51) and used for S. 
coelicolor. Heat shocked cells S. albus were then kept at 30 °C for four hours before being 
combined with ET12567 strains containing pUZ8002. 
Spore Stock Production 
To produce spore stocks of Streptomyces, four or five SFM plates with appropriate antibiotics 
were inoculated with a lawn of Streptomyces. After incubating at 30 °C for five days, around 
3 mL sterile water was added to each plate. A sterile wedge shaped spreader was used to free 
the spores and create a suspension, which was then collected. The suspension was filtered 
through sterile non-adsorbent cotton wool to remove any agarose that had been picked up. 
The suspensions were then centrifuged at 4000 rpm for five minutes to pellet the spores. The 
supernatant was removed and the cells re-suspended in approximately 1 mL of sterile 50% 
glycerol before being stored at -80 °C.  
 
Genomic Extraction of Genomic DNA from Streptomyces 
Genomic DNA extraction from Streptomyces was performed using the FastDNA Spin Kit for 
Soil from MP Biomedicals.(111) The protocol was followed exactly according to the kit. 
Genomic DNA from Streptomyces could then be screened using the same protocols as were 
just described for E. coli in Section 2.3.5 to check for the insertion of the desired genetic 
material. 
2.3.8 Measurement of Bioluminescence 
Luminescence was measured using a Photek - CCD (charge coupled device) camera. Photons 
hit the silicon surface of the CCD chip and an electron is liberated. This then creates an 
electron deficient site or ‘hole’. These charges are then stored until a voltage is applied and 
the collected charges can be shifted along, measured and converted into a digital copy of the 
light patterns. This provides both quantitative results of the amount of luminescence produced 
as well as a colour code image representing the amounts of luminescence produced by 
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different samples. The CCD used in this project is a HRPCS (high resolution photon counting 
system) and is so sensitive that it can measure single photons. 
The protocol for preparing cells for measuring bioluminescence was developed as part of the 
experimental investigation and can be found in Chapter 3. 
2.3.9 Site Directed Mutagenesis 
Mutants were created using the Agilent QuikChange Lightening kit.(109) The protocol was 
followed as specified in the manual and primers were designed using the online Agilent 
facility.(127) Screening was carried out with standard T7 primers. 
As a template for the mutagenesis the vector pET151:mmfR was used. The small size of this 
vector made the PCR aspect of the Agilent protocol easier to carry out than the pKMS01 
vector also trialled. Mutant mmfR sequences were then cloned via PCR and inserted into the 
pCC4 vector. This was done according to the restriction digest sub-cloning protocol described 
in Section 2.3.2. 
2.3.10 Bacterial Cultures for Protein Purification 
Liquid Culture 
Unless otherwise stated, liquid cultures of S. coelicolor strains containing the gbnB analogue 
were grown in baffled flasks with 2xYT media containing appropriate antibiotics at 30 °C in a 
shaking incubator at 200 rpm. Unless otherwise specified, these cultures were grown for 72 
hours before the secreted proteins were harvested. 
Solid Culture 
Strains were grown on SFM (soya flour mannitol) media at 30 °C with appropriate 
antibiotics, on top of a layer of sterile dialysis tubing to make collection of secreted proteins 
easier. Nutrients and other small molecules should be able to pass through the tubing but not 
any proteins secreted by the Streptomyces. The dialysis tubing was cut into appropriately 
sized pieces and autoclaved in a glass petri dish between layers of filter paper to stop it from 
sticking to itself. 
In later stages of protocol optimisation, plates also contained a final concentration of 1 mM 
EDTA to inhibit metalloproteases and were overlaid with the Sigma Aldrich Protease 
Inhibitor Cocktail for Tissue Culture after 24 hours growth (final concentration 1:500). For 
further details on the development of this protocol see Section 7.4. 
Unless otherwise specified, these cultures were grown for 72 hours before the secreted 
proteins were harvested. 
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2.3.11 Collection and Purification of Secreted Proteins from 
Culture Media 
Harvesting Secreted Proteins 
To harvest the secreted proteins from liquid media, cultures were spun down and the 
supernatant collected before being passed through a 0.22 µm filter to remove any residual cell 
mass. The supernatant was then concentrated using an Amicon Ultra 15 centrifugal filter unit 
with a molecular weight cut off of 10 kDa. Protein concentration was measured via a 
Bradford protein assay to establish when the samples had been concentrated enough. 
To harvest secreted proteins from the solid media, a cell scraper was used to detach cells from 
the dialysis tubing. The cell mass was then re-suspended in one of the protein purification 
buffers specified in Section 2.2.4 before being centrifuged and passed through an 0.22 µm 
filter to remove the cell mass. The volume of buffer used for re-suspension was kept very low 
meaning that further concentration of samples was not needed. 
Concentrated protein samples collected could then be run directly on an SDS-PAGE gel or 
carried forward for further purification using nickel Sepharose or were collected via 
precipitation with lithium chloride and trichloroacetic acid.  
Nickel Sepharose Purification 
The protein of interest was designed with an N-terminal polyhistidine-tag and therefore was 
purified via nickel Sepharose purification using GE Healthcare Ni Sepharose 6 Fast Flow. 
The Sepharose was washed according to the bench top protocol specified by GE healthcare1 
using the buffers specified in Section 2.2.4. (Initially the ‘protein purification buffer’ and later 
the corresponding ‘elution buffer’ were used and then after optimisation of the protocol, the 
‘optimised’ buffers were used, see Chapter 7.) 
After the washing of the Sepharose slurry however, the GE healthcare specified protocol was 
not followed for the remainder of the purification. The method being used for overexpression 
was novel and therefore required a lot of optimisation and produced huge numbers of samples 
to be processed. To save both time and resources a packing column was not used, instead, as 
with the initial Sepharose washing steps, the protocol was continued in microcentrifuge tubes 
with the supernatants being collected after elution steps, as is described now. 
Secreted protein samples were added to the Sepharose slurry and incubated at 4 °C for an 
hour to allow binding of the protein to the nickel. This mix was then spun down in a 
microcentrifuge at the highest speed for three minutes and the supernatant collected and 
                                                      
1 https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/131474296
7685/litdoc11002497AB_20110831013915.pdf 
Chapter 2 | Materials and Methods 
 43 
labelled as ‘unbound proteins’. The pellet was then washed once with 1 mL of the ‘protein 
purification buffer’, centrifuged and the supernatant collected as ‘unbound proteins wash’. 
This was followed by 500 µL elution buffer (containing imidazole) being added to the pellet, 
after centrifugation the supernatant collected was labelled as ‘elution’. The pellet was then 
washed twice with ‘protein purification buffer’ (containing no imidazole) and the 
supernatants collected were labelled as ‘wash 1’ and ‘wash 2’. The unbound proteins and 
elution fractions were then concentrated using an Amicon ultra 0.5 centrifugal filter unit with 
a 10 kDa molecular weight cut off before analysis by SDS-PAGE. 
This analysis was done as a proof of concept investigation into optimal conditions for protein 
over production in Streptomyces species. For a higher level of purity to achieve a single band 
on an SDS-PAGE gel and potentially obtain useable proteins, a more thorough purification 
protocol could be used, for example FPLC (fast protein liquid chromatography). 
Precipitation of Proteins from Solid Culture 
Proteins secreted by S. coelicolor growing on solid media could be purified by precipitation 
with lithium chloride and trichloroacetic acid according to a protocol taken from the 2006 
paper by Widdick et al.(128) 
A lawn of the Streptomyces strain of interest was grown on an SFM plate on top of a layer of 
sterile dialysis tubing for 72 hours. A cell scraper was used to collect the biomass from these 
plates and this was then dispersed in around 3 mL 5 M lithium chloride solution and left on 
ice for thirty minutes. Samples were then vortexed for two minutes and centrifuged at the 
highest speed in a microcentrifuge for five minutes before being passed through a 0.22 µm 
filter to remove the biomass. The secreted proteins should remain in the lithium chloride 
solution. Trichloroacetic acid was then added to the solution to a final concentration of 20% 
before the solution was again incubated on ice for thirty minutes before being centrifuged at 
the highest speed for 15 minutes. Two phases were formed, the proteins being in the lower 
phase. The upper phase was removed and water added to an equivalent volume. At this point 
the sample then turns cloudy as the proteins precipitate. The sample was then centrifuged for 
15 minutes at the highest speed to pellet the precipitated proteins. The pellet was then washed 
two or three times with -20 °C acetone (taking care not to disturb the precipitate too much). 
Samples were then air dried before being re-suspended directly into 2x SDS-PAGE loading 
buffer and checked via SDS-PAGE. 
Cell Lysis for Protein Analysis 
The expression system used in this investigation was designed so that the protein of interest 
should be secreted from Streptomyces. However, it was necessary to check inside the cells to 
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make sure that the export tag being used was indeed working. The Streptomyces cells were 
lysed using ‘lysis matrix E’, a component usually provided with the MP Biomedicals’ 
FastDNA spin kit. This matrix contains ceramic and silica spheres as well as a large glass 
bead to allow the mechanical shearing of cells. 
The pelleted Streptomyces cell mass collected from the solid cultures grown on dialysis 
tubing were added to a 2 mL lysing matrix tube followed by 1 mL sodium phosphate buffer 
with SIGMAFAST™ protease inhibitor cocktail (as described in Section 2.2.4). After 
vortexing for two minutes the suspension was allowed to settle before the supernatant was 
collected. The supernatant was then added to the nickel Sepharose, as described before, to 
check for the presence of any intraceullular histidine-tagged protein. 
2.3.12 SDS-PAGE 
All SDS-PAGE cells were run using a 12% resolving gel with a 4% stacking gel using the 
mixtures specified in Section 2.2.5. The 12% gel was allowed to set for 30 minutes before the 
4% gel was added on top. 
Collected protein samples were mixed 1:1 with 2X SDS-PAGE loading dye and boiled for 
five minutes before being allowed to cool. Between 10 and 20 µL stained protein sample was 
the loaded per gel and run at 180 V for five minutes and then 200 V for 35-40 minutes before 
being stained for one hour with InstantBlue™ Coomassie® stain and then washed with 
distilled water. 
2.3.13 SDS-PAGE Gel Extraction Protocol for Mass 
Spectrometry Analysis 
Proteins were extracted from SDS-PAGE gels for LC-MS analysis over two days using a 
protocol supplied by Dr Cleidiane Zampronio from the Proteomics Facility at the University 
of Warwick. 
First bands of interest were cut out of the SDS-PAGE gel using a clean razor blade and placed 
in a microcentrifuge tube before being cut into four or five smaller pieces to increase the 
surface area of the slice. These gel pieces were then washed using 150 µL 50% ethanol in 50 
mM ammonium bicarbonate and incubated at 55 °C for 20 minutes shaking. The supernatant 
was then pipetted off and the wash repeated until the gel was de-stained (usually one or two 
more times). 
The gel pieces were then be dehydrated by adding 100 µL pure ethanol and incubating for 
five minutes at 55 °C shaking. This produced a shrunken, white gel. The ethanol was then 
removed and disulphide bonds reduced by adding 100 µL 10 mM DTT in 50 mM ammonium 
bicarbonate and incubating for the samples 30 minutes at 56 ºC shaking. The free liquid was 
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then removed and samples allowed to cool before 100 µL 55 mM iodoacetamide (IAA) in 50 
mM ammonium bicarbonate was added. The IAA alkylates the cysteine residues in the 
protein. After the IAA was added samples were incubated for 20 minutes at room temperature 
while being kept in the dark. The free liquid was then removed and disposed of. 
The wash steps with 50% ethanol in 50 mM ammonium bicarbonate were then repeated, 
followed by dehydration in pure ethanol. A tryptic digest of samples was then carried out by 
adding 40 µL 2.5 ng/µL trypsin in 50 mM ammonium bicarbonate. After allowing the gel to 
rehydrate for ten minutes, and additional 15 µL 50 mM ammonium bicarbonate was added to 
make sure the gel was well covered and samples incubated overnight at 37 ºC with shaking. 
The next morning the tryptic digest was stopped by adding 100 µL 5% formic acid in 25% 
acetonitrile and sonicating samples for five to ten minutes. The supernatant was then collected 
and this formic acid-acetonitrile step repeated three more times, each time collecting the 
supernatant in the same microcentrifuge tube. The combined peptide supernatants were then 
dried in a Speed-Vac at 40 °C for four hours before freezing, ready for LC-MS analysis. 
The actual LC-MS analysis was then carried out by the Proteomics Facility, according to their 
standard protocols. 
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3 Development of Luciferase Reporter Gene 
Constructs 
3.1 Aims and Strategy of Investigation 
3.1.1 Reporter Genes 
Figure 3.1 shows a schematic of a general reporter gene system that can be used in vivo to 
study transcriptional regulation. Here, a regulatory sequence of interest is put upstream of a 
reporter gene instead of its usual cognate gene. This regulatory sequence can contain -35 and 
-10 promoter sequences as well as operators for transcription factors. The reporter gene is 
designed to produce a protein that results in a measureable result, for example a coloured 
product or a fluorescent/bioluminescent product. The amount of reporter produced should be 
proportional to promoter strength and be regulated by any control mechanisms present that 
normally influence the regulatory sequence in the wild type system. Thus, the production of 
the reporter protein should be representative of the expression of the wild type gene cognate 
to the regulatory sequence. Repressor proteins as well as their ligand inducers can also be 
added to the system and changes in the production of the reporter protein observed. 
 
Figure 3.1. Schematic of reporter gene systems and how they can be used to study 
transcriptional repressors and their cognate inducer ligands 
 
With the eventual aim of developing a novel inducible expression system, this investigation 
utilised a Photorhabdus luminescens luciferase reporter gene assay to produce a measurable 
bioluminescent product under the control of the methylenomycin BGC regulatory system. 
This luxCDABE system was recently optimised to be expressed in GC high streptomycetes by 
Justin Nodwell and this research group.(92) 
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3.1.2 Regulatory System of Interest – The Methylenomycin 
Biosynthetic Gene Cluster 
As discussed in the introduction, methylenomycin biosynthesis is tightly regulated by a 
number of different mechanisms including the use of a rare TTA codon, transcriptional 
repressors, transcriptional activators as well as the use of microbial hormones.(71)  
The entire methylenomycin cluster is found on a 19 kb region the S. coelicolor SCP1 
plasmid.(65) The arrangement of the five operons in this cluster and how they are thought to 
be regulated by transcriptional repressor MmfR and its cognate ligands, the MMFs, is shown 
in Figure 3.2. In this figure, operons and the direction of transcription is indicated by the red 
arrows and intergenic regions with MmfR-binding MARE operator sites are signified by 
vertical black lines. These are found between mmfR and mmfL, mmyR and mmfP, and mmyY 
and mmyB. This figure shows the influence of the presence and absence of the 
methylenomycin furans on the auto-regulation of this cluster as well as the influence over 
expression of other biosynthetic genes.(71) In the absence of MMF microbial hormones 
(shown in the blue section at the bottom of the figure), MmfR binds to DNA at the MARE 
operator, repressing transcription. Upon MMF binding (in the peach section at the top) there 
is a conformational change to MmfR, it is released from the DNA and transcription begins at 
the five operons. Replacing any one of the five operons with a reporter gene would allow the 
study of the regulation of that particular operon. (Please note that the diagram in Figure 3.2 is 
not to scale.) 
 
Figure 3.2. Proposed regulation of the methylenomycin biosynthetic gene cluster from 
the SCP1 plasmid of S. coelicolor by the TetR family member, MmfR and cognate MMF 
ligands 
Horizontal blue lines indicate the location of proposed MmfR binding operator sites with the 
vertical black lines represent where the MARE operators can be found. Red arrows indicate 
the operons regulated by these operators and the direction of transcription. Proposed 
functional attributions are mmfR and mmyR – transcriptional repressors, mmfLHP – 
methylenomycin furan biosynthetic genes, mmyT and mmyQ – methylenomycin biosynthetic 
genes, mmyB – transcriptional activator, based on the work of Chater and Bruton (65) 
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The biological function of the MmfR paralogue, MmyR is much less clear than that of MmfR 
and it is not know whether it will bind to any of the MARE operator sites or the MMFs. 
Although there is limited evidence that it would be a suitable choice for a repressor in an 
inducible expression system, understanding the role of this second repressor is also important 
in further interpreting the regulation of the methylenomycin biosynthetic cluster. For this 
reason, MmyR was also under investigation in this research, secondary to the work done with 
MmfR. 
 
The development of a bio-luminescing reporter gene assay involved the design of two 
separate vectors in a strategy that will now be described. One of these vectors contained the 
luxCDABE operon under the regulation of one of the three MARE operator containing 
intergenic regulatory sequences (indicated by vertical black lines in Figure 3.2). A second 
vector contained mmfR (or mmyR) under the regulation of ermEp*. 
 
Strategy for Luciferase Reporter Gene Assay 
Figure 3.3 shows a schematic of how the two vectors types just described should come 
together to form the reporter assay in S. coelicolor M145 for studying MmfR. Both vectors 
will integrate in different positions on the S. coelicolor genome and are replicated along with 
the rest of the genome as the cell replicates. 
The expression of luxCDABE is under the control of one of the promoters from the 
methylenomycin gene cluster (see Figure 3.6 for a diagram showing the positions of these 
promoters) as well as predicted regulation by MmfR repression at the MARE operator.  
As shown in Figure 3.3, in the absence of the MMFs, MmfR are predicted to be produced and 
bind on to the MARE operator, thereby repressing the expression of the lux genes. If one of 
the five MMFs are then added to the system they are expected to bind to MmfR and cause a 
conformational change, releasing it from the MARE operator and allowing the expression of 
the lux genes. Depending on the strength of binding of MmfR to the different MARE 
operators and level of release by the MMFs, different levels of luminescence could be 
expected. Data collected can then be compared to positive and negative controls and 
inferences made (see Figure 3.1). 
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Figure 3.3. Schematic of lux reporter system in Streptomyces coelicolor M145 
Two vectors are integrated into the Streptomyces genome; one containing mmfR (or an empty pCC4 
control vector) under the control of the ermEp* promoter and the other containing luxCDABE under 
the control of one of five relevant methylenomycin cluster promoters and one of three MARE operator 
sequences. In the absence of the furan ligands, MmfR will bind to the MARE operator and repress the 
expression of luxCDABE. Upon the addition of one of the methylenomycin furans (MMFs) there will 
be a conformational change in MmfR and it will be released from the MARE operator resulting in the 
production of luminescence via luxCDABE expression, producing luciferase and its substrate. 
 
For the investigation of MmyR, a similar system to that shown in Figure 3.3 was used, only 
with pKMS03 (containing mmyR) used instead of pKMS01 (containing mmfR) (see Table 
2.5). The outcome of the presence of different MARE operators and MMFs in this mmyR 
system was not known before studies began. 
Details on luxCDABE 
LuxA and LuxB together form the heterodimeric luciferase protein. LuxC, D and E are the 
enzymes needed to form tetradecanal, the fatty aldehyde substrate of luciferase.(97) All other 
biochemicals required by this reaction are found naturally in bacterial cells allowing a self 
generated bioluminescent response with no need for external manipulations.(98) Expression 
of the pentacistronic luxCDABE operon results in a blue-green light being emitted at 490 
nm.(129) 
 
3.2 Plasmid Design and Assembly 
3.2.1 Luciferase Vectors 
Figure 3.4 shows a diagram of a vector with a MARE operator containing intergenic sequence 
(Figure 3.2) inserted upstream of a 5668 bp optimised luxCDABE luciferase reporter gene 
Chapter 3 | Development of Luciferase Reporter Gene Constructs 
 50 
cluster.(92) The particular vector shown in Figure 3.4 is labelled as ‘L1’ and has the lux genes 
under the control of mmfLp, this was constructed by Professor Nodwell’s group in Canada 
and is an updated version of the pMU1 plasmid.(92) It contains the entire intergenic region 
from between mmfR and mmfL (labelled in the diagram as the ‘mmfLR regulatory sequence’). 
This plasmid formed the backbone for a number of other vectors produced during this project, 
with different intergenic regions being inserted next to the lux operon using the EcoRV and 
BamHI restriction sites shown in the figure.  
 
 
Figure 3.4. L1, an integrating luxCDABE reporter plasmid 
tfd – transcriptional terminator from phage fd, ori – origin of replication, AprR – apramycin 
resistance cassette, oriT – origin of transfer, int and attp – integrase and attachment site of 
ΦBT1 phage, allows integration via site specific recombination to matching attB site in the S. 
coelicolor genome, mmfLR regulatory sequence – intergenic region from between mmfR 
and mmfL, containing the ‘L1 MARE operator’ and in the direction of mmfLp, luxCDABE – 
genes for luciferase and the biosynthesis of its substrate.(92) Upstream of the mmfLR 
regulatory sequence is a RBS as well as a STOP sequence containing stop codons covering 
all three reading frames. 
Please note that the close up version of the insert between EcoRV and BamHI 
restriction sites is not to scale and is purely a representation of the layout of the vector. 
This vector was created by Justin Nodwell et al., optimised from work in (92). 
 
Dependent on the orientation of the three intergenic regions inserted between the EcoRV and 
BamHI restriction sites, the regulation of the five different operons (shown in Figure 3.2) 
could be studied. This created a total of five different lux plasmids, labelled as L1, L1F, L2, 
L3 and L3F. A schematic showing the designation of this nomenclature can be found in 
Figure 3.5. This nomenclature is now used throughout the rest of the project. 
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Figure 3.5. Assigned nomenclature for lux vectors containing different intergenic 
regions from the methylenomycin gene cluster, cloned upstream of luxCDABE 
Vertical blue lines indicate the location of proposed MmfR binding operator sites and black 
arrows denote the direction of transcription for each promoter. ‘F’ indicates the reverse 
sequence of a particular intergenic region. This diagram is to scale and based on individual 
gene sizes. 
Proposed functional attributions are mmfR and mmyR – transcriptional repressors, 
mmfLHP – methylenomycin furan biosynthetic genes, mmyT and mmyQ – methylenomycin 
biosynthetic genes, mmyB – transcriptional activator, based on the work of Chater and 
Bruton (65) 
 
In this nomenclature, ‘F’ indicates the same intergenic region that has been inverted and 
inserted back into the vector. For example, the intergenic region containing within L1F is the 
exact reverse sequence of that contained in the L1 vector. MmfR is homodimeric and so 
affinity in either orientation would be expected to be unchanged as the 24 bp MARE operator 
is the same in either orientation (see Figure 3.6B for sequences).(84) However, the orientation 
of the insert may result in promoters of different strengths being used. Figure 3.6A shows the 
predicted positions of the -35/-10 promoter sequences found in each methylenomycin cluster 
intergenic region. In one orientation, only one of the promoters should drive the expression of 
the lux genes.  
No L2F was created as there is only one promoter to study in the L2 intergenic region and so 
a reverse was not necessary for the study of promoter strength. If extra time had allowed 
however, a L2F vector could have been constructed and used as an extra negative control. 
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Figure 3.6A and B. Details on the methylenomycin cluster MARE operators 
A. Schematic of predicted MARE operator position with respect to the promoters they 
regulate in the intergenic regions of the methylenomycin biosynthetic cluster 
MmfR is predicted to bind three different MARE operators, thereby regulating five 
different operons by repressing five promoters. 
Please note that this diagram is not to scale. 
B. Predicted MARE operator sequences 
The MmfR-binding MARE operators are partially palindromic 24 bp sequences and 
display a motif found across a number of streptomycetes. The sequences shown here 
correspond to the operators in the adjacent schematics in A. 
Adapted from the work of Vincent Poon (84) 
 
The luciferase vectors were transferred into S. coelicolor via intergeneric conjugation 
(Section 2.3.7) where upon they stably integrate into a single place the Streptomyces 
coelicolor genome via the φBT1 phage system. This system is based on how bacteriophages 
integration into specific sites of the host genomes via site specific recombination using an 
integrase. The phage contains an attP site (Figure 3.4,) that matches an ‘attB’ site in the target 
host where it will integrate and establish a lysogenic state.(130) 
In the absence of MmfR, these lux vectors should work as a positive control. Constitutively 
luminescing, proportional to the strength of the promoter being analysed in that particular 
vector. A schematic of this type of positive control can be found in Figure 3.1. 
MmfR and MmyR were added to the reporter system on a different vector, described next. 
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3.2.2 Vectors Containing mmfR or mmyR  
The second type of vector used in this assay was based on pCC4 plasmids, containing the 
gene for transcriptional repressor MmfR or its paralogue MmyR. A schematic of the mmfR 
vector (pKMS01) can be found in Figure 3.7, showing the HindIII and NotI restriction sites 
used to insert this repressor gene into the pCC4 vector. The mmyR vector (pKMS03) was 
constructed in an analogous way, only with mmyR inserted instead of mmfR and using HindIII 
and StuI restriction sites instead of HindIII and NotI (see Table 2.10). 
Figure 3.7. pKMS01, an integrating plasmid with mmfR controlled by ermEp* (72) 
ori – origin of replication, int_pSAM2 – integrase site, hygR – hygromycin resistance, MmfR – TetR 
family transcriptional repressor gene, ermEp* – strong constitutive promoter, oriT – origin of transfer 
AprR – apramycin resistance. 
 
It was decided that MmfR production should be under the control of ermEp*,(131) a strong 
constitutive promoter unrelated to the methylenomycin cluster, rather than its own promoter. 
This should mean that MmfR will be produced at a constant rate, unaffected by its own self-
regulatory action (see Figure 3.2). The alternative, self-regulation of MmfR, would mean that 
under the control of mmfRp and the MARE operators MmfR would repress its own 
production. The levels of this repressor would be influenced by the concentration of MMF 
present, making luminescence readings hard to interpret (see Chapter 6 for more information 
on this topic). 
The self-regulation of MmyR is not known but this was also placed under the control of 
ermEp* to ensure consistency. 
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The pCC4 vectors are again transferred to Streptomyces via intergeneric conjugation where 
they integrate into the genome. This integration happens using a similar system to the 
attP/attB one from the luciferase vectors but plasmids integrate at a different position in the S. 
coelicolor genome. This pSAM2 system is not phage derived but comes from an 11 kb 
integrative element from Streptomyces ambofaciens.(120) This type of mobile genetic 
element is only thought to be found in Streptomyces but has been shown to work in a similar 
way to the temperate phage systems.(132) 
The construction of the pKMS01 and 03 vectors allowed the study of MmfR and MmyR 
binding to the three MARE operator sites as well as any release of the repressor upon MMF 
binding (see Figure 3.1 and Figure 3.3). 
3.3 Initial Investigation of the Reporter System 
3.3.1 Details on the Bioluminescence Assay 
Once the two vector types just described were integrated into the S. coelicolor genome and 
had been screened via PCR for successful conjugation, the levels of luminescence produced 
by different promoters and MmfR binding at the MARE operator and to the MMFs could then 
be studied. As this system had not been used before, optimisation of methods was required 
before a full investigation could take place. 
Preliminary tests with a limited number of repeats were done to optimise the luminescence 
assay and find the best ways of measuring light production before a complete data set with 
multiple readings was taken. This saved resources such as the synthetic MMFs which are not 
available commercially. A number of factors needed to be determined from optimisation 
trials, such as time points when readings were to be taken, the optimal concentration of MMF 
inducer molecule and when in the assay the inducer molecule should be added. The MmfR 
system was used to optimise the assay protocol as there was a clearer understanding of the 
type of results expected compared to MmyR. Once the methodology was optimised it could 
then be applied to the study of MmyR. 
Luminescence was measured using a Photek CCD camera and the associated software (see 
Methods section for details on this technique). S. coelicolor does not grow uniformly in liquid 
culture, they form large clumps of cells and will not sporulate and do not complete their full 
life cycle. An advantage of this luciferase system and the CCD camera was not only that it is 
highly sensitive but also that it could be used to take measurements from solid cultures, which 
should be more representative of transcriptional regulation in the wild type system and how it 
alters over the complex life cycle of S. coelicolor. 
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A lawn of Streptomyces was grown on selective SFM media for four to five days at 30°C. 
This formed a fresh starter culture for the rest of the study. A sterile loop was then used to 
inoculate the wells of a 12-well plate, each well containing 2.5 mL SFM media. Picking cells 
fresh from a selective SFM plate ensured that they would be luminescing optimally.1 
Different sample types were spread randomly across multiple plates. The Photek CCD camera 
took a more sensitive reading from the centre of its ‘view’ and so by rotating the way samples 
were spread out, anomalies or bias were avoided. Having this random spacing of samples also 
avoided any bias potentially caused by increased drying of samples in outer wells or a lack of 
oxygen to wells in the centre of the plate. 
3.3.2 Preliminary Observations 
Figure 3.8 shows an example of the type of readings taken using the Photek CCD camera. 
The strains used in this figure include M145 (negative control), L1+pCC4 (positive control 
with no repressor, labelled as ‘L1’ in Figure 3.8), L1+mmfR (labelled as ‘mmfR’) and 
L1+mmyR (labelled as ‘mmyR’). These were not grown in twelve well plates this one time for 
the sake of making this figure easy to read and label. For more details on the vectors in these 
strains please see Table 2.5 and Table 2.8. 
Figure 3.8A shows how the strains look when grown on solid culture and the corresponding 
image when being measured by the CCD camera for thirty seconds is shown in Figure 3.8B. 
Figure 3.8C shows schematics of all the vectors used in the strains included in this figure. It 
can be seen that the luciferase assay in Streptomyces strains produces very clear levels of 
luminescence, easily detectable and measurable within a thirty second reading.  
                                                      
1 Preliminary studies performed in this investigation showed that freezing samples and using 
glycerol stocks directly could compromise the amount of luminescence produced. 
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Figure 3.8A-C. Details on and visual representations of strains containing the lux genes 
under the control of mmfLp  
Assigned nomenclature = M145 – S. coelicolor M145 negative control with no luciferase 
genes, L1 – positive control with luxCDABE under the control of mmfLp and the empty pCC4 
vector, mmfR – strain containing L1 and pKMS01, mmyR – strain containing L1 and pKMS03 
A. Strains growing on SFM media 
B. Luminescence seen in the Photek CCD camera during a thirty second reading by 
strains shown in A. 
C. Schematic representation of reporter plasmids used 
 
As an initial observation from Figure 3.8, it appears that MmfR is a much better repressor 
than its paralogue MmyR, preventing lux expression a lot more efficiently (shown by the 
lower level of luminescence produced by the L1+mmfR strain versus the L1+mmyR strain). 
This was surprising as previous investigations by Sean O’Rourke et al. revealed that a mmyR 
knockout produces the phenotype of methylenomycin overexpression whereas a mmfR 
knockout does not.(71) Possible reasons for this inconsistency were further investigated and 
will be discussed further later in the report. Also of note, neither MmfR or MmyR appear to 
cause full repression of luxCDABE with both allowing some leaky expression, a detail also 
discussed later. As expected, the M145 negative control parent strain does not produce any 
measurable background luminescence whereas the positive control L1+pCC4 produced the 
greatest level of luminescence of the four strains. 
3.3.3 Timing of Measurements 
Streptomyces are slow growing bacteria, usually taking four to five days at 30 °C to get a 
lawn of bacteria on culture media. This is due to their complex mycelial lifecycle, which 
shows a number of similarities to the sporogenic fungi life cycle. A number of different time 
points were therefore trialled for measuring luminescence in this assay. 
Figure 3.9 shows the readings collected daily over 16 days for the M145 and L1+pCC4 
strains. These readings were taken to check when was best to measure luminescence. Here, 
and in all later trials, 0 hours refers to the time when plates have been inoculated and first 
placed in the incubator.  
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Figure 3.9. Changes in levels of luminescence over 16 days where luxCDABE is under 
the control of mmfLp, compared to a negative control 
The level of luminescence was calculated as a ratio of luminescence for L1+pCC4 compared 
to the negative M145 control strain (wild type S. coelicolor without SCP1 or SCP2). 
 
As can be seen in Figure 3.9, there appears to be a rapid change in the amount of 
luminescence at around the 24-hour time point and this would then continue to increase over 
the next few days. After around day three there would still be measureable luminescence but 
it appeared to fluctuate a lot, likely to be due to the bacteria entering different stages in the 
cell cycle. By two weeks of growth there was still detectable luminescence but the SFM 
media in the 12-well plate had started to dry out and crack therefore making the results hard 
to compare with the initial readings. 
Due to these findings, more time points were trialled around 24-72 hours including 
measurements being taken at 0.5, 4, 13.5, 16, 17, 18, 19, 20, 21, 22, 24, 38, 40, 48, 65 and 72 
hours. Readings from some of these investigations are shown later in Figure 3.10, Figure 3.12 
and Figure 3.13. Based on all of these experiments, measurements at time points of 21, 24, 
27, 48 and 72 hours were chosen for later tests. This allowed readings to be taken within the 
area of peak luminescent activity without having to take samples in and out of the incubator 
too often, risking both contamination and the effects of the decrease to room temperature in 
the Photek CCD camera.1 
3.3.4 Investigating How and When to Add the MMFs 
Tests were run to establish the effect of adding the MMFs L1+mmfR strains at different time 
points and using different protocols. The results from one of these trials are shown in Figure 
                                                      
1 The Photek CCD camera was used at room temperature as there was no heating option with 
the equipment. Readings would be taken as quickly as possible, minimizing the effects of this 
temperature change. 
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3.10. For this figure, trials were run where MMFs were added at the beginning of 
Streptomyces growth (0 hours) either on top of the media or to the molten media before it had 
set or where the MMFs were overlaid at 24 hours, after a lawn had started to grow. This was 
then compared to luminescence produced by a M145 negative control strain and the relative 
ratio of luminescence calculated. 
 
Figure 3.10. Changes in luminescence produced by the lux operon under the control of 
mmfLp and MmfR by adding 400 nM MMF4 at different time points  
The level of luminescence was calculated as a ratio of luminescence produced by the M145 
negative control strain. MMF4 added at 0hr and 24hr was overlaid on top of the SFM plate. 
Strains: L1+mmfR – luxCDABE under the control of mmfLp (L1 vector) and mmfR under 
the control of ermEp* (pKMS01 vector). 
 
As an initial observation, MmfR repression of the lux genes does indeed appear to be 
removed to some extent by the addition of MMF4. It was found that adding the MMFs at 24 
hours growth would disrupt the surface of the lawn of growing colonies. This disruption was 
enough to reduce the levels of luminescence produced. It would then take a few days for the 
luminescence levels (and cell growth) to recover to their previous level.  Figure 3.10 shows 
that luminescence for the strain where MMF4 was added at 24 hours is in fact lower than the 
non-induced L1+mmfR strain for the next five days until it recovers and increases again. 
Mixing the MMF with the SFM media appeared to produce very similar levels of 
luminescence to the L1+mmfR strain with no MMF, indicating that the furans might not 
diffuse through the SFM efficiently enough or that they were affected by the temperature of 
the molten SFM before it had set. (The SFM used had a pH of 7, previous investigations have 
indicated that the MMFs may diffuse better at around pH 5.)(14) Overlaying the hardened 
SFM with MMF4 at 0 hours shows a distinct peak in luminescence straight away. For these 
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reasons, it appeared best to add the MMFs on top of the media at ‘time 0’, when the plates are 
also being inoculated with Streptomyces. 
It is important to note that the concentration of MMF4 in these trials was only 400 nM. 
Although this produced detectable amounts of luminescence, future trials often used ten times 
this concentration of MMF to get a more distinct result. Also, the results from Figure 3.10 are 
taken over ten days, as discussed in Section 3.3.3 these later time points were not used in later 
investigations due to the plates drying out and the media cracking. 
 
3.3.5 Release of MmfR by Different Small Molecules 
To assess whether MmfR was released from the MARE operator by the different MMFs, 
MMF2, 4 and 5 were added to the L1+mmfR strain. Levels of luminescence were then 
compared to a negative control of the same strain with no MMFs as well as an L1+pCC4 
positive control  (representing how the system looks with no repression). 
Data was also collected for two other small molecules; molecule 70 and SCB1. Molecule 70 
is a synthetic analogue from the work of Nicolas Malet that has the same core structure as the 
MMFs but lacks the alkyl chain, which has been shown to be necessary for fitting the binding 
pocket.(55) SCB1 is a S. coelicolor butyrolactone signalling molecule, known to bind to the 
TetR family member ScbR. Neither of these analogues were expected to bind MmfR and so 
function as another negative control for this study. The chemical structures of these negative 
controls along with MMF2, 4 and 5 can be found in Figure 3.11. Luminescence results from 
these studies can be found in Figure 3.12. 
 
Figure 3.11. Chemical structures of MMF2, 4 and 5 and SCB1 from S. coelicolor and 
synthetic molecule 70 
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Figure 3.12. Changes in luminescence produced by the lux operon under the control of 
mmfLp and MmfR in the presence 100 µM of different microbial hormones 
Strains used: L1 – positive control, luxCDABE under the control of mmfLp and empty pCC4 
vector with no repressor, L1+mmfR –luxCDABE under the control of mmfLp (L1 vector) 
and mmfR under the separate control of ermEp* (pKMS01 vector). 
The level of luminescence was calculated as a ratio of luminescence produced by L1+mmfR 
with no MMFs present. 
 
In Figure 3.10 there was an observable increase in luminescence by L1+mmfR in the presence 
of 400 nM MMF4 after 48 hours growth. The inducibility of L1+mmfR strains can again be 
seen in Figure 3.12 where there is a clear increase in luminescence produced in the presence 
of 100 µM MMF2, 4 and 5 compared to no MMFs. At this concentration none of the MMFs 
achieve levels of luminescence compared to the L1+pCC4 positive control, indicating that 
higher concentrations could also be trialled. As expected, molecule 70 and SCB1 give levels 
of luminescence very close to those for the negative control (L1+mmfR with no small 
molecule added). 
Effect of the MMFs on a Positive Control 
The five MMFs were also added to the L1+pCC4 positive control strain at a concentration of 
100 µM. Upon a statistical analysis of data (not shown here), no significant difference was 
found in the levels of luminescence produced in the presence of the MMFs compared to the 
absence for this strain. This indicates that the concentrations being used, the MMFs are not 
having a toxic effect of Streptomyces growth or regulating the methylenomycin BGC in other 
ways, independent of MmfR/MmyR. 
Investigating the Release of MmyR by the MMFs 
When equivalent trials were run with L1+mmyR instead of L1+mmfR, there was no 
observable increase in luminescence upon the addition of the MMFs. This and the much 
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lower levels of luminescence repression observed for mmyR strains shown earlier in Figure 
3.8 indicates that MmyR has a very different role to MmfR. This is further discussed later in 
Section 5. 
3.3.6 Optimal Concentration of Inducers 
Following on from Figure 3.12 where it was seen that at 100 µM MMF did not achieve levels 
of luminescence in line with that of the L1+pCC4 positive control, a range of different MMF 
concentrations were trialled to see if full release of MmfR could be attained. Results from 
assays where MMF2 and 5 were added at various concentrations between 0.05 µM and 400 
µM are shown in Figure 3.13A and B.  
Figure 3.13A and B. Luminescence produced by the lux operon under the control of 
mmfLp and MmfR upon the addition of different concentrations of MMF2 and MMF5 
A. Data collected for MMF2 B. Data collected for MMF5 
Strain used: L1+pCC4 – positive control, luxCDABE under the control of mmfLp and empty pCC4 
vector with no repressor, L1+mmfR –luxCDABE under the control of mmfLp (L1 vector) and mmfR 
under the separate control of ermEp* (pKMS01 vector). The level of luminescence in both charts was 
calculated as a ratio of luminescence produced by L1+mmfR with no MMFs present. 
 
Figure 3.13A shows the results from an investigation that used MMF2 at a concentration 
range of 0.5 µM to 10 µM. All of these concentrations produce more luminescence than a 
control without MMFs with up to 3.5 more luminescence being produced for the highest 
concentration compared to no MMFs being present. However, around twice as much as this is 
needed to achieve the same levels of luminescence as the positive control. 
As can be seen in Figure 3.13B, MMF5 was trialled at concentrations between 2 µM and 400 
µM. Concentrations of MMF5 above 200 µM appear to no longer cause an increase in 
bioluminescence, possibly indicating the toxicity of the MMF compounds or a saturation of 
MmfR binding. A concentration of 100 µM was chosen as a standard to use in later 
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investigations as it was a concentration in the middle of those that showed good levels of 
luminescence. 
MMF2 was later trialled at concentrations in the range of 40 µM to 400 µM and MMF4 in the 
range of 2 µM and 400 µM (not shown here) and gave similar data sets to that seen for 
MMF5. 
3.3.7 Summary of Strategy Chosen to Investigate 
MmfR/MMF/MARE Operator Interactions 
In conclusion, the strategy designed to investigate MmfR/MMF/MARE operator interactions 
(Figure 3.3) and the research questions for this project proved to be functional in vivo in 
Streptomyces. The luciferase assay produced easily detectable levels of luminescence for the 
positive control (L1+pCC4) and MmfR repression of luxCDABE appeared to be released by 
the addition of three of the known MMFs at concentrations within the micromolar range. The 
luciferase assay was therefore deemed suitable for use in the remainder of the investigation 
into MmfR (an MmyR) interactions with the MMFs and MARE operators and the findings 
from this chapter formed the basis of much of the rest of the investigative work done in this 
project. 
An optimised protocol was designed using data collected in this chapter, considering the best 
time to add the MMFs, the optimal concentration to use, which time points to take readings at 
as well as how to prepare bacterial cultures for analysis. 
Finalised Bioluminescence Protocol 
The following protocol was used to collect all future bioluminescence data. To each well of a 
12 well plate, 2.5 mL SFM was added and allowed to set. The MMFs were diluted in DMSO 
to an appropriate concentration before being diluted one in ten with water and 10 µL added to 
each well. (A 10% DMSO solution was used instead as a control when no MMFs were 
required, giving a final DMSO concentration of 0.0004%.) To find out the Kd and Bmax for 
each MMF a concentration range of 5 µM to 400 µM was used. For all other tests requiring 
MMFs, a concentration of 100 µM MMF was used as a standard. 
After the MMFs were added, plates were inoculated with the Streptomyces strain of interest 
collected from a fresh starter culture plate and incubated at 30 °C with readings being taken at 
21, 24, 27, 48 and 72 hours using the Photek CCD camera. 
One down side of the luciferase assay was that there were large variations between results 
collected. For this reason, in the future multiple repeats were collected and data was again 
analysed as a ratio relative to a control sample. 
Chapter 3 | Development of Luciferase Reporter Gene Constructs 
 63 
 
3.4 Promoter Strength 
3.4.1 Strategy for Investigating Promoter Strength 
As explained earlier, there are three different MARE operator sites that MmfR is thought to 
bind to, regulating the expression of five different operons by blocking five promoter 
sequences. A diagram of the methylenomycin cluster can be found in Figure 3.5 and Figure 
3.6 with an explanation of the nomenclature used in this investigation. 
Each of the promoters downstream of a MARE operator sequence was tested by cloning 
different intergenic regions and placing them in different orientations upstream of the 
luxCDABE operon, according to the protocol explained in Section 3.2. These vectors were 
then studied in the absence of the transcriptional repressor MmfR or MmyR to investigate the 
strength of the promoter only, creating the L1+pCC4, L1F+pCC4, L2+pCC4, L3+pCC4 and 
L3F+pCC4 strains. No MMFs were added during this investigation and the optimised 
protocol laid out in Section 3.3.7 was used. A schematic of how this assay was set up can be 
found in Figure 3.14 (see also Figure 3.1). In the absence of MmfR/MmyR and the MMFs, 
the lux genes should be constitutively expressed and the bioluminescent output proportional 
to the strength of the promoter in the vector being used. 
 
Figure 3.14. Schematic of luciferase assay used to investigate the strength of promoters 
from the methylenomycin biosynthetic cluster 
To investigate promoter strength, one vector is integrated into the Streptomyces genome; containing 
luxCDABE under the control of one of the five relevant promoters from the methylenomycin cluster. 
No MmfR or MmyR is produced by these strains; instead an empty pCC4 vector is used as a control. 
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3.4.2 Results on Comparison of the Five Methylenomycin Cluster 
Promoter Strengths 
Figure 3.15 shows the levels of luminescence produced over 72 hours by strains containing 
the five different methylenomycin cluster lux vectors. Figure 3.16 is a boxplot of the data 
from Figure 3.15 at the 72 hour time point.1 This box plot includes data from 10-90% 
percentiles and all other results shown as outliers. For both figures, data is normalised against 
luminescence values for the M145 negative control. 
 
Figure 3.15. Luminescence produced by the lux operon when under the control of 
different promoters from the methylenomycin gene cluster 
Data normalised against luminescence values for the M145 negative control. 
Strains used: M145 – negative control strain (wild type S. coelicolor without SCP1 or SCP2), 
all other strains – contain luxCDABE under the control of different promoters from the 
methylenomycin gene cluster  
 
 
 
                                                      
1 This figure also contains results from analysis of ermEp*, detailed later in Section 3.4.3. 
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Figure 3.16. Boxplot of luminescence produced by the lux operon when under the 
control of different promoters, at 72 hours growth 
Data normalised against luminescence values for the M145 negative control. This box plot 
includes data from 10-90% percentiles and all other results are shown as outliers. 
Strains used: M145 – negative control strain (wild type S. coelicolor without SCP1 or SCP2), 
all other strains – contain luxCDABE under the control of different methylenomycin cluster 
promoters 
 
Figure 3.16 suggests the following order in terms of promoter strength; 
mmyRp > mmfRp > mmyYp > mmyBp > mmfLp 
L2 > L1F > L3F > L3 > L1 
Another way of displaying this is; 
TetR > TetR > biosynthetic gene > transcriptional activator > MMF production 
Both mmyRp and mmfRp produce an average of more than 100 times the level of 
luminescence produced by the M145 control whereas mmyYp and mmyBp produce between 
70 and 80 times that of the control. Even the weakest promoter, mmfLp, produced 45 times as 
much luminescence as the M145 control. 
It is also interesting to point out that the three promoters which produced the highest levels of 
luminescence (L1F, L2 and L3F) also show some phenotypical differences from the L3 and 
L1 strains. In particular, the blue pigments normally seen when growing S. coelicolor are 
missing. This indicates the possible toxicity of high levels of luxCDABE expression or just the 
drain on cell resources that such high expression levels produce. The cells do however appear 
to grow at the same rate and still sporulate after three or four days growth and a 16S analysis 
of the DNA (not shown here) did reveal that it was indeed S. coelicolor present rather than a 
contaminant strain. The implications of these observations are therefore unclear. 
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It should be noted that at 48 hours compared to 72 hours, mmyYp and mmyBp will swap 
places in terms of promoter strength (otherwise the order of promoter strength remains the 
same). It is hard therefore to say which is stronger overall; mmyYp or mmyBp. It may be more 
accurate to say; L2 > L1F > L3F ≈ L3 > L1. However, as the L3F strain shows the 
phenotypic differences associated with the stronger promoters and the L3 strain does not, it 
does seem that mmyYp is likely to be slightly stronger than mmyBp. Therefore the order of 
promoter strength displayed previously does seem the most probable. 
The implications of the TetR family repressors; MmfR and MmyR having the strongest 
promoters are unclear. The mmyR gene is known to be expressed after mmfR (71) so possibly 
the high levels of expression are necessary to make enough quickly enough for it to be able to 
carry out its repressive role. In addition, whereas one of each of the MmfLHP enzymes can 
make many MMF molecules, one repressor protein dimer can only bind and block one 
operator site and so many more are needed. A larger number of structural proteins are needed 
than enzymatic ones. 
When analysing this data it is also important to consider that all of the lux constructs used 
here have relied on the same RBS1 for controlling translation of the lux genes. These results 
therefore show the relative amount of expression generated by a promoter rather than the 
absolute amount (the number of elongating polymerases per second) (133) that may be found 
in the wild type system. Another factor which may influence the relative versus absolute 
promoter strengths is the interplay of sigma factors (Section 1.4.4). It is not known whether 
the different genes in the methylenomycin BGC recruit different sigma factor/polymerase 
complexes, thereby altering the absolute expression at a particular promoter.  
3.4.3 Comparison with Other Promoters 
The luciferase system used in this investigation was fairly recently developed and its use in 
Streptomyces has been limited. For this reason, it was decided to check the system using the 
well-known Streptomyces promoter ermEp* as a benchmark for the methylenomycin cluster 
promoters. The ermEp* promoter is well characterised (131) and known to work as a 
relatively strong promoter in S. coelicolor, it was also the promoter used to produce MmfR 
and MmyR at a constant level. Table 3.1 shows a comparison of the sequence for ermEp* 
with five of the methylenomycin cluster promoters. 
                                                      
1 RBS sequence used was 5’ AAGGAGG 3’ 
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Table 3.1. Comparison of the different methylenomycin cluster promoter sequences with 
strong constitutive promoter, ermEp*  
Promoter 
name 
-35 
(5’ to 3’) 
-10 
(5’ to 3’) 
Strength 
(from 
Figure 
3.16) 
Full double stranded promoter sequence (with -10 and 
-35 sequences underlined) 
ermEp* TTGCAT GAGGATCCT - 5’ AGCTTGCATGCCGGTCGACTCTAGAGGATCCTACC 3’ 3’ TCGAACGTACGGCCAGCTGAGATCTCCTAGGATGG 5’ 
mmfLp TTGCAT AGGTATATT 5 5’ CCCATTGCATAATACCTTCCCGCAGGTATATTTCT 3’ 3’ GGGTAACGTATTATGGAAGGGCGTCCATATAAAGA 5’ 
mmfRp TTGCCG CGGTAAGCT 2 5’ AGCTTACCGATCCCGGCTGTCTTGCAGCGCGGCAA 3’ 3’ TCGAATGGCTAGGGCCGACAGAACGTCGCGCCGTT 5’ 
mmyRp CTAACA GGGTATGTT 1 5’ CCCACTAACATACCTTCCCGAGGGTATGTTTTCCG 3’ 3’ GGGTGATTGTATGGAAGGGCTCCCATACAAAAGGC 5’ 
mmyBp TTAACT AGTCATAAA 4 5’ CCGGTTTAACTCTCCGTTACGAGTCATAAAAAACC 3’ 3’ GGCCAAATTGAGAGGCAATGCTCAGTATTTTTTGG 5’ 
mmyYp TTTATG AGTTAAACC 3 5’ CCCCGGTTTAACTCTCCGTTACGAGTCATAAAAAA 3’ 3’ GGGGCCAAATTGAGAGGCAATGCTCAGTATTTTTT 5’ 
 
An ermEp* vector was created as before, with the ermEp* promoter being subcloned 
upstream of luxCDABE using L1 as a template backbone.(92) This vector has been called L4 
(see Table 2.5) and was used to create the L4+pCC4 strain. This was then used to test the 
strength of ermEp* in the same way as the methylenomycin cluster promoters were tested 
(see Figure 3.14).  
Figure 3.16 shows the results collected using L4+pCC4 compared to the data collected for the 
methylenomycin cluster promoters. Data from this figure indicates that ermEp* falls within 
the following order of promoter strength; 
mmyRp > mmfRp > ermEp* > mmyYp > mmyBp > mmfLp 
An observation from Figure 3.16 is that there is not a huge difference between any of the 
promoters with the mean luminescence produced ranging between 45 and 126 times that of 
the M145 control at 72 hours. Other studies involving promoter strength often involve a much 
larger magnitude of variation in possible promoter strengths. For example, Bai et al. saw a 
190 fold difference in promoter strength when analysing different modular regulatory 
elements whereas there is less than a three fold different seen here.(134) It is conceivable that 
these promoters are all of similar strengths but it is also a possible indication of the limitations 
of the luxCDABE system in Streptomyces. Using luxCDABE compared to luxAB is beneficial 
because nothing needs to be added to the system. Both luciferase and its substrate are 
produced and so there is luminescence generated without any external manipulations. The 
down side of this is the possibility that the constitutive expression of luxCDABE is very 
taxing on the cell’s resources and perhaps the strongest promoters are not revealing their true 
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strength. Despite this possible limitation however, the technique is still useful for the aim of 
this project; to develop a novel inducible expression system. The luciferase reporter assay can 
reveal which promoter is strongest and therefore most suitable for use in the inducible 
expression system being designed. For this reason, and the successes encountered while 
optimising this technique, the luciferase assay was used for more investigations into 
MmfR/MMF/MARE operator interactions. 
A possible improvement to this protocol for the future would be to use the luciferase assay to 
assess other well-studied promoters. In this way, the effects of the potentially taxing 
expression of luxCDABE could be further explored. For example, the work by Bai et al. in 
2015 could be used as a benchmark for promoter strength. In this work, hundreds of 
promoters were compared using a novel streptomycete gfp assay. It would be interesting to 
see how the data they collected may correlate with data produced by the system studied here. 
The recently developed kasOp* promoter (135) has been found to be ~20 times stronger than 
ermEp* and if added to the lux system,(134) would provide an insight into the implications of 
high promoter strength in an energy-demanding reporter assay. 
 
3.5 Conclusions Drawn from Preliminary Investigation and 
Outlook for Future Investigations 
MmfR/MARE Operator Binding 
Investigations thus far have shown that MmfR will bind to the intergenic region between 
mmfR and mmfL. Using the finalised bioluminescence protocol (Section 3.3.7), MmfR 
binding to the two other intergenic regions between mmyY and mmyB, and mmyR and mmfP 
are also to be investigated. 
MmfR/MMF Binding 
Preliminary trials showed that MmfR repression could be released from the intergenic region 
between mmfR and mmfL upon the addition of MMF2, 4 or 5 (Figure 3.10 and Figure 3.12). 
Different concentrations of these MMFs trialled produced quantifiable results that were 
distinct from one another and would be suitable for testing using statistical analyses such as a 
t-test. Following on from this it was decided to trial all five MMFs using the finalised 
protocol described, using a range of concentration to obtain Kd and Bmax values for each of the 
MMFs and from this calculate the binding potential of each. The conclusions from trialling 
different concentrations of MMFs in Section 3.3.6 (Figure 3.13) were particularly useful 
when designing experiments to investigate the Kd and Bmax values for each of the MMFs. The 
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findings of the investigation into MmfR/MARE operator and MmfR/MMF binding can be 
found in Section 4. 
MmyR Interactions with the MARE Operators and MMFs 
The mechanism by which MmyR works is still unclear and the potential results from further 
investigations are intriguing. Preliminary trials indicated that there was little MmyR binding 
to the intergenic region between mmfR and mmfL and the addition of the MMFs did not 
produce an obvious change in luminescence produced (Figure 3.8). As with the plans for the 
further investigation into MmfR, MmyR was also investigated using the luciferase assay 
trialled here (Chapter 5). This was done to further investigate potential MmyR binding at the 
two other intergenic regions between mmyY and mmyB, and mmyR and mmfP as well as 
investigating possible ligands for this ‘pseudoreceptor’ type of TFR. 
Promoter Strength 
It was seen from the investigation carried out in Section 3.4 that the different promoters in the 
methylenomycin biosynthetic cluster had different strengths. In particular, the promoters for 
the transcriptional repressors were stronger than those for biosynthetic enzymes. This data 
will be useful as a benchmark and baseline when studying MmfR/MARE operator 
interactions adjacent to or in line with the DNA sequences for these promoters. 
Chapter 4 | Mode of Action of Transcriptional Repressor MmfR in Streptomyces 
coelicolor 
 70 
4 Mode of Action of Transcriptional Repressor 
MmfR in Streptomyces coelicolor 
4.1 Aims and Strategy of Investigation 
In this section, a more complete selection of bioluminescence results are displayed, looking 
specifically at the function of MmfR. The methodology used to collect this data is based on 
the finding of the preliminary results collected in Section 3 and the optimised protocol 
specified in Section 3.3.7. Vectors used to obtain results were explained previously in Section 
3.2 and Table 2.8. 
For each measurement there were at least 16 biological and technical repeats spread across at 
least three different ‘sessions’ of taking results. By taking measurements during different 
sessions any fluctuations due to variations in the communal incubator door being opened and 
different batches of media etc. should be accounted for. Data collected were analysed, finding 
averages and looking at the relative ratios between results as well as looking for statistical 
significance using a t-test. 
The investigation was split into two main parts designed to study MmfR binding to the 
MARE operator or the methylenomycin furan ligands. Variables tested to study MARE 
operator interactions include observing the reduction in luminescence produced upon MmfR 
binding at the MARE operator regions as well as investigating the level of MmfR release at 
the different MARE operator sites by a single concentration of MMF. Variables tested to 
study ligand interactions included trialling different concentrations of each of the five MMFs 
and calculating the binding potentials for each. Following on from this, the ligand binding 
pocket was investigated in silico and mutants created that allowed the further exploration of 
key ligand binding residues. 
 
4.2 Statistical Explanation of Data Handling 
As explained earlier in Section 3.3.1, Streptomyces coelicolor do not grow well in liquid 
culture, never reaching the sporulation stage and forming large clumps of aggregated cells. 
For this reason, the analysis was always done using solid cultures. A downside of the 
technique used was that the exact number of cells was never known. This therefore meant that 
there was a lot of variation between repeats and a high coefficient of variance. Measuring the 
mass of cells on solid culture can be a very lengthy process and would not allow samples to 
be used for repeat measurements. For this reason, luminescence was recorded as a relative 
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ratio of light produced compared to the negative control for a particular sample. By 
calculating a ratio, the variance between the different sample types should cancel one another 
out.  
It was also found that there is much less variability between readings at later time points (e.g. 
when looking at promoter strength in Figure 3.15) making these more reliable report points. 
More detailed statistical analyses of results collected were done with data from the 48 and 72 
hour times points, when the standard deviation and coefficient of variance was lower. A 
possible reason for why results appeared to stabilise at the later time points could be that the 
cells were entering the stationary phase of growth. 
 
4.3 MmfR-MARE Operator Interactions 
4.3.1 Details on the MARE Operator Sequences 
Within the intergenic regions of the lux vectors used (Figure 3.6A), it is not only the promoter 
region that is of interest but also mainly the MARE operator sequence and the binding affinity 
of MmfR to it. These methylenomycin auto-regulatory response elements vary in sequence 
between the three known sites. The different sequences therefore can be expected to have 
different affinities for MmfR. The sequence of the three methylenomycin cluster MARE 
operators can are as follows:  
L1  5’ ATAATACCTTCC CGCAGGTATATT 3’ found between mmfL and mmfR 
 3’ TATTATGGAAGG GCGTCCATATAA 5’ 
 
L2 5’ AACATACCTTCC CGAGGGTATGTT 3’ found between mmfP and mmyR 
3’ TTGTATGGAAGG GCTCCCATACAA 5’ 
 
L3 5’ AAAAAACCTTCG GGAAGGTTTGAC 3’ found between mmyY and mmyB 
3’ TTTTTTGGAAGC CCTTCCAAACTG 5’ 
 
The nucleotides found across all three MARE operators are highlighted in yellow. A reminder 
of the nomenclature used in strains created corresponding to the location of these MARE 
operators can be found in Figure 4.1.  
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Figure 4.1. Schematic showing nomenclature of lux vectors, based on the MARE 
operator being studied for a particular methylenomycin cluster intergenic regions 
Here the earlier nomenclature of L1 and L1F and L3 and L3F have been combined simply as L1 and 
L3 respectively. Please note that this diagram is not to scale. 
For a scale diagram please see Figure 3.5. 
 
To investigate MmfR-MARE operator interactions, experiments were done with the aim of 
observing the reduction in luminescence produced upon MmfR binding at the MARE 
operator regions as well as exploring the level of MmfR release at the different MARE 
operator sites by a single concentration of MMF. This investigation requires the full two-
vector luciferase system to be used, with both the lux vector and the pKMS01 vector (Figure 
3.3). 
MmfR is homodimeric and so affinity to the MARE operator in either orientation within a 
vector would be expected to be unchanged as the 24 bp MARE operator is the same in either 
direction (i.e. L1F should be the same as L1). However, the relative location of the promoter 
sequences to MmfR binding site (Figure 3.6A) may have an effect of the degree of repression 
that is achieved meaning that there may be differences between repression seen in L1F versus 
L1 and L3F versus L3 strains. In this investigation into MARE operator binding the L1, L2 
and L3 vectors were used but not L1F or L3F. If more time had been allowed then L1F and 
L3F would also have been trialled, adding pKMS01 to create L1F+mmfR and L3F+mmfR. 
4.3.2 Strength of MmfR Binding to the MARE operators 
Figure 4.2 shows the results of an investigation into the strength of MmfR binding to the three 
different MARE operators. In this figure, luminescence produced by L1, L2 and L3 vectors 
are compared when pKMS01 is present versus a pCC4 control with no mmfR. This study gave 
information on the level of repression that is achieved in the presence of MmfR compared to a 
negative control (M145) and positive control (L1+pCC4, L2+pCC4 or L3+pCC4) for a 
particular operator. 
For Figure 4.2, all data is normalised and calculated as a ratio of the level of luminescence 
produced by the M145 control at 48 hours. L1+pCC4, L2+pCC4 and L3+pCC4 represent the 
level of luminescence expected to be produced at a particular promoter in the absence of any 
repression. 
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Figure 4.2. Luminescence produced by the lux operon under the control of different 
methylenomycin cluster operators in the presence and absence of MmfR at 48 hours 
growth compared to a S. coelicolor M145 negative control 
Box plot includes data from 10-90% percentiles and all other results shown as outliers. 
Key: ‘mmfR’ refers to the presence of the pKMS01 vector with mmfR under the control of 
ermEp*, L1, L2 and L3 refer to the lux vectors with luxCDABE under the control of different 
MARE operators, pCC4 is an empty vector used as a control for pKMS01 
 
From Figure 4.2 it can be seen that there is a 10-fold decrease in luminescence from the L1 
operator upon MmfR binding compared to 3.5-fold and 6.5-fold for L2 and L3 respectively at 
48 hours growth. This indicates that MmfR binds best to the L1 MARE operator, between 
mmfL and mmfR, followed by the L3 MARE operator, between mmyY and mmyB, and least 
strongly to the L2 MARE operator, between mmfP and mmyR. A similar pattern of results was 
also seen at 72 hours (not displayed here). 
Of note is that at no operator site was there seen to be full repression of the lux operon (for all 
mmfR strains there was always more measureable luminescence than the level produced by 
the M145 negative control).  At 48 hours L1+mmfR produced three times as much 
luminescence as the M145 control and for L3+mmfR there was almost nine times as much 
whereas there was over 24 times as much luminescence for L2+mmfR compared with the 
M145 control. This revealed varying degrees of apparent leakiness in the system. The level of 
luminescence will be influenced not only by the strength of MmfR binding but also the 
promoter strength at each of the sites. 
The biological implications of this leakiness is unclear but it is potentially helpful in 
regulating methylenomycin biosynthesis and maintaining equilibrium between MmfR release 
and repression. If there is leakiness in the wild type system, the five operons may be 
expressed at a low level including the production of small amounts of MMFs by the mmfLHP 
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operon. This does not however appear to be enough to trigger the production of 
methylenomycin under normal laboratory conditions.(71) The mmfR and mmyR promoters are 
the strongest (Section 3.4), high levels of these repressors maybe enough to switch off the 
system until a threshold concentration of MMFs is achieved and the level of MmfR cannot 
keep up with the de-repression. However, there are a number of reasons why this leakiness 
may not actually be found in the wild type system. One is that in the wild type system, mmyB 
and mmfL expression are also controlled by the temporal use of a rare TTA codon, which can 
only be expressed in later stages of the cell cycle, when it’s tRNA is available. Also, in vivo in 
wild type S. coelicolor A3(2), where SCP1 and the entire methylenomycin cluster and other 
regulatory elements are present, it is reasonable to predict that maybe the leakiness observed 
in this assay would be lower due to the constant self-regulatory production of MmfR (see 
Chapter 6 for more details). Once MmfR is under the control of its own promoter and MARE 
operator (rather than ermEp*) there is likely to be tighter regulation of the levels of this 
repressor. There is also potential additional assistance from sigma factors and other regulatory 
molecules on the regulation of this repressor when in the wild type system. The extent to 
which these different factors may play a role however, is unclear. 
4.3.3 Investigation into Release of MmfR from the MARE Operator 
by MMF4 
MmfR affinity for the MARE operator could also be studied by looking at how easily the 
repressor is released in the presence of the MMF at each of the three sites. A concentration of 
100 µM MMF4 was added to L1+mmfR, L2+mmfR and L3+mmfR and the levels of 
luminescence compared to the same strains with no MMFs. By comparing the results with the 
same strains with no MMFs, it was possible to offset the variation caused by different 
promoter strengths next to the different MARE operators. Data for the positive control as a 
ratio of each mmfR strain is also shown to represent maximal luminescence for a particular 
promoter in the absence of repression (L1+pCC4, L2+pCC4 and L3+pCC4 strains). The 
results from this investigation are found in Figure 4.3. 
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Figure 4.3. Boxplot of luminescence produced by the lux operon under the control of 
different MARE operators and MmfR in the presence and absence of 100 µM MMF4, 
compared to luminescence produced by luxCDABE under the control of the same 
operator but no MmfR at 48 hours 
The data for the mmfR strains with MMF4 were normalised against the same strain with no 
MMF to give a relative ratio of 1 for the negative control. The box plot includes data from 10-
90% percentiles and all other results shown as outliers. Key: ‘mmfR’ refers to the presence of 
the pKMS01 vector with mmfR under the control of ermEp*, L1, L2 and L3 refer to the lux 
vectors, pCC4 is an empty vector used as a control for pKMS01 in the positive control strains. 
 
Comparison with the Negative Control 
Upon the addition of MMF4 to mmfR strains at the 48 hour time point there is an average of 
around between 3 and 3.3 times as much luminescence produced for the L2 and L3 operators 
respectively, compared to over nine times more for L1. This reveals that as well as binding 
most strongly to the L1 MARE operator (Figure 4.2), MmfR is also released most readily 
from it in the presence of its ligand. 
Comparison with the Positive Control 
The results comparing MmfR/MMF4 data with the pCC4 positive controls for each MARE 
operator follows a similar pattern. The L1+mmfR strain with MMF4 achieves the closest 
levels of luminescence to the positive control, producing 96% of the luminescence that the 
positive control produced. On the other hand, L3+mmfR with 100 µM MMF4 only achieves 
around 50% of the luminescence produced by the positive control and L2+mmfR achieves 
around 87%. This indicates that MmfR is less readily released at the L3 MARE operator, 
followed by L2 with L1 being the most readily release. The data from Section 4.3 is 
summarised in Table 4.1. 
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4.3.4 Discussion of MmfR/MARE Operator Binding Data 
Table 4.1 shows a comparison of all the results obtained from the luminescence assay on the 
affinity of MmfR for each of the methylenomycin cluster intergenic regions it is known to 
bind as well as data on the strength of promoters in each region. 
Table 4.1. Summary of MmfR-MARE operator binding data 
The data in this table summarises the findings from Figure 4.2, Figure 4.3 and Figure 3.16. Data in 
this table is taken from analyses done at either 48 or 72 hours growth. 
MARE 
operator 
site 
Corresponding 
promoter 
Strength 
of MmfR 
binding 
MmfR release in the 
presence of MMF4 
compared to a 
negative control 
MmfR release in the 
presence of MMF4 
compared to a 
positive control 
Relative 
promoter 
strength (1 
being 
highest) 
L1 mmfLp Greatest Greatest Greatest 5 
L1F mmfRp - - - 2 
L2 mmyRp Weakest Weakest Middle 1 
L3 mmyBp Middle Middle Weakest 4 
L3F mmyYp - - - 3 
 
It appears, according to the comparison of results in Table 4.1, that MmyR production has the 
strongest promoter but is one of the ‘hardest’ to switch on with the lowest level of release of 
MmfR measured from the L2 intergenic region upon the addition of MMF4 compared to the 
same strain with no MMFs. This may explain why MmyR production has previously been 
shown to occur after the production of MmfR.(54) 
The mmyBY intergenic region (L3) appears to produce results in the middle in terms of both 
promoter strength and MmfR binding whereas the mmfR and mmfLHP operons are quite 
clearly the easiest to switch on and off. The MARE operator between these two operons (L1 
MARE operator) was also shown to be the least leaky, producing only three times as much 
luminescence in the presence of MmfR as the M145 control compared to 24 times for the L2 
MARE operator. For this reason, the L1 MARE operator seems to be the most suitable choice 
for use in a novel inducible expression system. Following on from this, the L1 vector was also 
used in all future investigations in Section 4.4. L1 was chosen for this instead of L1F strains 
due to the phenotypic differences in the strains with stronger promoters (referred to after 
Figure 3.16 on page 65). It is as yet unclear what the implications of using the high strength 
promoters in the resource demanding luxCDABE system so to ensure consistent and reliable 
results the more ‘healthy’ looking L1 strains were used. Also, the differences in promoter 
strength were just over two fold between L1 and L1F, not a huge difference when one looks 
at the almost 200 fold difference in promoter strength see by Bai et al. (134) when this 
Chinese group studied a variety of promoters. A two-fold difference in promoter strength 
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therefore is not significant enough to pick one promoter over another, especially where one 
appears phenotypically distinct from the wild type. 
The findings in Section 4.3 complement the previous gel shift assays run by Peter Harrison 
where the implication was that MmfR is more readily released for the mmfRL intergenic 
region (L1 MARE operator) than the mmyBY intergenic region (L3 MARE operator). 
The results from Section 4.3 indicate the potential importance of the nucleotides that are not 
conserved between the three MARE operators in terms of providing the differential strength 
of binding to MmfR. The L1 (mmfLR) MARE operator was shown to bind most strongly to 
MmfR. Nucleotides that are found in this operator but neither of the other two MARE 
operators are highlighted; 
5’ ATAATACCTTCC CGCAGGTATATT 3’ 
3’ TATTATGGAAGG GCGTCCATATAA 5’ 
 
These nucleotides are potentially what give this L1 MARE operator its strength of binding 
and so are potential targets for future site directed mutagenesis to see how they impact the 
strength of MmfR binding. 
 
4.4 MmfR-MMF Interactions 
4.4.1 Different MMFs 
Five methylenomycin furan ligands are naturally produced by S. coelicolor A(3)2. As seen in 
Figure 4.4, the structures of the different MMFs vary in the length and branches of the alkyl 
chain, and have all been shown experimentally to bind MmfR and induce methylenomycin 
production by previous researchers.(55) 
Figure 4.4. Chemical structures of the methylenomycin furans (MMFs) 
These five molecules have experimentally been shown to be involved in the regulation of 
methylenomycin biosynthesis 
When optimising the luciferase assay in Section 3.3.6, a range of different MMF 
concentrations of MMF2, 4 and 5 were trialled. It was found that methylenomycin furan 
concentrations above 5 µM produced a detectable change in luminescence. Concentrations up 
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to 400 µM were trialled and saturation of MmfR appeared to occur between 200 and 400 µM 
for MMF5. From this it was decided that a final concentration of 100 µM MMF should be 
used as a standard for future tests. 
Each MMF was added at a final concentration of 100 µM to the L1+mmfR strain and the 
increase in luminescence compared to the same strain with no MMFs was measured. The 
results from this investigation are presented in Figure 4.5 and Figure 4.6. Figure 4.5 shows the 
effect on luminescence of all five MMFs over five time points for 72 hours. In this figure, 
data is normalised against L1+mmfR with no MMFs and also shows a comparison with the 
L1+pCC4 strain (positive control, no MmfR). Figure 4.6 shows a bar chart of the data from 
Figure 4.5 at 48 hours only. Data from this figure is again normalised against L1+mmfR in the 
absence of MMFs. A t-test was run with the data collected for Figure 4.6 to establish whether 
there was significant release of MmfR by each of the five MMFs, this data is displayed in 
Table 4.2. 
 
Figure 4.5. Luminescence produced by the lux operon when under the control of mmfLp 
and MmfR upon the addition of 100 µM of different MMFs compared to no MMFs over 
time 
Luminescence produced is calculated as a ratio of the luminescence produced by the 
L1+mmfR with no MMFs, meaning that the luminescence produced by this strain has a value 
of one. Strains used: L1+pCC4 – positive control, luxCDABE under the control of mmfLp, 
L1+mmfR – luxCDABE under the control of mmfLp and mmfR under the control of ermEp* 
(pKMS01) 
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Figure 4.6. Bar chart of luminescence produced by the lux operon when under the 
control of mmfLp and MmfR in the presence of 100 µM of different MMFs compared to 
no MMFs at 48 hours 
Luminescence produced is calculated as a ratio of the luminescence produced by the 
L1+mmfR with no MMFs, meaning that the luminescence produced by this strain has a value 
of one. Error bars show the standard deviation from the mean with all data points collected 
plotted. Strains used: same as Figure 4.5 
 
Table 4.2. A t-test analysis of significant changes in the luminescence produced by 
luxCDABE when under the control of mmfLp and MmfR in the presence of different 
MMFs compared to no MMFs 
Two tailed t-test with unpaired samples of equal variance used as parameters. The average 
induction of luminescence is calculated as a ratio of L1+mmfR with no MMFs (giving this 
sample type a value of 1). 
MMF added to 
L1+mmfR p-value 
Significant 
increase? 
Average 
induction at 48 
hr (R.R.) 
MMF1 6.62E-26 TRUE 11.48 
MMF2 1.29E-15 TRUE 7.28 
MMF3 6.40E-24 TRUE 10.65 
MMF4 6.08E-18 TRUE 9.49 
MMF5 3.19E-17 TRUE 9.29 
 
As expected, the t-test analysis (see Table 4.2) showed that all five MMFs cause a significant 
release of MmfR from the DNA, with the p-value being well below 0.05 for all at 48 hours 
growth.  
Data from Figure 4.5 and Figure 4.6 indicates that the two branched chain MMFs (MMF1 and 
3) cause slightly higher levels of MmfR release than the other MMFs. Figure 4.5 shows that 
levels of luminescence being produced in the presence of the MMFs were anywhere between 
seven and 12 times that of the same strain without induction. However, despite varying 
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efficacy of the MMFs, at a concentration of 100 µM none of the MMFs cause total MmfR 
release, with levels of luminescence still being below those produced by the L1+pCC4 strain 
(positive control, representing no repression). 
Figure 4.6 shows the following order of efficacy for the MMF molecules at 48 hours: 
MMF1 > MMF3 > MMF4 > MMF5 > MMF2 
The biological need for five different inducer molecules with similar levels of binding to 
MmfR is unclear. However, an explanation may be that the MmfLHP biosynthetic enzymes 
are not specific enough to make a single type of MMF, thereby resulting in five similar 
molecules that can all bind to MmfR. 
Data for 72 hours growth also showed a significant increase in luminescence in the presence 
of the five MMFs (data not shown here) and measurements at this time point produced the 
same order of efficacy by the different MMFs as was seen at 48 hours. 
4.4.2 Different Concentrations of MMFs 
Once it was established that the addition of all five MMFs produced significant changes in the 
luminescence produced by the L1+mmfR strains and could be suitably analysed using the 
luciferase assay, further investigations were carried out to look at the binding affinities of 
each MMFs, calculating the Kd and Bmax values from a standard curve. The Bmax represents 
the maximum luminescence produced by L1+mmfR in the presence of the MMFs as a relative 
ratio of same strain with no MMFs whereas the Kd represents the equilibrium binding 
constant, the concentration (in µM) needed to achieve half the maximum binding of the 
MMFs to MmfR. The equation for a standard curve is as follows; Y = Bmax x X / (Kd + X), 
where Y is the ratio of luminescence and X is the final concentration of the MMFs. 
MMF4 is used as an example of how these binding potential for each of the MMFs were 
determined and a full set of data is shown in Figure 4.7 and Figure 4.8. The same analysis was 
then done for the other four MMFs and the data summarised in Figure 4.9, Figure 4.10 and 
Table 4.3. 
Figure 4.7 shows the data collected for the L1+mmfR strain in the presence of six different 
concentration of MMF4 over 72 hours compared to a negative and positive control. Figure 4.8 
shows a standard curve produced using luminescence readings from the just 48-hour time 
point. 
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Figure 4.7. Dose-response of MMF4 over time, in strains where lux operon expression is 
controlled by mmfLp and MmfR 
Luminescence produced is calculated as a ratio of the luminescence produced by the 
L1+mmfR with no MMFs. Strain used: L1+mmfR – luxCDABE under the control of mmfLp 
(L1) and mmfR under the control of ermEp* (pKMS01) 
 
Figure 4.7 revealed that 400 µM MMF4 appeared to cause the greatest release of MmfR from 
the MARE operator, producing up to 20 times the luminescence of the non-induced strain. In 
fact, at a number of time points, 400 µM MMF4 being added to L1+mmfR produced higher 
levels of luminescence than even the positive control for the same operator sequence 
(L1+pCC4). It is not entirely clear why this is the case. Possibly the reason for this is the 
margin of error for the data collected, which does have some overlaps (not shown here). 
Alternatively, the MMFs may have a separate activator role as well as directly triggering the 
release of MmfR. Possibly the MMFs can be used to recruit sigma factors or other 
transcriptional regulators, but there is no experimental evidence of this being the case as yet. 
Further investigation would be needed to test this theory, particularly as the presence of the 
MMFs caused no significant change in the luminescence produced by the positive control 
strains (Section 3.3.5). 
Data collected for final concentrations between 50 µM and 200 µM appear to be very similar, 
particular at later time points, indicating that MmfR/MMF binding is saturated and a 
threshold level of MMFs has been reached that is enough to activate the total biosynthetic 
pathway. 
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In Figure 4.7, at the time points around 24 hours, there does not appear to be a direct 
correlation between concentration and luminescence. Some lower concentrations appear to 
produce greater levels of luminescence than the higher concentrations. There was a huge 
deviation between these earlier results however, so this lack of correlation in some cases may 
just be an artefact of biological variation and the cells stabilising in growth. At 48 and 72 
hours however, there is a direct correlation between MMF concentration and luminescence 
produced as well as there being a lower standard deviation and coefficient of variance 
between results which makes this data more suitable for comparisons. For this reason, these 
later time points were used to create a standard curve and determine the Bmax and Kd values in 
Figure 4.8. 
 
Figure 4.8. Dose-response curve of MMF4 at the 48 hour time point, in strains where lux 
operon expression is controlled by mmfLp and MmfR 
Shown in black is the actual data for each MMF with the fitted standard curve shown in red. 
Strain used: L1+mmfR – luxCDABE under the control of mmfLp (L1) and mmfR under the 
control of ermEp* (pKMS01) 
 
In Figure 4.8, the fitted hyperbolic curve to the data is shown in red, this has an R2 value of 
0.9597, indicating a very good fit of the model to the data (where 1 is a perfect fit and 0 is no 
relationship). The equation for this standard curve is Y = Bmax*X/(Kd + X), where Y is the 
relative ratio of luminescence at a particular concentration compared to the same strain with 
no MMFs. The Bmax for this data is 18.3. In other words, the maximum amount of 
luminescence produced by adding high concentrations of MMF4 is 18.3 times the 
luminescence produced when there is no MMF added. The Kd reveals that an average of 
69.42 µM MMF4 is expected to achieve half the Bmax. 
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Following on from the analysis of different concentrations of MMF4, Figure 4.9 shows the 
standard curves collected for MMF1, 2, 3 and 5 at 48 hours. Again, shown in black is the 
actual data for each MMF with the fitted standard curve shown in red. To make comparison 
of one MMF with another easier, the fitted standard curves for all five MMFs have been 
combined into a single chart, shown in Figure 4.10. The details of the Bmax and Kd and the 
relative binding potential for each of the MMFs are shown in Table 4.3. The binding potential 
is calculated by dividing the Bmax by the Kd and is representative of how ‘good’ each MMF is 
as a ligand for MmfR.(136) It is a value that combines both the availability of MmfR ligand 
binding pockets and the affinity each MMF has for the residues in this pocket.  
 
 
Figure 4.9. Dose response curves for MMF1, 2, 3 and 5 at 48 hours growth using strains 
where lux operon expression is controlled by mmfLp and MmfR  
Shown in black is the actual data for each MMF with the fitted standard curve shown in red. 
Y = Bmax x micromolar concentration / (Kd + micromolar concentration) 
Strain used: L1+mmfR – luxCDABE under the control of mmfLp (L1) and mmfR under the 
control of ermEp* (pKMS01) 
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Figure 4.10. Compiled dose-response standard curves showing the relationship between 
the concentration of all five MMFs and the luminescence produced in strains where lux 
operon expression is regulated by mmfLp and MmfR, at 48 hours growth 
 
In Figure 4.9 and Figure 4.10 it can be seen that different MMFs have different Bmax values. It 
is unclear why this is the case but again, one possible explanation is the possible involvement 
of unknown regulatory mechanisms, genetically separate to the methylenomycin gene cluster 
and therefore still present in the S. coelicolor M145 control strain which are effected by the 
MMFs. It should be noted that the L1+pCC4 positive control strain will give an average 
maximum ratio of luminescence (compared to L1+mmfR with no MMFs) of around 10. All of 
the MMFs, except MMF2, have an average Bmax above this, further indicating that the MMFs 
are doing more than just releasing MmfR from the MARE operator. 
If these MMFs do have an extra role you may also expect to see a difference in luminescence 
produced by the L1+pCC4 positive control strain in their presence. However, L1+pCC4 in the 
presence and absence of the five MMFs gives statistically similar luminescence readings at 
the time points and concentrations trialled (Section 3.3.5). How exactly this extra 
functionality of the MMFs works is therefore unclear. Potentially MmfR needs to be present 
and bound to the MMFs for them to have this extra regulatory function. Alternatively, this 
strain was only tested with a maximum concentration of 100 µM of each MMF and maybe a 
higher threshold concentration of MMFs is needed to cause a significant change in the 
luminescence produced by the L1+pCC4 control strain. 
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Table 4.3. Binding kinetics data for MmfR with each of the five methylenomycin furans 
including the Bmax, Kd and binding potential values for each at 48 hours growth 
Binding potential = Bmax/Kd 
Analysis MMF1 MMF2 MMF3 MMF4 MMF5 
Bmax 12.12 9.796 12.88 18.30 12.93 
Kd (µM) 17.99 44.87 25.38 69.42 39.06 
Binding potential 0.6737 0.2183 0.5074 0.2636 0.3310 
 
From these findings the following order of efficacy for the MMFs is given as; 
MMF1 > MMF3 > MMF5 > MMF4 > MMF2 
This is very close to the first estimation made from preliminary work in Section 4.4.1. Only 
MMF4 and MMF5, which already gave very similar results, have swapped places. It can be 
seen from Table 4.3 that the two branched chain MMFs (MMF1 and MMF3) have the highest 
binding potentials. Following on from this, the MMFs with the longest straight alkyl chains 
have the highest binding potentials. The MMF with the lowest binding potential was MMF2, 
which has the shortest alkyl chain. This indicates that the bigger and longer alkyl chains are 
needed to best fit the MmfR binding pocket. The findings in this investigation therefore 
suggest that either MMF1 or MMF3 are most suitable for use when developing the novel 
inducible expression system. 
In Vitro Work - Data from Gel Shift Assays 
Interestingly, in vitro work was carried out by another lab member, Shanshan Zhou, to 
analyse the binding of the five MMFs to MmfR. For their investigation they performed a gel 
electrophoresis mobility shift assay (EMSA) using purified MmfR and each of the five furan 
ligands. This showed a very similar pattern of binding abilities between the five furans as the 
in vivo data collected from the luciferase assay. The main differences in the data were that 
MMF1 and 3 gave very similar shifts to one another as did MMF4 and 5. An EMSA did not 
provide the resolution to distinguish between possible binding differences in these two pairs 
of ligands. 
Binding profiles established from the EMSA were as follows; 
MMF1 ≈ MMF3 > MMF5 ≈ MMF4 > MMF2 
It is promising that both in vivo and in vitro data give a very similar pattern of MmfR/MMF 
binding affinities. 
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4.4.3 In Silico Analysis of MmfR Ligand Binding Pocket 
Following on from the luminescence assay investigation of MmfR/MMF binding, the amino 
acids directly involved in ligand binding are of interest. A crystal structure of MmfR has 
previously been solved both in the apo form and with MMF2 bound. (73) This allowed 
analysis of the ligand-binding site at an atomic resolution. Shown in Figure 4.11 is the crystal 
structure found for MmfR with MMF2. This was then compared with a protein:ligand 
docking analysis carried out using ‘SwissDock’ for the apo crystal structure of MmfR and 
MMF2 and it was found to be a close match, indicating that an in silico docking may be a 
useful and accurate way of studying MmfR/MMF binding. The docking was therefore done 
with the apo crystal structure of MmfR and all five MMFs as well as synthetic analogue 
molecules 70 and 121 and S. coelicolor hormone SCB1 as controls, using the SwissDock 
online software with the default parameters. A summary of these results is found in Table 4.4 
and the structures of the ligands are displayed in Figure 4.12. 
 
Figure 4.11. LigPlot+ schematic of MmfR bound to MMF2, as shown by X-ray 
crystallography data 
The schematic created for this figure was done using the LigPlot+ software, designed by 
Wallace et al. (116) and is based on the protein work by Rea et al. (73) 
 
SCB1 is a S. coelicolor butyrolactone signalling molecule, known to bind to the TetR family 
member ScbR. This SCB is structurally distinct from the MMFs (Figure 1.3 and Figure 4.12) 
and has been shown experimentally in vitro not to bind MmfR and so works as a negative 
control for the docking analyses (see results from Section 3.3.5). Molecule 70 is a synthetic 
MMF analogue that can also be used as a negative control, it has the same core structure as 
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the MMFs but lacks the alkyl chain, which has been shown to be necessary for inducing 
antibiotic production.(55) Molecule 121 is another synthetic MMF analogue, again it has the 
same core structure as the MMFs but its alkyl chain is one carbon longer than MMF5. The 
nomenclature for these synthetic molecules comes from the work of Nicolas Malet at the 
University of Warwick.(55) 
A docking analysis was also attempted with MmyR and ScbR for comparison with MmfR but 
without access to crystal structures for these TetR family members the level of accuracy 
achieved from protein modelling was not good enough to get realistic results from a docking 
analysis. 
 
Figure 4.12. Chemical structures of the MMFs, SCB1 and other synthetic analogues 
 
Table 4.4. Summary of docking analysis of MmfR with the MMFs and other synthetic 
and natural analogues 
Key: (?) - Sometimes it was unclear whether a particular amino acid was involved in ligand 
binding, being present in some models but not all. This has been denoted with a question 
mark. 
Ligand 
Scoring 
function 
(Best ΔG) 
Amino acids involved in H-
bonding 
No. of H-
bonds 
MMF1 -7.24 Histidine 84 (?), Tyrosine 85, Tyrosine 144 4 
MMF2 -7.17 Histidine 84 (?), Tyrosine 85, Tyrosine 144 4 
MMF3 -7.03 Tyrosine 85, Tyrosine 144 2 
MMF4 -6.86 Tyrosine 85, Tyrosine 144 3 
MMF5 -6.88 Tyrosine 85, Tyrosine 144 2 
Molecule 70 -6.43 Tyrosine 85, Tyrosine 144 2 
Molecule 121 -6.13 No realistic matches, Glycine 94(?) 1 
SCB1 -6.33 No realistic matches, Arginine 87 (?), Aspartate 120 (?) 2 
 
It appears that tyrosines 85 and 144 are consistently involved in hydrogen binding with the 
furan ligands in the models and so are likely to be crucial to the conformational change 
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leading to the release of the MmfR protein from the MARE operator sequence of DNA. 
Histidine 84 may also play a role but was not constantly found between different models and 
so seems to be less important. There are also a number of other amino acids that are 
consistently involved in hydrophobic interactions with the ligand in the MmfR binding pocket 
(shown in Figure 4.13).  
In silico, molecule 121 appears to not bind MmfR, despite it being shown to induce 
methylenomycin production in previous in vivo experimentation by Nicolas Malet,(55) with 
the implication from his research that molecule 121 can cause the conformational change in 
MmfR that will release it from the DNA. This disparity indicates that the simulations from 
this in silico analysis are only estimations and cannot be taken as final proof of what occurs in 
vivo. The lack of flexibility of MmfR and the ligand molecule during the docking is the most 
likely cause of the anomaly.  
Molecule 70 is lacking the alkyl chain usually found in the MMFs. In vivo it has been shown 
not to induce methylenomycin production. The docking shows that molecule 70 can still bind 
to the active region of MmfR but it would seem that with the lack of alkyl chain, these 
hydrogen bonds alone would not be enough to induce a conformational change to MmfR. In 
vivo, there would also be water molecules present in this docking and so potentially such a 
small molecule would not bind to the active site. As expected, the docking done with SCB1 
showed no convincing binding models to MmfR. 
Results from the luciferase assay done to study MmfR/MMF binding indicated that MMF1 
and 3 worked best to release MmfR from the MARE operator sites. The in silico analysis did 
not show exactly the same pattern however. As just mentioned, there are a number of 
limitations of the in silico docking analysis and so the in vivo data is therefore likely to be 
more representative of the wild type MmfR/MMF binding profiles. The docking analysis is 
however, useful in narrowing down the selection of residues for mutagenesis to further study 
the MmfR ligand binding pocket. 
The 11 amino acids involved in hydrogen binding and hydrophobic interactions between 
MmfR and the MMFs have all been highlighted in Figure 4.13 to show how they are spread 
across the primary structure of MmfR. It was then possible to compare these residues to 
motifs found in MmfR orthologues. 
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Figure 4.13. Positions of ligand binding residues in the MmfR amino acid sequence 
Yellow – hydrogen bonds, Green – hydrophobic interactions 
This is based on the crystal structure of MmfR/MMF2, solved by Dean Rea et al. (73) 
 
A number of other systems in different Streptomyces strains encode TetR family proteins, 
orthologous to MmfR including SAV_2270 from S. avermitilis and SgnR from S. venezuelae. 
The presence of the two probable key ligand binding tyrosine residues in these streptomycete 
homologues would further increase the likelihood that these amino acids are indeed involved 
in ligand binding and therefore should be studied further. 
The key MmfR residues in ligand binding are spread across the entire amino acid and so 
entire sequence alignment and comparison was carried out between MmfR and orthologues 
SAV_2270 and SgnR. The results from this alignment are displayed in Figure 4.14. Matches 
to the MmfR polypeptide sequence are shown in blue with mismatches shown in yellow. 
Figure 4.14. Comparison of MmfR ligand binding amino acid residues with the 
sequences of orthologous TFRs SgnR and SAV_2270 
 Blue – matches with MmfR, Yellow – mismatches with MmfR 
Amino acid sequences used: MmfR – methylenomycin cluster transcriptional repressor, 
SgnR – MmfR homologue from Streptomyces venezuelae, SAV_2270 – MmfR homologue 
from Streptomyces avermitilis 
 
 
MmfR          ---MTSA--QQPTPFAVRSNVPRGPHPQQERSIKTRAQILEAASEIFASRGYRGASVKDV 
SAV_2270      MDVMSSERNGQSTRLPAGTPFDDTAHLKQQRAIRTRGTILNAAAAAFATDGFPQVTIKDI 
SgnR          -------------------MATPRSQPKQERARRTKVHILQSAAELFAERGYATVTLQDV 
                                         :* *: :*:  :*::*:  **  *:  ..:  : 
 
MmfR          AERVGMTKGAVYFHFPSKESLAIAVVEEHYARWPAAMEEIRIQGF-TPLETVEEMLHRAA 
SAV_2270      ADGAEMTKGAVYFHFPNKEALAVAVLEEFYRRMQEAVNGALEHGDPTSPTTVVDVMRRLA 
SgnR          AERAEMTKGAVYFHYTNKEALAVAVVQEHYARWPEILKGAEGDHA-EPFDMLTAVLDTVT 
              *  . *****:* *: .*::**  ::.:         .             :  ::   : 
 
MmfR          QAFRDDPVMQAGARLQSERAFIDAELPLPYVDWTHLLEVPLQD----AREAGQLRAGVD- 
SAV_2270      RAFHEDVFIHAGARLQIERPYIKAELPVPYVGTLKVLTELLDQ----CRTAGNLPKSTK- 
SgnR          RAFARDIVVQAGARLQIERALIDAELPEPYVGWEDYLTRLIAE----ARDAGQLRDGVE- 
              : :  *  .:*. **  :          *     . *     :    .* : :     .  
 
MmfR          -----PAAAARSLVAAFFGMQHVSDN-LHQRA--DIMERWQELRELMFFALRA---- 
SAV_2270      -----PEALARALGSAVFGAQHISWV-LNDRE--DIVERVEEIIDAFVPLH------ 
SgnR          -----PRAAARVLVSAFFGMQHISDV-LSGRS--DLTERYEELRTVLLEGLRR---- 
                   * . .: * :. :* .. :      *      :  : :   :    
 
 
> MmfR [Streptomyces coelicolor A3(2)] 
MTSAQQPTPFAVRSNVPRGPHPQQERSIKTRAQILEAASEIFASRGYRGASVKDVAERVGMTKGAVYFHF 
PSKESLAIAVVEEHYARWPAAMEEIRIQGFTPLETVEEMLHRAAQAFRDDPVMQAGARLQSERAFIDAEL 
PLPYVDWTHLLEVPLQDAREAGQLRAGVDPAAAARSLVAAFFGMQHVSDNLHQRADIMERWQELRELMFF 
ALRA 
 
Chapter 4 | Mode of Action of Transcriptional Repressor MmfR in Streptomyces 
coelicolor 
 90 
It appears that tyrosine 85 and 144 are conserved across the three orthologous amino acid 
sequences further suggesting that they are indeed crucial to ligand binding and are appropriate 
targets for site directed mutagenesis to further demonstrate their role in ligand binding. 
A number of the amino acids shown to involved in hydrophobic interactions with the MMF 
ligand for MmfR are also conserved in its orthologues, especially SgnR. It is possible 
therefore that these orthologues will interact with MMF-like ligands as the similarities in their 
ligand binding pockets mean that they could provide similar interactions with the acyl chain 
of the MMFs. 
4.4.4 Effect of Site Directed Mutagenesis on the Ligand Binding 
Domain of MmfR 
Site directed mutagenesis was carried out on the mmfR gene to create mutants with either Y84 
or Y144 converted to a phenylalanine residue in the MmfR protein using the Agilent 
QuikChange Lightening Site Directed Mutagenesis Kit. Figure 4.15 shows details of which 
atoms from the MmfR tyrosine residues are involved in MMF binding and how this will be 
effected in the phenylalanine mutants. 
As can be seen in this figure and Figure 4.11, it is the OH group of Y85 which interacts 
directly with the MMF molecule and the NH2 group of Y144. The NH2 group will still be 
present in the same position for the Y144F mutant. The conversion of tyrosine to 
phenylalanine will also not considerably change the size of the binding pocket and so it is 
expected that little change will be seen from this mutation. The NH2 group will be present in 
all amino acids so it would be very hard to create a mutant that will properly check for the 
function of Y144 in ligand binding. The Y144F mutant therefore worked as a negative control 
compared to the results from the Y85F mutant. In the Y85F mutants, it is expected that a 
more considerable effect on ligand binding will be seen due to the absence of the key OH 
group. In this Y85F mutant, the similarity in size between tyrosine and phenylalanine and the 
presence of the benzene ring should minimize the effects of changing the size and 
conformation of the binding pocket, allowing the analysis of just the hydroxyl group and its 
role in ligand binding. 
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Figure 4.15. Schematic highlighting the hydroxyl and amine groups of tyrosines 85 and 
144 from MmfR involved in MMF binding 
This schematic is based on the crystal structure of the MmfR/MMF2 complex. (73) 
 
Once the mmfR sequence was mutated in E. coli to now code for phenylalanine instead of 
tyrosine, the sequence was inserted into the pCC4 vector where the wild type mmfR was 
normally inserted, creating pKMS85 and pKMS144. This could then be integrated into the 
Streptomyces coelicolor M145 genome along with the L1 luxCDABE vector, allowing the 
mutants to be analysed using the luciferase reporter assay. This assay was carried out as with 
the wild type MmfR and a final concentration of 100 µM or 200 µM MMF was added to 
cultures and the luminescence produced compared to no MMFs measured. The results 
collected from the initial trials with the Y85F and Y144F mutants can be found in Figure 4.16 
and Figure 4.17. Figure 4.16 shows the luminescence produced at five time points over 72 
hours by L1+WTmmfR,1 L1+mmfR Y85F and L1+mmfR Y144F in the presence and absence 
of MMF4.2  Figure 4.17 is a bar chart of data from Figure 4.16 at the 48-hour time point only. 
A t-test analysis of data can be found in Table 4.5 with L1+WTmmfR and 100 µM MMF4 
being compared to the Y85F and Y144F mutants with MMF4 to look for significant 
differences in ligand binding properties. 
                                                      
1 This is the same strain as was referred to earlier as simply L1+mmfR. 
2 MMF4 is used as it has been synthesised on a larger scale than the other MMFs and so was 
more readily available. 
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Figure 4.16. Luminescence produced by the lux operon when under the control of 
mmfLp and MmfR tyrosine mutants compared to wild type MmfR, in the presence and 
absence of MMF4 
Luminescence produced is calculated as a ratio of the luminescence produced by the 
L1+WTmmfR with no MMFs. Strains used: L1+WTmmfR, L1+mmfR Y85F and L1+mmfR 
Y144F – luxCDABE under the control of mmfLp (L1) and mmfR under the control of 
ermEp* producing either the wild type MmfR, a Y85F mutant or a Y144F mutant (pKMS01, 
pKMS85 and pKMS144 respectively). 
 
 
Figure 4.17. Boxplot of luminescence produced by the lux operon when under the 
control of mmfLp and MmfR tyrosine mutants, compared to wild type MmfR measured 
in the presence of MMF4 at 48 hours 
Luminescence produced is calculated as a ratio of the luminescence produced by the 
L1+mmfR with no MMFs, meaning that the luminescence produced by this strain has a value 
of one. Error bars are shown as the standard deviations of data with all data points collected 
also shown on the chart. Strain used: same as Figure 4.7 
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Table 4.5. A t-test analysis luminescence produced by luxCDABE when under the 
control of mmfLp and the Y85F and Y144F MmfR mutants in the presence of 100 µM or 
200 µM MMF4 to look for significant differences in the removal of repression 
Strain used p-value Significant difference? 
Average induction at 48 hr 
compared with L1+WTmmfR 
and 100 µM MMF4 (R.R.) 
Y85F and 100 µM 
MMF4 1.60E-5 YES 0.576 
Y85F and 200 µM 
MMF4 2.30E-1 NO 0.865 
Y144F and 100 µM 
MMF4 3.36E-2 YES 1.284 
 
The Y85F strain did show a lower level of de-repression by MMF4 compared to the wild type 
strain. Only at twice the level of MMF4 did the Y85F strain produce statistically similar 
levels of induction to those seen in the wild type. As predicted, the Y144F mutation did not 
cause a significant reduction in release of MmfR by MMF4. Interestingly it did actually 
appear to produce significantly higher levels of luminescence upon the addition of 100 µM 
MMF4, with more than 125% of luminescence of the wild type strain with MMF4 at 48 hours 
(see Figure 4.17). Whether this mutation has indeed ‘optimised’ the binding pocket and made 
it more sensitive is as yet unclear but would be an interesting idea to investigate further in the 
project. It was an artefact also identified by Shanshan Zhou when running an in vitro gel shift 
assay, further indicating that a version of MmfR with improved ligand binding has indeed 
been produced.  
Another observation from Figure 4.16 is that neither the Y85F or Y144F mutants appear to be 
as good at repressing luminescence as the wild type MmfR at the mmfLR intergenic region 
with both L1+mmfR Y85F and L1+mmfR Y144F producing higher levels of luminescence 
L1+WTmmfR in the absence of the MMFs. Y144F appears to be a better repressor than Y85F 
however. Although the mutations were to the ligand binding pocket, they are close to the 
dimer interface and so could be also effecting the overall structure of the protein and therefore 
its DNA binding properties. 
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Data from Figure 4.17 in particular, reveals large standard deviations and huge overlaps in the 
error bars. A t-test did show that the variation in the different sets of results were statistically 
significant but it is unclear whether from this data alone, reliable conclusions can be made 
about the activities of the mutant MmfRs compared to the wild type. For this reason it was 
decided that a range of concentrations of MMF4 would be trialled and the Bmax and Kd values 
derived in the hope of achieving some more distinct differences between samples. To obtain 
the Bmax and Kd values, MMF4 was added at the same ranges of concentrations as were added 
to the wild type MmfR strains in Section 4.4.2. 
The standard curves collected for MMF4 binding to L1+mmfR Y85F and L1+mmfR Y144F 
compared to earlier data collected for L1+WTmmfR with MMF4 are shown in Figure 4.18. 
Using this data, the Bmax, Kd and binding potential of MMF4 to each of the mutants was 
calculated. These values have been compared to those from the wild type MmfR in Table 4.6. 
 
Figure 4.18. Standard curve for production of luminescence as a result of MMF4 
binding to and releasing the wild type MmfR compared to tyrosine 85 and 144 mutants 
Strain used: L1+WTmmfR, L1+mmfR Y85F and L1+mmfR Y144F – luxCDABE under the 
control of mmfLp (L1) and mmfR under the control of ermEp* producing either the wild type 
MmfR, a Y85F mutant or a Y144F mutant (pKMS01, pKMS85 and pKMS144). 
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Table 4.6. Binding kinetics data for MMF4 binding wild type MmfR compared to the 
tyrosine 85 and 144 MmfR mutants, including the Bmax, Kd and binding potential values 
for each at 48 hours growth 
Binding potential = Bmax/Kd 
L1+mmfR strain Bmax Kd (µM) Binding potential 
WT and MMF4 18.3 69.42 0.26 
Y85F and MMF4 2.8 37.51 0.07 
Y144F and MMF4 5.8 11.13 0.52 
 
As can be seen in Table 4.6, the binding potential of the Y85F MmfR mutant to MMF4 is 
much lower than the wild type binding to the same ligand. This data further confirms that the 
hydroxyl group of the tyrosine residue in position 85 of MmfR is likely to be necessary for 
ligand binding and the resultant conformational change causing its release from the MARE 
operator. The Y144F mutant on the other hand appears to have a binding potential of almost 
double that of L1+WTmmfR with MMF4. It again appears therefore that this mutation has 
optimised the repressor, reducing the amount of MMFs needed to achieve de-repression. 
Further investigation is needed to establish whether the same would be seen for all five 
MMFs. 
It is also of note that both the Y85F and Y144F mutants have a lower Bmax than the wild type. 
This indicates that for both of these mutants, there were differences in the level of MmfR 
release from the MARE operator that can be achieved the presence of the MMFs at a 
saturating concentration. The differences in DNA binding properties of the mutants is still 
poorly understood however. 
Alanine Mutants 
Alanine mutants of the tyrosine residues were also created by another group member and 
were used to carry out gel shift assays. It appears that despite the NH2 group being present in 
alanine, the change the shape of the binding pocket by the smaller amino acid was enough to 
significantly alter MMF binding in the Y144A mutant. This therefore gives further evidence 
to tyrosine 144 being key to ligand binding as well as the tyrosine in position 85. 
4.4.5 Discussion of MmfR/MMF Binding Data 
Figure 4.19 summarises the data found on MmfR/MMF binding using the luciferase reporter 
gene assay, combining both the analyses done on the binding affinities of the five MMFs to 
the wild type MmfR as well as the MmfR ligand binding pocket tyrosine mutants. Unless 
otherwise stated, this figure refers to the wild type mmfR strains. 
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Figure 4.19. Bar chart showing a comparison of the binding potentials of MMF1-5 for 
WT MmfR, as shown by the levels of luxCDABE expression when under the control of 
mmfLp and WT MmfR, compared to the binding potential for MMF4 with the Y85F or 
Y144F MmfR mutants  
Binding potential = Bmax/Kd Strains used: L1+WTmmfR – luxCDABE under the 
control of mmfLp and wild type mmfR under the control of ermEp* (pKMS01), L1+mmfR 
Y85F – luxCDABE under the control of mmfLp and mmfR with a mutation to tyrosine 85 
under the control of ermEp* (pKMS85), L1+mmfR Y144F – luxCDABE under the control of 
mmfLp and mmfR with a mutation to tyrosine 144 under the control of ermEp* (pKMS144). 
Unless otherwise stated, L1+WTmmfR is used for all data points. 
 
Results from the luciferase assay revealed that there are detectable changes in lux gene 
expression with concentrations of the MMFs as low as 5 µM, with the Kd values ranging 
between 18 and 70 µM for the five molecules. Saturation of MmfR appears to occur sometime 
after around 200 µM, and varies between the particular ligands. The binding potentials varied 
between the different MMFs, with the branched alkyl chains providing the best efficacy. 
Four out of the five MMFs had a calculated Bmax bioluminescence reading greater than the 
maximal reading for the positive control (L1+pCC4) indicating that they may have more of a 
dose effect that just releasing MmfR and may work as some kind of activator. This is 
something which would be exciting to investigate further, potentially with a more high 
throughput assay than the luciferase one used here. 
An in silico analysis of MmfR and its homologues indicated that there are two key residues 
involved in ligand binding in MmfR, that of tyrosines in amino acid positions 85 and 144. 
This was indicated to be consistent in binding across all five MMFs and mutants created for 
these residues provided an interesting set of data. 
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To summarise the findings from Section 4.4, the following binding potentials were calculated 
for all of the samples tested (see Figure 4.19); 
MMF1 > Y144F MMF4 > MMF3 > MMF5 > MMF4 > MMF2 > Y85F MMF4 
The binding potential of the Y85F MmfR mutant to MMF4 is much lower than the wild type 
binding to the same ligand, or indeed any of the other furans. The Y144F MmfR mutant on 
the other hand appears to have increased release from the MARE operator in the presence of 
MMF4 when compared to the wild type. This mutant also appears to have greater binding 
potential to MMF4 than the wild type strain does to either MMF2, 3 or 5. 
Although the Y144F mutant appears to be more sensitive to the MMFs, it was not deemed 
suitable for later use in the novel inducible expression system due to its decreased repressive 
activities. These decreased repressive activities were also seen for the Y85F mutant, possibly 
as a result of the ligand binding residues selected for mutation being close to the dimer 
interface of MmfR and therefore are potentially having an effect on MmfR conformation and 
consequently, DNA-binding ability. 
 
 
4.5 Outlook for Further Investigations 
In this chapter MmfR has been shown to cause repression at the three known methylenomycin 
gene cluster MARE operators as well as being released upon the binding of all five MMFs, in 
line with the hypotheses for this investigation. When stating these hypothesis, it was 
explained that the role of the MmfR paralogue, MmyR was much less understood. Knockouts 
of this protein, a potential pseudo MMF receptor, produce the phenotype of methylenomycin 
overproduction.(71) It is therefore clear that it has a repressive role. The DNA binding 
sequences and ligands of this second type of TFR are ambiguous however. The next stage of 
this investigation into methylenomycin cluster repressor/ligand interactions is to use the 
luciferase assay to study the role of paralogue, MmyR. Many of the methods used in Chapter 
4 were also used for this investigation. For example, an investigation into strength of MARE 
operator binding could be done in the same way with this alternate repressor. 
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5 Mode of Action of Transcriptional Repressor 
MmyR in Streptomyces coelicolor 
5.1 Comparison of MmyR with MmfR and Homologous 
Regulatory Pathways 
Before the investigations in this project, the ligand and DNA binding properties of MmyR 
were unknown and it was thought to be a protein akin to the GBL pseudoreceptor type TetR 
family members. An investigation of identity and similarity between MmfR and MmyR 
reveals that they share 35% identity and 56% similarity over 110 amino acids (just over 50% 
of their sequences) (see Table 7.3, Table 7.4 and Appendix C). Unsurprisingly the area where 
most identity is shared covers the N-terminal TetR family HTH domain. MmyR also shares 
47% and 39% identity across 58% and 94% of its amino acid sequence with its orthologues 
GbnR and SAV_2268 from S. venezuelae and S. avermitilis respectively compared to 36% 
and 50% identity seen with their paralogues, SgnR and SAV_2270 (across 72% and 34% of 
its sequence). Despite these general similarities however, there are key differences in the 
ligand (Section 5.4) and DNA binding (Section 5.3.1) regions of MmfR and MmyR. 
Figure 4.14 shows an entire amino acid sequence alignment and comparison carried out for 
homologues MmfR, MmyR, SAV_2270 and SgnR. Residues identified as being found in the 
ligand binding pocket of MmfR in Section 4.4.3 have been highlighted. Matches to the MmfR 
polypeptide sequence are shown in blue with mismatches shown in yellow. 
It appears that the tyrosines in positions 85 and 144, believed to be involved in hydrogen 
binding the ligand, are conserved across all of the MmfR orthologues but are absent in the 
paralogous MmyR and its own orthologues (not shown here). Preliminary trials with the 
luciferase assay indicated that MmyR is not released upon the addition of MMFs to the 
media, it is not surprising therefore that MmyR is not shown to include either of these 
tyrosine residues or the majority of the residues involved in hydrophobic interactions. This 
and the low levels of repression by MmyR seen in the luciferase assay indicate that MmyR 
works in a very different way to MmfR. These differences are under investigation in this 
chapter, also using the luciferase assay.  
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Figure 5.1. Comparison of MmfR ligand binding amino acid residues with the sequences 
of homologues MmyR, SgnR and SAV_2270 
 Blue – matches with MmfR, Yellow – mismatches with MmfR 
Amino acid sequences used: MmfR – methylenomycin cluster transcriptional repressor, 
MmyR - methylenomycin cluster transcriptional repressor, SgnR – MmfR homologue from 
Streptomyces venezuelae, SAV_2270 – MmfR homologue from Streptomyces avermitilis 
 
5.2 Aims and Strategy of Investigation 
Previous investigations have shown that recombinant MmyR is not soluble when purified 
from standard E. coli expression systems and it has therefore not yet been possible to purify it 
for crystallisation. Without currently being able to purify this protein, the types of analyses 
that can be run on it are more limited, for example a gel shift assay cannot be run. Without the 
3D structure of this protein in silico docking analyses are also much less reliable. The 
bioluminescence assay therefore offers a very useful technique for studying MmyR in vivo.  
Again, the two vector system was used (Figure 3.3) with mmyR added in a vector under the 
control of ermEp* (pKMS03) instead of mmfR (pKMS01) in addition to the lux vector with 
luxCDABE under the control of one of the MARE operators containing methylenomycin 
cluster intergenic regions. As was done for MmfR, this investigation was split into two main 
parts. The first was to investigate MmyR/MARE operator binding, looking at the three known 
MmfR binding sequences, this time with MmyR. The second part of the investigation looked 
at MmyR/MMF binding. This also included an investigation into other potential cognate 
 
MmfR          ---MTSA--QQPTPFAVRSNVPRGPHPQQERSIKTRAQILEAASEIFASRGYRGASVKDV 
MmyR          --------------------------MKQARAMRTRDQVLDAAAEEFALHGYAGTNLATV 
SAV_2270      MDVMSSERNGQSTRLPAGTPFDDTAHLKQQRAIRTRGTILNAAAAAFATDGFPQVTIKDI 
SgnR          -------------------MATPRSQPKQERARRTKVHILQSAAELFAERGYATVTLQDV 
                                         :* *: :*:  :*::*:  **  *:  ..:  : 
 
MmfR          AERVGMTKGAVYFHFPSKESLAIAVVEEHYARWPAAMEEIRIQGF-TPLETVEEMLHRAA 
MmyR          AVRTGMTKGALYGHFPSKKALADELVSQSTETWNTIGRSIAETAC-APETALRALVLAVS 
SAV_2270      ADGAEMTKGAVYFHFPNKEALAVAVLEEFYRRMQEAVNGALEHGDPTSPTTVVDVMRRLA 
SgnR          AERAEMTKGAVYFHYTNKEALAVAVVQEHYARWPEILKGAEGDHA-EPFDMLTAVLDTVT 
              *  . *****:* *: .*::**  ::.:         .             :  ::   : 
 
MmfR          QAFRDDPVMQAGARLQSERAFIDAELPLPYVDWTHLLEVPLQD----AREAGQLRAGVD- 
MmyR          RQMKHDIRFRAALRLAADC-------TMPAGGAPDLLDRIRREMAAAARDTQQQQAPYSP 
SAV_2270      RAFHEDVFIHAGARLQIERPYIKAELPVPYVGTLKVLTELLDQ----CRTAGNLPKSTK- 
SgnR          RAFARDIVVQAGARLQIERALIDAELPEPYVGWEDYLTRLIAE----ARDAGQLRDGVE- 
              : :  *  .:*. **  :          *     . *     :    .* : :     .  
 
MmfR          -----PAAAARSLVAAFFGMQHVSDN-LHQRA--DIMERWQELRELMFFALRA---- 
MmyR          LATQPPDVVVHLLLTVAYGLSFAAERGAPGRSPATTDKVWELLLTALQLEDISTCHN 
SAV_2270      -----PEALARALGSAVFGAQHISWV-LNDRE--DIVERVEEIIDAFVPLH------ 
SgnR          -----PRAAARVLVSAFFGMQHISDV-LSGRS--DLTERYEELRTVLLEGLRR---- 
                   * . .: * :. :* .. :      *      :  : :   :    
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ligands for MmyR, in line with the differential ligand binding properties of the pseudo GBL-
receptors, analogous to this protein. 
In addition to the in vivo reporter gene analysis of MmyR activity, a number of in silico 
amino acid sequence analyses were also carried out in an attempt to better understand the 
differences between MmyR and the paralogous MmfR and which motifs in their amino acid 
sequences may be responsible for any different functionality seen. 
 
5.3 MmyR-MARE Operator Interactions 
5.3.1 Strength of MmyR Binding to the MARE Operator 
In the previous chapter, MmfR was shown to cause repression of the lux operon in the 
presence of all three predicted 24 bp MARE operators, here we are investigating if this is also 
the case for MmyR. The same nomenclature for strains is used here as were followed in 
Chapters 3 and 4. 
Figure 5.2 shows a bar chart of data collected of luminescence produced by Streptomyces 
strains at 48 hours in the presence of MmyR compared to no repressor at the same MARE 
operator (pCC4 positive control) and the M145 negative control. If MmyR were binding to a 
particular MARE operator then a reduction in luminescence would be expected for that strain 
compared to the positive control strain with no repressor. The luminescence produced by the 
M145 control strain represents how the system looks in the absence of luxCDABE expression. 
Data on MmfR repression at each MARE operator is also included in Figure 5.2 as a 
reference point of what significant repression in this luciferase reporter system may look like. 
The data from Figure 5.2 was then used to perform a t-test to check if the level of repression 
caused by MmyR at each MARE operator was a statistically significant level of repression or 
down to natural fluctuations in bioluminescence. The results from this t-test are found in 
Table 5.1. The p-values for the mmyR and mmfR strains were calculated against the results for 
the L1, L2 or L3 + pCC4 positive control strains (offsetting the influence of promoter strength 
on data). The mean and median luminescence shown in Table 5.1 was calculated as a ratio, 
relative to the luminescence produced by the M145 control. 
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Figure 5.2. Bar chart of luminescence produced by S. coelicolor M145 strains at 48 
hours, where luxCDABE expression is controlled by different MARE operators, in the 
presence or absence of MmfR or MmyR 
Luminescence produced is calculated as a ratio of the luminescence produced by the M145 
negative control. Error bars are shown as the standard deviations of data with all data points 
collected also shown on the chart. 
Strains used: M145 – negative control strain, L1, L2 and L3 + pCC4 - luxCDABE under the 
control of mmfLp, mmyRp or mmyBp with empty pCC4, L1, L2 and L3 + mmfR – 
luxCDABE under the control of mmfLp, mmyRp or mmyBp and mmfR under the control of 
ermEp* (pKMS01), L1, L2 and L3 + mmyR – luxCDABE under the control of mmfLp, 
mmyRp or mmyBp and mmyR under the control of ermEp* (pKMS03). 
 
Table 5.1. Statistical analysis of luminescence produced by S. coelicolor M145 strains at 
48 hours, where luxCDABE expression is controlled by different MARE operators, in 
the presence or absence of MmfR or MmyR 
Strains used: same as Figure 5.2. Luminescence produced is calculated as a ratio of the 
luminescence produced by the M145 negative control. Results for t-test were calculated 
against the results for the L1, L2 or L3 + pCC4 positive control strains. 
Strain 
Mean 
luminescence 
produced 
Median 
luminescence 
produced 
t-test results of 
data compared 
to L1, L2 or L3 
+ pCC4 
Significant 
binding at the 
MARE 
operator? 
M145 1.0 0.86 - - 
L1+mmfR 3.2 2.81 6.8E-17 YES 
L1+mmyR 21.7 21.59 1.2E-03 YES 
L1+pCC4 32.0 31.94 - - 
L2+mmfR 24.4 23.81 1.9E-11 YES 
L2+mmyR 94.9 103.60 3.9E-01 NO 
L2+pCC4 86.2 86.54 - - 
L3+mmfR 8.7 8.34 1.1E-13 YES 
L3+mmyR 34.6 31.95 1.1E-04 YES 
L3+pCC4 57.7 53.09 - - 
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As can be seen from the results of the t-test (Table 5.1), there was indeed a significant level of 
repression by MmyR at two of the three MARE operator sites; the L1 and L3 MARE 
operators. The levels of repression at both these sites are much lower than MmfR binding 
however with between 3.9 and 6.8 times more luminescence being produced by the mmyR 
strains compared to the mmfR strains at the L3 and L1 MAREs respectively. 
The t-test indicated that at the MARE between mmyR and mmfP (L2 MARE operator) there is 
not a significant change in luminescence when MmyR is present compared to when it is not. 
It is interesting that MmyR does not appear to bind to the MARE operator that regulates its 
own expression, meaning that it is potentially not self regulatory in the way that MmfR is (see 
Chapter 6). MmfR does show significant binding to the L2 MARE, but it is the weakest 
binding of the three, indicating that this operator has the least regulation. 
To further compare findings from Table 5.1 and Figure 5.2 with the data collected on MmfR 
in last chapter; MmfR binds to the L1 intergenic region with the greatest affinity showing a 
average of 90% reduction in luminescence, followed by L3 with an 85% reduction and then 
L2 at 72% reduction compared to a positive control. MmyR on the other hand appears to bind 
best to the L3 intergenic region, seeing a 40% reduction in luminescence compared to the 
positive control without repressors followed by the L1 intergenic region strains which sees an 
average reduction in luminescence of 32%. 
To understand the differences in MmfR and MmyR binding to the MARE operators it is 
necessary to check their amino acid sequences. Both MmfR and MmyR have a predicted 
DNA binding motif within their TetR type HTH domains. Within this 20 bp region, there 
were found to be conserved similarities and differences between MmfR and MmyR and their 
individual orthologues from S. venezuelae and S. avermitilis. Table 5.2 shows a comparison 
of these DNA binding motifs in the six homologues. There is a conserved GAVYFH sequence 
found in MmfR, SgnR and SAV_2270 whereas MmyR and its orthologues have an alternative 
conserved GALYGH sequence. These conserved two amino acid variations are the potential 
cause of the different DNA binding profiles. This would make an interesting target for site 
directed mutagenesis, to see if the DNA binding profiles of MmfR and MmyR can be 
exchanged by altering only these two residues. 
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Table 5.2. Sequences of DNA binding regions from MmfR, MmyR and their homologues 
Name Sequence (20 aa) 
MmfR SVKDVAERVGMTKGAVYFHF 
SgnR TLQDVAERAEMTKGAVYFHY 
SAV_2270 TIKDIADGAEMTKGAVYFHF 
SAV_2268 NLQNIADRIRLTKGALYGHF 
GbnR NLADITARTGLTKGALYGHF 
MmyR NLATVAVRTGMTKGALYGHF 
 
Having seen the limited repressive activity of MmyR on the methylenomycin cluster MARE 
operators it begs the question of how a mmyR knockout brings about the phenotype of 
methylenomycin over production when the mmfR knockout does not (Table 6.1). Based on the 
findings of there being a conserved and different DNA binding motif in MmyR and its 
orthologues to MmfR, it would not be unrealistic to conclude that maybe MmyR binds 
additional, as yet unknown, DNA targets and regulates methylenomycin biosynthesis by 
another means. It may repress less strongly than MmfR but have many more genetic targets. 
Another possible theory is that it is only the strength of the mmyR promoter (L2 strains, see 
Section 3.4) and therefore the amounts of MmyR produced that allow repression of the 
methylenomycin cluster by MmyR to take place. In this system, MmyR levels are limited by 
the weaker ermEp* promoter and so the full level of repression expected in vivo in the wild 
type system may not be seen. An alternative hypothesis is that maybe MmyR is only active as 
a repressor in a ligand bound form rather than the apo form. 
The luciferase assay was therefore again utilised to try and further understand the complex 
relationship between MmyR and methylenomycin regulation. An initial investigation was 
done in the same way as was done for MmfR in the previous chapter, looking for the release 
of MmyR by a single concentration of MMF4 at each of the MARE operators. 
5.3.2 Investigation into Release of MmyR from MARE operators by 
MMF4 
Preliminary research (Section 3.3.5) indicated that MmyR will not bind to the MMFs and be 
released from the DNA as MmfR is. MmyR also lacks the two tyrosine residues present in the 
ligand binding pocket of MmfR that are believed to form hydrogen bonds with the furan 
ligands. However, the potential release of MmyR by the MMFs did need to be checked to 
confirm the preliminary findings using the fully optimised luciferase assay. This assay was 
carried out in the same manner as the investigation into MmfR in Section 4.3.3. However, 
reduction as well as increase in luminescence was looked for this time, in case MmyR was 
only working as a repressor in a ligand bound form.  
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Figure 5.3 shows the luminescence from L1+mmyR and L3+mmyR strains in the presence of 
100 µM MMF4 compared to the same strains without MMF4. This data was then checked 
with a t-test to see if there was any significant change in the amount of luminescence 
produced in the presence of MMF4, the results of which are displayed in Table 5.3. The 
L2+mmyR strain was also included in this study as a control, no significant MmyR binding to 
the L2 MARE operator was seen and therefore no removal of repression would be expected to 
be seen either. 
 
Figure 5.3. Bar chart of luminescence produced by the lux operon when under the 
control of different MARE operators and MmyR, in the presence and absence of 100 
µM MMF4 at 48 hours 
The data for the mmyR strains with MMF4 were normalised against the same strain with no 
MMF to give a relative ratio of 1 for each negative control. The error bars for this data show 
the standard deviations. Strains used: L1, L2 or L3 + mmyR – luxCDABE under the control 
of mmfLp, mmyRp or mmyBp and mmyR under the control of ermEp* (pKMS01) 
 
Table 5.3 Statistical analysis of luminescence produced by the lux operon when under 
the control of different MARE operators and MmyR, in the presence and absence of 100 
µM MMF4 at 48 hours 
Strains used: same as Figure 5.3. The data for the mmyR strains with MMF4 were 
normalised against the same strain with no MMF to give a relative ratio of 1 for each 
negative control. 
Strain 
Mean ratio of 
luminescence 
produced 
p-value Significant change in luminescence? 
L1+mmyR 0.93 0.3122 NO 
L2+mmyR 0.94 0.5756 NO 
L3+mmyR 0.56 0.0016 YES (significant decrease) 
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As expected, there was no significant change in the L2+mmyR strain in the presence of 
MMF4. The same was also found for L1+mmyR. The results were more noteworthy for 
L3+mmyR however, where a significant decrease in luminescence was observed in the 
presence of MMF4. This is inline with the hypothesis that MmyR is active in its ligand bound 
form and indicates that MmyR binds better to the L3 MARE operator in the presence of 
MMF4. However the change is not large, with L3+mmyR with MMF4 still producing an 
average of 19 times as much luminescence as the M145 control (compared to nine times more 
for L3+mmfR1). This decrease in luminescence may still not be sufficient to make a 
significant impact on the expression of methylenomycin biosynthetic cluster. The true 
implication of this result is therefore as yet unclear. Due to a lack of data on the structure of 
MmyR it is unfortunately not possible to determine the 3D ligand binding pocket to try and 
interpret these results better. MmyR binding at the mmyB/mmyY intergenic region was 
therefore further investigated in Section 5.4.3 on page 113 using the luciferase assay. 
5.3.3 Discussion of MmfR/MARE Operator Binding Data 
Table 5.4 summarises the findings found of MmyR binding and release from the three 
methylenomycin cluster MARE operators. It can be seen that MmyR binds best at the 
operator between mmyY and mmyB (L3) and this binding is appears to strengthen upon the 
addition of 100 µM MMF4. Binding is also shown to the L1 MARE operator but with no 
significant change upon the addition of MMF4. No binding to the L2 MARE operator was 
detected either in the presence or the absence of the MMFs. 
Table 5.4. Summary of binding data for MmyR and the MARE operators 
MARE 
operator 
site 
Corresponding 
promoter 
Strength of MmyR 
binding 
Significant change in 
MmyR binding upon 
addition of MMF4 
Relative promoter 
strength (1 being 
the highest) 
L1 mmfLp Weakest NO 5 
L1F mmfRp - - 2 
L2 mmyRp No binding shown NO 1 
L3 mmyBp Greatest YES (increased binding) 4 
L3F mmyYp - - 3 
 
When comparing the sequences of the three individual operators it was found that there is 
almost 80% identity between the L1 and L2 MARE operator but each of these only share 62-
67% identity with the L3 MARE operator (for L1 and L2 respectively), according to an 
alignment (137) run with T-Coffee; 
 
                                                      
1 See Section 4.3 
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L1   5’ ATAATACCTTCC CGCAGGTATATT 3’ 
3’ TATTATGGAAGG GCGTCCATATAA 5’ 
 
L2   5’ AACATACCTTCC CGAGGGTATGTT 3’ 
3’ TTGTATGGAAGG GCTCCCATACAA 5’ 
 
L3   5’ AAAAAACCTTCG GGAAGGTTTGAC 3’ 
3’ TTTTTTGGAAGC CCTTCCAAACTG 5’ 
                  *  * ******   *  *** *    
 
It seems strange therefore, that it is the L2 MARE operator, rather than L3, which has the 
more distinct MmyR binding profile. This weaker binding and repression at the L2 MARE 
operator is also something that is seen for the data collected on the mmfR strains in the 
previous chapter however, emphasising the potential importance of the two residues that are 
conserved between the L1 and L3 MARE operators (highlighted in yellow) but not present in 
L2 in interacting with the HTH DNA binding domain of MmyR (and MmfR). 
The investigation in Section 5.3.2 gave evidence of possible MmyR/MMF interactions and 
there was a interest in investigating this further. L1+mmyR strains were first used to trial all of 
the MMFs (Section 5.4.1) to allow a direct comparison with data from L1+mmfR. The 
potentially more important L3+mmyR strains were then investigated with the MMFs, the data 
from which can be found in Section 5.4.3. 
 
5.4 MmyR-MMF Interactions 
5.4.1 Effect of MMFs on MmyR Binding at the L1 MARE Operator 
As reported in Section 5.3, it is clear that 100 µM MMF4 does not cause the release of MmyR 
from the L1 MARE operator. It seems unlikely that any of the other MMFs will bind to and 
release MmyR from the DNA at this site either. However, there is limited experimental data 
to prove that this is the case and so all were therefore analysed, particularly as some MMFs 
have a greater relative binding potential than others. The structural differences between the 
five MMFs mean that the possibility of MmyR binding to some MMFs, even if it was not 
seen in the case of MMF4, cannot be discounted. MMF1, 2, 3 and 5 (Figure 5.6) were all 
added at a concentration of 100 µM to the L1+mmyR strains and the luminescence assay 
carried out in the same way as it was done for L1+mmfR strains in Section 4.4. 
The findings from measuring luminescence at five time points over 72 hours can be found in 
Figure 5.4. This data was then analysed as before using a bar chart to look results at from 48 
hours only, this can be found in Figure 5.5. A t-test was then used to determine if there are 
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any statistically significant results, the results of which can be found in Table 5.5. Results for 
L1+mmfR are also included to represent what more significant repression in this system might 
look like. 
 
Figure 5.4. Luminescence produced by the lux operon when controlled by mmfLp and 
MmyR in the presence of 100 µM MMF1-5 compared to no MMFs 
Average light production is calculated as a relative ratio of luminescence produced by 
L1+mmyR with no MMFs (giving this sample a value of 1). Strains used: L1+mmfR – 
luxCDABE under the control of mmfLp and mmfR under the control of ermEp* (pKMS01), 
L1+mmyR – luxCDABE under the control of mmfLp and mmyR under the control of 
ermEp* (pKMS03). Unless otherwise specified, all data points are for the L1+mmyR strain. 
 
As can be seen in Figure 5.4, there are some fluctuations in luminescence produced by 
L1+mmyR in the presence of the MMFs compared to no MMFs present but results using 
different furans never vary significantly from the negative control (L1+mmyR, no MMFs). 
The levels of luminescence produced by L1+mmfR are distinctly lower that those for the 
L1+mmyR strain in the presence of the MMFs at all time points however. This indicates that 
the MMFs are not causing MmyR to act as a repressor in a ligand bound form at the L1 
MARE operator. Figure 5.5 and Table 5.5 also support this. 
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Figure 5.5. Effect on luminescence produced by the lux operon, when controlled by 
mmfLp and MmyR, by the addition of 100 µM MMF1-5 at 48 hours growth 
Average light production is calculated as a relative ratio of luminescence produced by 
L1+mmyR with no MMFs (giving this sample a value of 1). Strains used: Same as Figure 
5.4. Unless otherwise specified, all data points are for the L1+mmyR strain. 
 
Table 5.5. A t-test analysis of the effects on luminescence produced by the lux operon, 
when controlled by mmfLp and MmyR, by the addition of 100 µM MMF1-5 at 48 hours 
growth 
Average light production is calculated as a relative ratio of luminescence produced by 
L1+mmyR with no MMFs (giving this sample a value of 1). The p-value was also calculated 
based on L1+mmyR with no MMFs. Data for L1+mmfR is included as a comparison to 
represent how more significant repression look in this kind of assay. 
MMF added to 
L1+mmyR p-value 
Significant 
difference? 
Average light 
production at 48 
hr (R.R) 
MMF1 (100 µM) 0.2008 FALSE 1.09 
MMF2 (100 µM) 0.3266 FALSE 0.93 
MMF3 (100 µM) 0.1041 FALSE 1.13 
MMF4 (100 µM) 0.3122 FALSE 0.93 
MMF5 (100 µM) 0.3327 FALSE 1.08 
L1+mmfR (no MMF) <0.0001 TRUE 0.15 
 
The t-test results shown in Table 5.5 confirm that there is no significant release or extra 
binding of MmyR upon the addition of the five MMFs when looking at measurements for the 
L1 MARE operator. Without there being any significant effects on luminescence by adding 
the MMFs to the L1+mmyR strains, no further analyses were done to try and work out the Kd 
and Bmax values for this strain. 
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Following on from the work with MmyR with the five MMFs, a further investigation was 
carried out to look for other potential cognate ligands for MmyR, in line with the hypothesis 
that this pseudo GBL-receptor analogue may bind alternative ligands to MmfR. 
5.4.2 Effect of Other Potential Ligands on MmyR Binding at the L1 
MARE Operator 
Previous studies of MmyR homologues such as ScbR2 have shown that this pseudo GBL 
receptor will bind to and be released by endogenous antibiotics, potentially a form of cross 
regulation between pathways.(138) It would appear logical that either an MMF or the end 
product of the methylenomycin biosynthetic cluster; methylenomycin A, or one of its 
precursors may bind to MmyR. In this case however, with limited repression seen in the apo 
form, MmyR may only be ‘activated’ as a repressor by the cognate antibiotic. Binding to 
methylenomycin A or a precursor could be a method to prevent the over production of the 
antibiotic, something that would be potentially toxic to the streptomycetes as well as a drain 
on cell resources if the antibiotic is not needed anymore. As yet, there has been no 
experimental evidence of this negative feedback loop. 
Both methylenomycin A and the precursor methylenomycin C (Figure 5.6) trialled with the 
L1+mmyR strain to look for any significant change in luminescence produced. This could be 
either an increase in luminescence if these small molecules cause the release of MmyR or a 
reduction in luminescence if they are ‘activating’ MmyR as a repressor. 
 
 
Figure 5.6. Chemical structures of methylenomycin furans, methylenomycin A and its 
precursor; methylenomycin C 
 
Methylenomycin A and C have lengthy purification procedures which do not yield large 
amounts of product. For this reason, preliminary trials were run where the methylenomycins 
were added in different concentrations to sterile filter paper discs on top of a lawn of 
L1+mmyR, in an effort to decrease the volumes of these small molecules needed. From this, 
the aim was that more thorough trials could be designed and run when more was known about 
optimal concentration of the potential ligands. The methylenomycin molecules were diluted 
in DMSO and added at a range of concentrations that have been shown by other researchers 
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in the group to not be toxic to Streptomyces. Figure 5.7 shows these L1+mmyR plates with 
methylenomycin C and A added. 
        
Figure 5.7. CCD camera images of luminescence produced by a lawn of S. coelicolor 
M145 containing the lux operon under the control of mmfLp and MmyR in the presence 
of methylenomycin A and C compared to a DMSO control 
Methylenomycin A and C were used diluted in DMSO at a concentration of 5.5 mM and 6.0 
mM respectively and added to sterile paper dots on a lawn of L1+mmyR. Equivalent amounts 
of DMSO were added as a negative control. 
 
As can be seen in Figure 5.7, there does not appear to be any obvious difference in 
luminescence when adding methylenomycin A or C when compared to a DMSO control. 
However, it was very hard to spread an even lawn of Streptomyces over such a large plate, 
meaning that any small changes in luminescence may be missed due to a non-uniform lawn of 
streptomycetes present. This investigation was therefore carried forward to tests involving 
quantitative data taken from 12-well plates as was done in all previous investigations with the 
luciferase assay. The data for this investigation can be see in Figure 5.8 and Figure 5.9. Due 
to the lack of methylenomycins available however, the number of trials that could be run were 
limited and not every possibility could be tested. 
Figure 5.8 compares luminescence produced by the L1+mmyR strain in the presence and 
absence of methylenomycin A or C compared to the L1+mmfR strain over five time points in 
72 hours. 
Chapter 5 | Mode of Action of Transcriptional Repressor MmyR in Streptomyces 
coelicolor 
 111 
  
Figure 5.8. Luminescence produced by luxCDABE, under the control of mmfLp and 
MmyR, in the presence of different concentrations of methylenomycin A and C 
Average light production is calculated as a relative ratio of luminescence produced by 
L1+mmyR with no potential ligand added (giving this sample a value of 1). 
Strains used: L1+mmfR – luxCDABE under the control of mmfLp and mmfR under the 
control of ermEp* (pKMS01), L1+mmyR – luxCDABE under the control of mmfLp and 
mmyR under the control of ermEp* (pKMS03). Unless otherwise specified, all data points are 
for the L1+mmyR strain. 
 
The data collected from the methylenomycins show more promise in having interactions with 
MmyR at the L1 MARE operator than the MMFs. As can be seen in Figure 5.8, there is a 
general decrease in the levels of luminescence in the presence of methylenomycin A and C 
compared to those seen for the MMFs in Figure 5.4.  
The effects of methylenomycin C and A on luminescence appear greatest in the first 27 hours 
but this fluctuates a lot, with different concentrations swapping in position in terms of greatest 
level of light produced. It was found in earlier investigations (see Chapter 3 and 4) that 
readings from the 48 and 72 hour time points had smaller standard deviations and the cell 
cultures appeared to have stabilised in growth. The methylenomycins were added at a 
concentration below the predicted lethal level but will likely still cause stress to the cells and 
so potentially disrupt their growth. This may explain why a general dip in luminescence was 
seen at 21 hours in Figure 5.8 before increasing again over the next few days. As a control, 
methylenomycin C was added to L1+pCC4 strains (data not shown here), this showed no 
significant difference in luminescence produced when compared to the same strain in the 
absence of methylenomycin C during the first four time points. There was however a decrease 
in luminescence at the 72-hour time point, possibly due to cell death caused by the antibiotic. 
For these reasons, a statistical analysis run from MmyR/methylenomycin data at the 48 hour 
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time point, to avoid this potential cell death and the larger deviations at the earlier time points 
as well as allowing direct comparisons with all other data collected in previous chapters. The 
results from this analysis can be found in Figure 5.9 and the corresponding Table 5.6. 
 
Figure 5.9. Bar chart of the effect on luminescence produced by luxCDABE, under the 
control of mmfLp and MmyR, by the presence of different concentrations of 
methylenomycin A and C at 48 hours growth 
Average light production is calculated as a relative ratio of luminescence produced by 
L1+mmyR with no potential ligand added (giving this sample a value of 1). 
Strains used: Same as Figure 5.8. Unless otherwise specified, all data points are for the 
L1+mmyR strain. 
 
Table 5.6. A t-test analysis of the effect on luminescence produced by luxCDABE, under 
the control of mmfLp and MmyR, by the presence of different small molecules at 48 
hours growth  
Average light production is calculated as a relative ratio of luminescence produced by 
L1+mmyR with no MMFs (giving this sample a value of 1). p-value was also calculated 
based on L1+mmyR with no MMFs. Data for L1+mmfR is included as a comparison to 
represent how more significant repression may be seen in the assay. 
MMF added to 
L1+mmyR p-value 
Significant 
difference? 
Average light 
production at 48 hr 
(R.R) 
MMF1 (100 µM) 0.2008 FALSE 1.09 
MMF2 (100 µM) 0.3266 FALSE 0.93 
MMF3 (100 µM) 0.1041 FALSE 1.13 
MMF4 (100 µM) 0.3122 FALSE 0.93 
MMF5 (100 µM) 0.3327 FALSE 1.08 
MmA (2.2 µM) 0.0003 TRUE 0.72 
MmC (2.4 µM) 0.0017 TRUE 0.79 
MmC (7.2 µM) 0.3645 FALSE 0.90 
MmC (12 µM) 0.5558 FALSE 0.95 
L1+mmfR (no MMF) <0.0001 TRUE 0.15 
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Figure 5.9 and the corresponding t-test analysis from Table 5.6 reveal that both 
methylenomycin A and C will cause a significant change in luminescence produced by 
L1+mmyR. However, this was only the case for the lowest concentration of methylenomycin 
C, with the higher ones showing no significant effect on luminescence produced by 
L1+mmyR. Equivalent trials were also run with methylenomycin A but there was not enough 
compound available to get the full set of repeats and so these are not presented here. 
Nonetheless, the few trials that were run did indicate the same pattern, where only the lowest 
concentration of methylenomycin A caused a significant change in luminescence produced. 
The change produced even by the lowest concentrations of methylenomycin A and C are not 
large however, with a reduction in luminescence of less than 30% for L1+mmyR compared to 
the same strain with no compound being present. This compares to presence of MmfR 
(L1+mmfR) producing 85% less luminescence than the L1+mmyR strain (Table 5.6). It is still 
possible that methylenomycin A or C do cause the ‘activation’ of MmyR as a repressor but 
results are currently inconclusive and will likely remain so until the effect of methylenomycin 
concentration and its mechanism of antibiotic action is understood better. 
5.4.3 Further Investigation - Effect of MMFs on MmyR Binding at the 
L3 MARE Operator 
In Section 5.3, MMF4 was shown to cause a significant reduction in luminescence produced 
by the L3+mmyR strain, something not seen at either of the other MARE operators. It was 
therefore decided to investigate further into this result, adding 100 µM MMF2 and MMF5 to 
L3+mmfR and inspecting for changes in luminescence. The assay was carried out using the 
same methods as were used for L1+mmyR strains and results are shown in Figure 5.10, Figure 
5.11 and Table 5.7. Data has also been compared to luminescence produced by L3+mmfR 
(representing more significant repression in this assay) and the positive control; L3+pCC4. 
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Figure 5.10. Luminescence produced by the lux operon under the control of mmyBp and 
MmyR in the absence and presence of 100 µM MMF2, 4 or 5 compared to a positive 
control over 72 hours 
Average light production is calculated as a relative ratio of luminescence produced by 
L3+mmyR with no MMFs (giving this sample a value of 1). Strains used: L3+mmfR – 
luxCDABE under the control of mmyBp and mmfR under the control of ermEp* (pKMS01), 
L3+mmyR – luxCDABE under the control of mmyBp and mmyR under the control of 
ermEp* (pKMS03), L3+pCC4 – luxCDABE under the control of mmyBp, no repressors. 
Unless otherwise specified, all data points are for the L3+mmyR strain. 
 
 
Figure 5.11. Bar chart of luminescence produced by the lux operon under the control of 
mmyBp and MmyR in the absence and presence of 100 µM MMF2, 4 or 5 compared to a 
positive control at 48 hours 
Average light production is calculated as a relative ratio of luminescence produced by 
L3+mmyR with no MMFs (giving this sample a value of 1). 
Strains used: Same as Figure 5.10. Unless otherwise specified, all data points are for the 
L3+mmyR strain. 
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Table 5.7. A t-test analysis of luminescence produced by the lux operon under the 
control of mmyBp and MmyR in the presence of 100 µM MMF2, 4 or 5 at 48 hours  
Average light production is calculated as a relative ratio of luminescence produced by 
L3+mmyR with no MMFs (giving this sample a value of 1). The p-value was also calculated 
based on L3+mmyR with no MMFs. Data for L3+mmfR is included as a comparison to 
represent more significant repression seen in this kind of assay. 
MMF added to 
L1+mmyR p-value 
Significant 
difference? 
Average light 
production at 48 
hr (R.R) 
MMF2 (100 µM) 0.5222 FALSE 0.88 
MMF4 (100 µM) 0.0016 TRUE 0.56 
MMF5 (100 µM) 0.0002 TRUE 0.39 
L3+mmfR (no MMF) <0.0001 TRUE 0.26 
 
The findings of the t-test analysis in Table 5.7 showed that both MMF4 and MMF5 caused a 
significant decrease in luminescence of the L3+mmyR strain, with up to a 61% reduction in 
luminescence seen compared to no MMFs. This compares to a reduction in luminescence of 
74% for L3+mmfR versus L3+mmyR indicating that the presence of MMF5 brings MmyR 
repression almost to the level of that seen for MmfR. MMF2 did also cause a slight decrease 
in luminescence but it was not enough of one to be classed as statistically significant. 
Therefore, the greater the binding potential of the MMF to MmfR the greater the apparent 
decrease in luminescence it brought about in the L3+mmyR strain as well as the lower the p-
value. A higher concentration of MMF2 therefore may reveal more significant results if 
trialled. 
It should be noted that due to time constraints, L3+pCC4 had not been trialled with all five of 
the MMFs as a control during the preliminary investigations in Chapter 3. However, when 
trialled with L1+pCC4, none of the MMFs produced a significant change in luminescence at a 
100 µM concentration. It cannot be said with certainty that this is also the case with the 
L3+pCC4 strain but it reduces the chances that the MMFs are bringing about a change in 
luminescence for the L3+pCC4 strain in the absence of MmyR/MmfR. There is also currently 
no experimental evidence of this extra MMF transcriptional regulation. Therefore, until 
further research is done, MMF interactions with MmyR rather than any other transcriptional 
control are the most reasonable explanation for the changes in luminescence seen in Table 5.7 
and Figure 5.11. 
Based on the analysis from Table 5.7 and Figure 5.11 therefore, it is possible that at least 
some of the MMFs can bind to MmyR to an extent and, in combination with the DNA 
binding sequence at the L3 MARE operator, cause MmyR to work better as a repressor. It has 
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been shown by amino acid sequence analysis that MmyR does not have the same ligand-
binding pocket as MmfR (Figure 5.1). However, if MmyR was indeed binding the MMFs at 
the L3 MARE operator, it appears to lead to a conformational that may help it better bind the 
DNA instead of its release. It is not inconceivable therefore that the ligand-binding site could 
vary considerably between MmfR and MmyR and yet they can still both interact with the 
MMFs, with the differences in the structure of the binding pocket resulting in the opposite 
effect that the MMFs have on each. 
When looking at the levels of repression achieved by L3+mmyR in the presence of the MMFs, 
there is never more than a 60% reduction in luminescence compared to when no MMFs are 
present. The impact of this leaky repression in the wild type system is not known. It must not 
be forgotten however, that the mmyR promoter was shown to be the strongest of the five 
studied in the methylenomycin cluster (Figure 3.16), indicating that relatively high levels of 
MmyR are produced in the absence of repression. In this assay, MmyR repression is limited 
by the strength of the ermE* promoter. MmyR also appears to not regulate itself at the L2 
MARE operator, potentially leading to even greater levels produced in a wild type system 
compared to MmfR, which can repress its own production. 
If the MMFs are promoting the binding of MmyR at the L3 MARE operator then the 
implications would be the repression of the mmyBQEDXCAPK and mmmYF operons, where 
mmyB codes for a pathway specific transcriptional activator and all other genes code for 
enzymes thought to be used in methylenomycin biosynthesis. If there are greater levels of 
MmyR produced in a wild type system than this synthetic system then there may be total 
repression of the production of MmyB, which could be enough to stop the entire biosynthetic 
pathway from being expressed. 
In Section 5.3, it was found that MmyR caused the greatest repression at the L3 MARE 
operator, followed by the L1 MARE operator, with no binding shown at the L2 operator. It is 
not totally clear why MmyR did not also work as a better repressor at the L1 operator in the 
presence of the MMFs. It is possible that the weaker binding of MmyR at 24 bp L1 MARE 
operator sequence means that the addition of 100 µM MMFs was not enough to cause a 
significant change in luminescence. If this is the case, a higher concentration of MMFs being 
added to the L1+mmyR may reveal higher levels of repression. Alternatively, when MmyR 
binds to the L1 MARE operator it may do so in a conformation that makes it harder for the 
MMFs to enter or interact with its ligand-binding pocket. The operator at the L3 intergenic 
region shares less than 63% identity (137) with the one at the L1 intergenic region, it is 
possible therefore that MmyR is in a slightly different conformation when bound at each of 
these sites. 
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5.4.4 Discussion of MmyR-Ligand Interactions 
The results from the investigation into MmyR ligands revealed that there is no significant 
binding to any of the five MMFs in the L1+mmyR strain at a concentration of 100 µM. The 
data collected on methylenomycin A and C as possible ligands was inconclusive with only the 
lowest concentrations giving a significant decrease in luminescence produced for the 
L1+mmyR strain. At this point, it is unclear why the higher concentrations did not show the 
same effects.  
At the L3 MARE operator, the addition of the 100 µM MMFs did appear to cause a 
significant reduction in luminescence produced, indicating the ‘activation’ of MmyR as a 
repressor in the presence of some of the MMFs (particularly those that showed a higher 
MmfR binding potential). To further understand the exact role of MmyR however, 
supplementary investigations are needed. 
A number of papers have indicated that in systems with two repressors such as MmfR/MmyR, 
the second repressor binds a much wider variety of DNA targets as well as ligands.(50) It is 
unclear how many different DNA sequences MmyR may be able to bind to and what its exact 
set of receptor-ligand interactions are. The regulatory role of MmyR appears to be much more 
complicated than that of MmfR. In particular, finding out more about the structure of MmyR 
would be very helpful. As mentioned before, it has not been possible to purify MmyR from 
standard E. coli expression systems available. However, there are some close homologues of 
MmyR from other Streptomyces strains that have shown promise in terms of solubility and 
during crystallisation trials. A broader understanding of the role of one of the MmyR 
homologues would greatly assist in finding out about potential ligands for MmyR as well as 
understanding the conformational change these ligands bring about. These results would also 
hopefully shed some light on how and when MmyR will bind to the MARE operators or other 
DNA sequences.  
As well as work on the structure of MmyR, if larger amounts of methylenomycin A and C 
could be obtained, some more trials could to be run, possibly with lower concentrations of 
these molecules to look for more conclusive results than those found in this investigation. It 
would also be helpful to test L3+mmfR with the remaining MMF1 and MMF3 ligands to 
check whether these two furans also help to activate MmfR as a repressor. These two ligands 
had the greatest binding potential to MmfR and so could be expected to also perform well 
with MmyR. The reason these extra trials with MMF1 and 3 were not run were due to time 
limits on the project as well as lack of availability of the ligands at the time when experiments 
were being run.  
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5.5 Outlook for Further Investigations 
Following on from this investigation of MmyR, it would be interesting to compare the data 
gained here with that obtained for MmfR and together, draw some conclusions about the 
overall regulation of methylenomycin biosynthesis, in particular looking at the combined 
regulation of their own genes as well as other biosynthetic operons. Of particular interest are 
the positive and negative feedback loops that MmfR and MmyR may create through the 
regulation of mmfLp, mmfRp and mmyRp. Through these feedback loops it appears that S. 
coelicolor A(3)2 can retain silence in the methylenomycin gene cluster until needed and then 
switch it off again once no longer required. A further investigation was carried out in the 
following chapter, including the collection of new luminescence data as well as an analysis of 
data already collected from Chapters 3, 4 and 5. From this investigation, there is hope that a 
more complete picture of regulation can be achieved, something that will then be used in the 
development of a novel inducible expression system. 
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6 Investigation of MmfR/MmyR Self-Regulation 
6.1 Background and Strategy of Investigation 
This chapter follows on from the work done with MmfR and MmyR in the previous three 
chapters and their binding affinities to the three MARE operators and five MMFs. It appears 
clear that MmfR and MmyR have different roles in regulation and come together to create a 
complex regulatory network, responding differently to the MARE operators and MMFs. 
The five operons thought to be directly regulated by MmfR are mmyR, mmfLHP, mmfR, 
mmyBQEDXCAPK and mmyYF. In Chapter 4, MmfR was shown to bind to the three 
operators between these operons and be released upon the addition of any of the five MMFs. 
Like other TetR repressors therefore, MmfR appears to controls its own expression as well as 
influencing the expression of the methylenomycin biosynthetic genes (directly or indirectly). 
MmyR on the other hand showed weak binding to only two of the three operators and showed 
no significant release by the MMFs (Chapter 5). Interestingly, MmyR did not show any 
significant binding to the operator that controls its own expression, indicating that unlike 
MmfR, it is not directly auto-regulated. Although no significant release of MmyR was seen in 
the presence of the MMFs, there did however seem to be some interaction of the MMFs with 
MmyR at the L3 MARE operator, with an increased repression of luxCDABE seen.  
The two vector luciferase reporter systems described in Figure 3.3 were used to study MmfR 
and MmyR regulation with the transcriptional repressors being produced under the control of 
the constitutive promoter ermEp* at a constant rate. To study the auto-regulatory action of 
MmfR, a vector that contained mmfR under the control of its native promoter was utilised. 
This vector was constructed by Justin Nodwell and his team and named as 11NY (see Table 
2.5 and Table 2.8).(92) MmyR was also further investigated via another equivalent vector 
named sp105, also constructed by Justin Nodwell and his team. Both 11NY and sp105 have 
the same sequence as the L1 vector (shown previously in Figure 3.4) except for the addition 
of mmfR or mmyR, upstream of the L1 intergenic region (Figure 6.1). These variations are 
represented in the diagram in Figure 6.2C. 
The diagram in Figure 6.1 highlights the intergenic region (found between mmfR and mmfL) 
that is contained in the L1, 11NY and sp105 vectors. It can be seen than in these vectors, 
luxCDABE is under the control of mmfLp and mmfR or mmyR under the control of mmfRp. 
The expression of both luxCDABE and mmfR or mmyR were also predicted to be regulated by 
any repression of the MARE operator. 
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Both MmfR and MmyR were shown to cause significant repression of the reporter genes in 
strains that contained the L1 MARE operator. Therefore, in both 11NY and sp105 containing 
strains, MmfR or MmyR should hypothetically be able to regulate their own expression. 
Figure 6.1. Visual representation of the intergenic region located between mmfR and 
mmfL, as found in the 11NY and sp105 vectors 
Please note that this diagram is not to scale and purely a representation of the approximate position of 
the -35/-10 sites and MARE operator. 
The 11NY and sp105 vectors are from the work of Nodwell et al. (92) 
 
By studying repression and possible release of MmfR and MmyR by the MMFs from strains 
containing the 11NY and sp105 vectors and comparing it to data collected for mmfR and 
mmyR under the control of ermEp* it was possible to draw further conclusions about the 
complex regulation of the methylenomycin biosynthetic cluster and the significance of TetR 
family auto-regulation. 
6.2 Preliminary Observations 
Figure 6.21 shows initial readings taken for the strains containing 11NY and sp105 compared 
to M145, L1+pCC4 (labelled as ‘L1’ in Figure 6.2), L1+mmfR (labelled as ‘mmfR’) and 
L1+mmyR strains (labelled as ‘mmyR’). In this figure, M145 works as the negative control 
whereas L1+pCC4 is the positive control, with no repressor present. Figure 6.2A is a photo of 
how these strains look when grown on solid culture and the corresponding image of the same 
plates when being measured by the CCD camera for thirty seconds is found in Figure 6.2B. 
Figure 6.2C on the other hand shows the schematics of key reporter vectors from the strains 
included in this figure. 
 
                                                      
1 This figure is based on the earlier Figure 3.8 which contained data on M145, L1+pCC4, 
L1+mmfR and L1+mmyR only 
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Figure 6.2. Details on and visual representations of strains containing the lux genes 
under the control of mmfLp, with or without the repressor proteins MmfR or MmyR 
under the control of ermEp* or mmfRp 
Assigned nomenclature = M145 – S. coelicolor M145 negative control with no luciferase 
genes, L1 – positive control with luxCDABE under the control of mmfLp and the empty 
pCC4 vector, 11NY – luxCDABE under the control of mmfLp and mmfR under the control of 
mmfRp, sp105 – luxCDABE under the control of mmfLp and mmyR under the control of 
mmfRp, mmfR – contains L1 and pKMS01, mmyR – contains L1 and pKMS03 
A. Strains growing on SFM media 
B. Luminescence seen in the Photek CCD camera during a thirty second reading by the 
strains shown in A 
C. Schematic representation of reporter plasmids used 
 
In Figure 6.2B, when mmfR expression is under the control of mmfRp (in the 11NY strain), 
MmfR appears to more completely repress the expression of the reporter genes as opposed to 
when it is controlled by ermEp* (in the L1+mmfR strain). Firstly, Figure 3.16 indicated that 
ermEp* is a weaker promoter than mmfRp, meaning that without the presence any other 
regulatory mechanisms, a higher level of MmfR could potentially be expected in 11NY strain 
compared to L1+mmfR, thereby causing a greater level of repression. However, mmfRp was 
not considerably stronger than ermEp* (showing a 1.1 fold increase in luminescence) and 
hence would not be expected to produce such a pronounced difference in luminescence as 
was observed in Figure 6.2. Secondly, it is also unlikely that the tighter repression of the lux 
genes is due to MmfR being able to work as an activator at its own promoter but repress other 
genes. The differences in luminescence for strains containing the 11NY vector compared to 
pKMS01 are therefore an indicator of the benefits of the self-regulatory control of mmfR by 
MmfR at the MARE operator. As soon as MmfR is released in the 11NY strain there will be 
no repression of mmfR expression and so more MmfR will be made, ensuring a constant level 
of repression. It is this tight control over MmfR production, allowing synthesis of this 
repressor as and when needed, that appears to be the likely cause of more complete repression 
achieved in the 11NY strain compared to when mmfR is under the control of the unrelated 
ermEp*.  
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On the other hand, when under the control of mmfRp, MmyR (in the sp105 strain) appears to 
repress luminescence to a lesser degree than when MmyR production it is controlled by 
ermEp* (in the L1+mmyR strain). Put simply, this phenotype indicates that MmyR under self-
regulation does not result in improved repression of the L1 MARE operator. 
The mmyR strain phenotypes seen in Figure 6.2 help confirm the observations made in 
Section 5.3 where it was found that MmyR caused the greatest repression at the L3 MARE 
operator, followed by the L1 MARE operator, with no binding indicated at the L2 MARE 
operator. If MmyR will not bind to the L2 MARE operator then it will not regulate mmyRp 
and its own expression. As there was no repressive advantage observed for having mmyR 
under an auto-regulatory control system it is possible that this second repressor is not auto-
regulatory. MmyR may be regulating itself in some way, but it is evidently different to the 
direct control mechanism MmfR exerts on mmfR. 
It should be noted however that these results are not quantitative and purely based on visual 
observations and so may not hold true when further analysed quantitatively. 
 
6.3 Effect of the MMFs on MmfR When Under MARE 
Operator Regulation 
In Chapter 4 it was seen that when any of the five MMFs were added to the L1+mmfR strain, 
there was an apparent release of MmfR and an increase in luxCDABE expression. MMF4 was 
added to the 11NY strain and the effects on luminescence observed. The results from this 
assay can be found in Figure 6.3. Data for 11NY was compared to the M145 negative control 
and L1+pCC4 positive control. 
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Figure 6.3. Relative level of luminescence produced by the lux operon under the control 
of mmfLp and MmfR (under its own auto-regulatory control) in the presence and 
absence of 400 nM MMF4 over time 
The level of luminescence was calculated as a ratio compared to that of the M145 strain 
 
The 11NY strain was more representative of the wild type system than L1+mmfR, i.e. mmfR is 
being controlled by its native promoter rather than ermEp*. Despite this, it can be seen from 
Figure 6.3 that the expression of the lux genes was not inducible upon the addition of MMFs 
in the 11NY strain. In the presence of MMF4, the levels of luminescence remain very close to 
those produced by the M145 negative control. The reason for this is again likely to be the 
auto-regulatory nature of MmfR. Upon the release of MmfR from the operator by MMF4, 
there is only a short window of lux expression before more MmfR is also made, repressing the 
expression of the luciferase genes almost immediately. Finding this very short window of 
luminescence was not experimentally practical.  
A concentration of 400 nM MMF4 was used for the 11NY data collected, this is the same 
concentration as was used for the experiment displayed in Figure 3.10 where there was an 
observable increase in luminescence by L1+mmfR in the presence of MMF4. As the 
L1+mmfR strain has mmfR under the control of the constitutive ermE* promoter, it means that 
there are much longer lasting effects of de-repression by the MMFs. MmfR is produced at a 
relatively constant rate, where expression is presumed to be unaffected by the addition of the 
MMFs and is independent of its own repressive activity. 
Trials where the concentration of the MMFs was increased did not show any more release of 
MmfR in the 11NY strains (data not shown here). 
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It is unclear how these findings on the lack of observable effect of the addition of the MMFs 
in the 11NY strain is representative of what actually occurs in the wild type system. Studies 
with mmfLHP mutants have shown that the addition of MMFs will induce the production of 
methylenomycin (Table 6.1).(71) There are a number of possible explanations on how this 
release of MmfR occurs in the wild type system when it was not seen in this reporter system. 
The first is that there was a small window of MmfR release (and therefore increased 
luminescence) but due to readings only being taken every 24 hours, this period of luxCDABE 
expression was missed. A small window of expression may be enough to result in the 
expression of mmyB and thereby switching on the entire biosynthetic cluster. Another 
possible explanation is that in the wild type system it is a very specific threshold 
concentration of the MMFs needed to release MmfR. A concentration too far above or below 
this specific threshold level may not alter the MmfR/MMF/operator feedback loops in a way 
that results in methylenomycin production. This precise threshold concentration of MMFs is 
not known but if more time was available, a gradient of different MMF concentrations could 
be trialled with the 11NY strain to check this hypothesis (see Figure 6.4). A final 
consideration as to how MmfR is released in the wild type system is that other factors may 
also be at play, altering the window of time during which MmfR is released. In the M145 
strain used in this assay, none of the methylenomycin BGC is present except those genes 
added in the lux vectors and so any extra regulation by this cluster would also be lacking. 
Figure 6.4. Schematic of proposed assay to measure the effects of a gradient of MMFs on 
the repression of the lux operon when mmfR expression is under auto-regulatory control 
The lux operon is under the control of mmfLp and the L1 MARE operator. If there is a narrow 
threshold window of MMF concentration that will induce the strains containing the 11NY vector, this 
will be seen as a circle of luminescence on the plate. 
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6.4 Effect of the MMFs on MmyR When Under MARE 
Operator Regulation 
When MMF4 was trialled with the sp105 strain, no obvious change in luminescence was 
observed (data not shown here). This is consistent with the data reported in Section 5.4 where 
the addition of MMF4 produced no significant changes in luminescence for strains containing 
the L1 intergenic region with mmyR under the control of ermEp*. Having mmyR under the 
control of the L1 MARE operator and mmfRp would not be expected to change this phenotype 
as there should be no change in the ligand-binding pocket of MmyR. 
Although MmyR may not directly control the expression of its own gene, there is a possibility 
that it has an indirect regulatory effect on its own activity. This hypothesis relates to putative 
interactions with the MMFs and will now be discussed.  
In Chapter 5, a reduction in lux expression was observed for mmyR strains in the presence of 
100 µM MMF2, 4 and 5 at the L3 MARE operator. It appears therefore that in some cases, the 
MMFs may improve the repressive ability of MmyR. This however was a property not seen 
for MmyR binding at the L1 MARE operator. It is possible that weaker binding of MmyR 
seen at the 24 bp L1 MARE operator sequence is not strong enough for the addition of 100 
µM MMFs to cause a significant change in luminescence. If this is the case, a higher 
concentration of MMFs added to the L1+mmyR may reveal higher levels of repression. 
Alternatively, MmyR may bind to the two operator sites in a slightly different conformation. 
The L1 and L3 MARE operators share less than 63% identity (137) and it is possible that this 
difference could have enough of an effect on the MmyR tertiary structure to alter the way that 
the MMFs can enter its ligand-binding pocket. 
There is a biological explanation for why the wild type system may be set up so that at the L1 
MARE operator, MMFs would not enhance MmyR binding. This is due to the genes actually 
being regulated at the L1 MARE site; mmfR and mmfLHP. In particular, mmfLHP which code 
for MmfLHP, the enzymes used in the assembly of the MMFs. 
If the MMFs could bind to MmyR at the L1 MARE operator and make it a better repressor, it 
would create a negative feedback loop. A MMF-induced enhancement of MmyR repression 
would switch off the production of more MMFs. This decrease in the concentration of the 
MMF ligands would then lead to MmyR becoming a less efficient repressor again and a 
return the system to the over-production of the MMFs. This would then become a feedback 
cycle alternating between enhanced and reduced MmyR activity, something that would 
clearly not be productive whilst trying to switch off methylenomycin production. It is 
therefore not logical for MmyR to only be able to optimally switch off MmfLHP production 
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at the L1 MARE operator in the presence of the MMFs. The more MmyR represses these 
genes, the more it would be down regulating its own effects and thus preventing further 
repression. The hypothesised different conformations of MmyR therefore may make it 
indirectly auto-regulatory, based on its resultant control over the levels of MMFs produced, 
which are possibly needed for its full repressive activity at the L3 MARE operator. 
This inference is entirely hypothetical however, and purely based on there results collected in 
this projects investigation. It does appears however that the different MARE operator 
sequences are more important in controlling the promiscuous effects of MmyR than MmfR, 
the latter of which appears to be less selective and have a more similar role at each operator 
site.  
It is very hard to shed light on the exact role of MmyR, which proves to be much more 
elusive and complex than MmfR regulation. One area that may help develop hypotheses 
about MmyR activity (and MmfR) is that of a mathematical model of the methylenomycin 
regulatory system. 
 
6.5 Mathematical Modelling of the MmfR/MMF/MARE 
Operator Regulatory Network 
During this PhD, work has been carried out in conjunction with the Department of 
Engineering at the University of Warwick where a PhD student, Jack Bowyer, was 
mathematically modelling the methylenomycin regulatory system. Here Bowyer et al. created 
five different architectures of possible regulatory systems and then compared the output of the 
models with a range of laboratory generated experimental findings.(79) This collaboration 
involved extensive discussion between the Department of Engineering and the School of Life 
Sciences as well as the sharing of raw data to be compared with the mathematical models. 
From this analysis, one particular architecture was chosen as being the most representative of 
the MmfR/MmyR regulation. This architecture accounts for reversible MmfR and MmyR 
binding at the MARE operators, where expression of these two regulators is controlled within 
the methylenomycin cluster. 
Other alternative architectures trialled has a number of variable components including the 
regulation of MmfR by a constant and external parameter (mirroring the control by ermEp*, 
investigated in this thesis) or having MmfR only being able to bind to the MMFs in a 
MmfR/DNA complex rather than in its apo form when it is free in solution. 
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The experimental data used to test these architectures focussed on the seminal 
methylenomycin paper by Sean O’Rourke et al. from 2009.(71) In this paper, a number of 
mutants were created for methylenomycin cluster elements, for example mmfR and mmyR 
knockouts. The genetic and metabolic profiles for these mutants were then assessed by 
O’Rourke et al., shedding light on the role of the individual genes of the 19 kb 
methylenomycin cluster. A summary of the findings of these assays can be found in Table 
6.1. Here it can be seen that methylenomycin production increases drastically in the mmyR 
mutants but not mmfR mutants. The mutants for transcriptional activator MmyB on the other 
hand, show repressed methylenomycin production but increased levels of the MMFs. Only 
mathematical models that presented these phenotypes as outputs when altering different 
parameters were deemed to be representative of wild type MmfR/MmyR regulation. 
Table 6.1. Phenotypes of methylenomycin cluster mutants 
The phenotypes displayed were reported by Sean O’Rourke et al.(71) 
Mm = methylenomycin 
Strain Gene deletion Mm production MMF production MMF responsive 
J1506  - + n/a n/a 
J2629 ΔmmyR::aac(3)IV +++ n/a n/a 
J2650 ΔmmfP::scar ++ n/a n/a 
J2642 ΔmmfH::scar − − + 
J2643 ΔmmfL::scar − − + 
J2635 Δ(mmfP→mmfL)::aac(3)IV – − + 
J2636 ΔmmfR::aac(3)IV –/+ n/a n/a 
J2637 Δ(mmyR→mmfR)::aac(3)IV +++ n/a n/a 
J2638 Δ(mmyR→mmfL)::aac(3)IV – − + + 
J2639 Δ(mmfP→mmfR)::aac(3)IV –/+ − − 
J2641 ΔmmyR::aac(3)IV,ΔmmfR::scar +++ n/a n/a 
J2644 ΔmmyB::scar − + − 
 
In all the model systems created by Jack Bowyer, the methylenomycin BGC was split into 
two parts. The first is the apm or antibiotic producing module, this encompasses mmyTOG, 
mmyBQEDXCAPK and mmyYF and is controlled by the L3 MARE operator. The second 
module is the fpm or the furan producing module, this includes mmyR, mmfR and mmfLHP 
which is are controlled by both the L1 and L2 MARE operators. 
The diagram in Figure 6.5 shows the model architecture that was shown to produce results 
closest to those in the wild type system. This figure was adapted from a conference paper 
written by Jack Bowyer et al. in 2016 to go with his research findings.(79) In this model, 
MmfR is produced by the fpm in an auto-regulatory fashion and is bound to the fpm and apm 
in the ‘resting state’. Both MmfR and MmyR are modelled to bind and regulate the two 
modules but only MmfR was modelled to bind and be released by the MMFs. 
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Figure 6.5. Model architecture of the methylenomycin biosynthetic cluster 
apm – antibiotic producing module, fpm – furan producing module, Ø - degradation 
Reversible and irreversible reactions are represented by double and single ended arrows respectively. 
Underlined elements denote those with initial non-zero concentrations. 
 
The modelling from this architecture is very simplified compared the wild type system 
however. Although the chosen model architecture does not contradict any of the findings 
from this thesis, it combines the L1 and L2 MARE operator regulation as well as not factoring 
in the TTA codons or any other potential transcriptional control. It also does not consider all 
potential MmyR ligand interactions, alternative DNA binding sequences or mmyR regulation 
that is separate from the fpm. In addition, the modelling did not consider the findings found 
on variations in operator binding for MmyR compared to MmfR as well as the differing 
binding potentials of the five MMFs. Finally, the initial construction of each alternative 
architecture was also largely based on assumptions present at the beginning of the work e.g. 
that the MMFs will only bind MmfR when it is bound to the MARE operators and that MmyR 
will not be released by the MMFs. It is therefore not possible to draw firm conclusions from 
this work, instead the model produced offers an indication of the regulation in the 
methylenomycin network and helps to point researchers in the right direction when planning 
future experiments.  
Despite its limitations however, the chosen model architecture does suggest that the self-
regulatory function of MmfR is key to producing results in line with those for the wild type. 
Models that showed constant mmfR expression under the control of separate regulatory 
regions did not match experimental data. It was only when mmfR is under the control of the 
fpm that the system was closest to the phenotype of wild type one. The model also predicted 
that the MMFs would not bind to MmfR when it was free in solution, they would only 
interact when MmfR was bound to the apm or fpm, then causing its release upon a 
conformational change. 
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Models where MmyR was released by the MMFs did not produce results in line with 
experimental data. This matches the findings of Section 5.4, where no significant de-
repression of luxCDABE was seen in the presence of any of the MMFs for the L1+mmyR 
strain. (De-repression was not seen in any of the MMFs trialled in the L2+mmyR or 
L3+mmyR strains either.) However, the models investigated by Bowyer et al. did not consider 
an increased binding of MmyR in the presence of the MMFs and so no conclusions can be 
drawn on this aspect of regulation using this model. 
The modelling also excluded the feasibility of architectures where MmyR was released from 
the fpm upon binding to methylenomycin. The experimental findings from this thesis using 
the luciferase assay into MmyR/methylenomycin binding were inconclusive (Section 5.4.2). 
The model indicates that this hypothesis can most likely be discounted but some future 
experimentation may be helpful with validating this aspect of the chosen architecture. 
There are plans in the future to use findings from this thesis, including those collected in the 
luciferase assay on MMF Kd and Bmax values and the binding affinities of MmfR and MmyR 
for each of the MARE operators, in a more rigorous validation of the currently proposed 
mathematical model. The inclusion of this extra data should helping to give the model more 
capacity for the conclusions that can be drawn from it and increase the likelihood of it being 
biologically representative and reliable. 
By combining all the information collected via this mathematical model as well as the 
experimental findings from this and the previous three chapters it is possible to bring together 
the findings on MmfR repression in combination with those of MmyR and propose how they 
may work together to regulate methylenomycin biosynthesis. 
 
6.6 Proposed Function of MmfR and MmyR In Regulating 
Methylenomycin Biosynthesis 
Figure 6.6 is a schematic showing a visual representation of the proposed regulation of the 
methylenomycin biosynthetic cluster by MmfR and MmyR based on all experimental 
evidence revealed in this project. Parts A-G of this figure are referred to in the following text, 
where this proposed pathway is explained. 
In Section 4.3, MmfR was shown to bind best at the L1 MARE operator, controlling the 
expression of itself and that of mmfLHP. MmfR will also bind and repress at the L2 and L3 
MARE operators but with less strength, thereby regulating the expression of mmyR and the 
operons starting with mmyB and mmyY (A). There is some leakiness in the system at this point 
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but MMF levels remain below the threshold needed to release MmfR and result in 
methylenomycin biosynthesis. 
Upon production, or detection by quorum sensing, of a threshold level of the MMFs and the 
consequent release of MmfR from all three operators (B), the five operons will be expressed 
and methylenomycin biosynthesis begins. 
The release of repression from the mmfLHP and mmfR intergenic region results in the 
production of the enzymes needed to produce the MMFs as well as MmfR. Two MmfR 
monomers are needed to repress at one MARE operator site, however each MmfL, H and P 
produced will result in the synthesis of thousands of MMFs molecules generating a positive 
feedback loop in MMF over-production (C). Although MmfR is also being produced it is 
continuously released by the MMFs. 
The research in this investigation has implied that the repression of mmfR and mmfL at the L1 
MARE operator is most easily released (B), followed by mmyB and mmyY and then finally 
mmyR (Table 4.1). This potentially causes lag in the expression of these operons with a 
potentially later expression of the mmyB and mmyY operons (D) followed closely by the 
mmyR gene (E) (see also later discussion on page 133).  
Once MmyR has been produced, my suggestion is that it will then bind the MMFs (F), 
allowing it work more fully as a repressor in combination with the right genetic sequence for 
DNA binding. MmyR/MMF binds the L3 MARE operator to regulate the production of 
transcriptional activator MmyB and biosynthetic enzyme MmyY and the operons they come 
from, starting to switch off methylenomycin production once it is no longer needed. As 
mentioned in the introduction, it is hypothesised that the main role of MmfR/MmyR/MMF 
regulation may be to control the expression of mmyB, this proposed pathway is in line with 
this hypothesis therefore. 
MmyR also appears to cause some repression at the L1 MARE operator (further regulating 
mmfR and mmfLHP) but this does not appear to be influenced by the presence of the MMFs at 
the concentrations trialled (G). At this point MmfR is no longer significantly repressing the 
production of MmyR due to its release by the MMFs, and MmyR does not regulate itself at 
the L2 MARE operator leading to huge amounts of this second repressor being produced. Due 
to this lack of mmyR repression it is likely that once expression has begun, MmyR production 
will not be switched off again until the entire biosynthetic pathway has been turned off and 
MMF production/detection has ceased. 
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As MMF levels drop again, repression by MmfR will increase (and MmyR decrease). MmfR 
has been shown to have least affinity for the L2 MARE operator and so it is possible that this 
is the last place to be repressed, allowing mmyR expression (and therefore its repressive 
activity) to continue for longer than the expression of other elements of the BGC, returning 
the methylenomycin cluster to its ‘resting state’ (A). 
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Figure 6.6. Schematic of proposed MmfR/MmyR regulation of the methylenomycin 
biosynthetic cluster 
This schematic is based on the findings of the luciferase assay utilised in this project. 
Assigned functions: mmfR and mmyR – transcriptional repressors, mmfLHP – 
methylenomycin furan biosynthetic genes, mmyJ and mmr – methylenomycin resistance, 
mmyB – transcriptional activator, all others – methylenomycin biosynthesis 
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There are of course still gaps in this proposed pathway and it does not account for the TTA 
codon, sigma factors or any potential extra signalling roles of the MMFs or any other possible 
transcriptional regulation. However, this proposed pathway does not contradict the 
mathematical model produced and combines all of the experimental findings of the luciferase 
assay. 
Research by O’Rourke et al. indicated that transcripts of mmyR, mmfL and mmfR were 
produced before mmyB which in turn was produced before any of transcripts for biosynthetic 
genes.(71) This does show slight differences to the proposed pathway here, which is based on 
ease of MmfR release from each operator. In particular, the presence of mmyR transcripts 
early on is something not proposed in Figure 6.6. It is unclear however whether these 
transcripts observed by O’Rourke et al. were due to the leakiness of the system rather than 
expression having been actively switched on and whether a threshold level of MmyR is 
needed before it can have its regulatory function. The presence of a mmyR transcript also does 
not mean that it is binding to the MARE operators and is exerting its repressive activity, 
especially as it has been indicated to have weaker binding that MmfR and therefore may take 
more time. Alternatively, there may be extra translational regulation of the system that is as 
yet unknown which could explain these differences. 
An extra comment on the findings of O’Rourke et al. is that the release of MmfR from the L2 
and L3 MARE operators seen in Section 4.3 was at times very similar or the order reversed 
(depending on whether compared to its negative or positive controls), so it is possible that 
there is not the lag in the production of their associated genes shown in Figure 6.6, and steps 
D and E therefore may be either combined or reversed. However, the proposed pathway still 
remains even if MmfR has the same strength of release at the L2 and L3 sites. If mmyR is 
expressed alongside the mmyB and mmyY operons or even before them, the enzymes and 
activators will catalyse many more reactions than the structural MmyR which can only 
repress one site at a time. Only a short window of de-repression of the mmyB and mmyY 
operons may be needed for the activation of methylenomycin biosynthesis, before MmyR 
accumulation and resultant repression occurs to a significant level and prevent the production 
of more enzymes. 
 
6.7 Conclusions and Summary 
It is clear from this investigation that methylenomycin regulation is very complex. In the wild 
type system, MmfR production and its release by the MMFs will be influenced by not only its 
own auto-regulation but also MmyR repression, quorum sensing and the presence of 
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endogenous and exogenous MMFs as well as potential interactions of sigma factors and other 
regulator proteins that are yet to discovered. Although the findings of this chapter do not 
show the whole picture of MmfR auto-regulation it is clear that when under the control of its 
wild type operator and promoter, much tighter regulation of gene expression is obtained. 
MmyR on the other hand does not appear to have a direct effect on its own expression. The 
role of MmyR is still much less well understood than that of MmfR. 
Moving forward from the luminescence work and onto the development of a novel inducible 
expression system, it appears clear that as we much better understand the role of MmfR, it is a 
much more suitable component for an optimised inducible system. Of the three MmfR 
binding intergenic regions, the L1 region (between mmfL and mmfR) appears to be most 
suitable, with the greatest repression by MmfR seen as well as the greatest increase in 
luminescence produced upon the addition of a single concentration of MMFs (Figure 4.3). Of 
the five MMFs, the furans with the branched alkyl chains; MMF1 and 3, appeared to have the 
greatest binding potential to MmfR at the L1 MARE operator (Figure 4.19) and are therefore 
obvious choices as ligands to induce the system that will be developed. Work was moved 
forwards to start developing this novel inducible expression system for use in streptomycetes. 
In this system the MmfR/MARE operator regulatory sequence was placed upstream of a gene 
of interest. The auto-regulation of MmfR was chosen to be excluded from the system, due to 
the poorly understood nature of how MmfR is released by the MMFs when under this control, 
instead regulation by ermEp* was used, as is described and explained in the following 
chapter. 
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7 Development of a Novel Inducible Expression 
System for Streptomycetes 
7.1 Aims at Strategy of Investigation 
7.1.1 Existing Heterologous Expression Systems 
There are a number of well-known and validated E. coli expression systems that are utilised 
for controlling the production of a huge variety of proteins.(102) E. coli is not always suitable 
for every protein of interest however, with a number of polypeptides proving to be insoluble 
or difficult to purify in these Gram-negative bacteria. It can be hard to predict the conditions a 
specific protein needs for the synthesis of an active product, with problems encountered in 
proteins folding into the correct conformation, poor expression levels as well as an inability to 
carry out the necessary post-translational modifications. It is unsurprising therefore that the 
same system cannot be used to achieve the successful purification of soluble proteins in all 
cases. Expression systems have been developed for a number of different types of organism, 
increasing the variety of conditions present in hosts and broadening the number of 
recombinant genes that can be expressed but again this does not cover all cases. The Gram-
positive Streptomyces have shown promise as heterologous expression hosts, with the 
possibly of improved expression of genes from other GC high or Gram-positive bacteria.(139, 
140) There is hope that the MmfR/MMF/MARE operator system, analogous to LacI/IPTG/lac 
operator, could possibly be used to provide an alternative inducible expression system for the 
overexpression of recombinant genes. 
7.1.2 MmfR/MMF/MARE Operator as an Inducible Expression 
System in Gram-Positive Bacteria 
In the previous four chapters, the MmfR/MMF/MARE operator system from the 
methylenomycin cluster of the SCP1 plasmid of S. coelicolor has been investigated. It has 
shown promise as an inducible expression system in terms of promoter strength as well as 
removal of MmfR repression by the furans ligands. Using these findings, research has been 
carried out in two main areas, firstly an investigation into the choice of a Streptomyces host 
suitable for an inducible expression system. Secondly, preliminary work was undertaken to 
start to develop an inducible expression system that can be used to control the production of 
recombinant proteins that are otherwise difficult to obtain e.g. because they are toxic to the 
host. 
To turn the modified lux system into a novel inducible expression system that can be adapted 
to study and produce recombinant proteins of interest, using a strain with a reduced genome 
could be advantageous, to decrease the chances of background interactions with the system as 
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well as metabolically streamlining the host to conserve resources for the over production of 
the protein of interest. Up until now, all of the investigations into MmfR/MMF/ operator 
using the luciferase assay were done using S. coelicolor M145. This is a genetically reduced 
derivative of the wild type and model organism Streptomyces coelicolor A3(2). The M145 
variant was developed via the removal of the SCP1 and SCP2 plasmids. Conveniently, all of 
the methylenomycin cluster, including all biosynthetic, regulatory and resistance genes are 
found on the SCP1 plasmid. This made M145 a suitable host strain for the luciferase reporter 
gene assay with no background interactions from the methylenomycin cluster being present in 
this strain. In particular, the absence of the native mmfR, mmyR and mmfLHP were 
particularly beneficial. Components of the methylenomycin cluster were added as and when 
needed. For the development of the novel inducible expression system, a further investigation 
was carried out into whether an even more streamlined host could be achieved, trialling 
Streptomyces albus as a potential superior expression host. 
7.2 Streptomyces albus as a Potential Host 
7.2.1 Introduction to S. albus 
S. albus has one of the smallest known genomes of any in the streptomycete genus at only 6.8 
Mb.(27, 93) This strain provides a very interesting case study when looking at phylogenic 
relationships and the evolution of genetic elements due to the natural removal of any 
apparently unneeded genetic material from the genome. S. albus has recently started to be 
widely studied with the potential of it being used as a premium host for heterologous 
expression of natural products.(93, 141) In this report, genomic, transcriptomic and in vivo 
analyses have been carried out on S. albus strain J1074 to better understand how it can be 
used as a super host and whether there will be any background interactions with 
MmfR/MMF/MARE operator from native gene expression. 
7.2.2 Luminescence Assay in S. albus 
To check S. albus for suitability as an expression host, the previously used luciferase reporter 
gene assay was transferred over to this strain. For this strain to be a suitable host for the 
MmfR/MMF/MARE operator inducible expression system, results collected for the lux strains 
created would need to be akin to those collected for S. coelicolor M145. Comparable results 
would indicate that the MmfR/MMF/MARE operator system works in S. albus as well as S. 
coelicolor without any background interactions from existing S. albus networks. 
The L3 vector (containing mmyBp) used in the earlier luciferase assay as well as mmfR and 
mmyR (in pKMS01 and 03) were all integrated into S. albus creating S. albus L3+mmfR and 
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L3+mmyR strains.1 These were then analysed via the measurement of luminescence produced 
using the Photek CCD camera in the same way that the S. coelicolor M145 strain was in the 
previous four chapters. Measurements were again taken at 21, 24, 27, 48 and 72 hours growth 
and the luminescence compared to a negative control strain with no luxCDABE insert and a 
positive control strain with no repressor (L3+pCC4). The findings of this investigation are 
shown in Figure 7.1 and Figure 7.2. Figure 7.1 shows the luminescence produced at the five 
time points over 72 hours for all samples and Figure 7.2 shows a bar chart that compares 
luminescence at just the 48 hour time point. A t-test analysis was then run with data from 
Figure 7.2, the results of which can be found in Table 7.1. 
 
Figure 7.1. A comparison of luminescence produced by the luxCDABE operon in S. 
albus, as regulated by the presence and absence MmfR, MmyR and MMF4 over 72 
hours 
Average light production is calculated as a relative ratio of luminescence produced by the S. 
albus negative control with no insert (giving this sample a value of 1). Strains used: S. albus 
– wild type negative control strain, S. albus L3+pCC4 - luxCDABE under the control of 
mmyBp and pCC4, S. albus L3+mmfR – luxCDABE under the control of mmyBp and 
mmfR under the control of ermEp* (pKMS01), S. albus L3+mmyR – luxCDABE under the 
control of mmyBp and mmyR under the control of ermEp* (pKMS03) 
 
                                                      
1 This nomenclature is the same as that which was used for the equivalent investigation in 
Streptomyces coelicolor M145, see Chapter 3. 
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Figure 7.2. Bar chart comparing luminescence produced by the luxCDABE operon in S. 
albus, as regulated by the presence and absence MmfR, MmyR and MMF4 at 48 hours 
Average light production is calculated as a relative ratio of luminescence produced by the S. 
albus negative control (giving this sample a value of 1). Strains used: same as Figure 7.1 
 
Table 7.1. A t-test analysis of the luciferase assay results collected from S. albus data at 
48 hours 
Average light production is calculated as a relative ratio of luminescence produced by S. 
albus with no insert (giving this sample a value of 1). The p-value was also calculated based 
on S. albus with no insert. Strains used: same as Figure 7.1 
Strain p-value Significant difference? 
Average light 
production at 48 
hr (R.R) 
S. albus L3+pCC4 5.06E-01 FALSE 0.82 
S. albus L3+mmfR 8.27E-01 FALSE 0.95 
S. albus L3+mmyR 8.64E-12 TRUE 77.07 
S. albus L3+pCC4 MMF4 9.87E-01 FALSE 1.01 
S. albus L3+mmfR MMF4 2.27E-02 TRUE 2.25 
S. albus L3+mmyR MMF4 1.32E-13 TRUE 97.72 
 
It was found that the MmfR/MMF/MARE operator inducible expression system in S. albus 
was not comparable to that in S. coelicolor M145 indicating that S. albus is not a suitable 
heterologous expression host for this particular expression system. As can be seen in both 
Figure 7.1 and Figure 7.2, the S. albus L3+pCC4 positive control and L3+mmfR both appear 
to have almost entirely repressed levels of luminescence. The L3+mmyR strain on the other 
hand produces high levels of luminescence both in the presence of the MMFs and without. 
The findings of the t-test in Table 7.1 show that there is a significant increase in luminescence 
produced by the L3+mmfR strain in the presence of MMF4 but this is only minimal with 
twice as much luminescence being produced as is for the control strain with no lux insert. 
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This is still nowhere near close to the levels of luminescence produced by S. albus L3+mmyR 
or the levels of induction seen for the equivalent system in S. coelicolor. 
A possible interpretation as to why the L3+pCC4 and L3+mmfR strains produce no 
luminescence is that a protein from the S. albus genome could be causing repression at the 
MARE operator sequence. The L3+mmyR strain still produces high levels of luminescence 
and the conclusion inferred from this is that MmyR can bind genetic elements in the S. albus 
genome and thereby repress the expression of this native TetR that might otherwise bind the 
MARE operator. 
Where it is possible that a native protein from S. albus is binding to the MARE operator 
sequence and preventing the expression of the luciferase genes, it appears unlikely that this 
protein also has the correct binding pocket for the MMFs and for this reason the addition of 
100 µM MMF4 causes little or no induction of lux expression. This potential native S. albus 
TetR, homologous to MmfR/MmyR, is discussed further in the following paragraphs.  
It is also necessary to consider that, despite the plasmid inserts in S. albus being checked by 
PCR and the ex-conjugants gaining the selective apramycin and hygromycin resistance from 
the vectors inserted, it is still entirely possible that the inserted genes are not being expressed 
properly in S. albus. As mentioned previously, S. albus is known to have a streamlined 
genome due to genetic reshufflings and deletions of ‘unnecessary’ genes, this is something 
which may have occurred to the L3, pKMS01 and pKMS03 inserts after they had been 
screened by PCR. In hindsight it may have been helpful to run extra screenings of the ex-
conjugants during and after the luciferase assays to check for maintenance of the insert. Until 
this has been investigated further therefore, the analyses just discussed should be studied with 
caution. 
7.2.3 Investigating potential GBL-related TetRs in S. albus 
Discovery of SSHG_01258 
A literary and database investigation was carried out to look in the S. albus genome for a 
potential native TetR family member that would bind to the methylenomycin cluster MARE 
operator sequences. Zaburannyi et al. described the sequencing of the streamlined S. albus 
genome, where duplicates and redundant genes have efficiently been removed (93) meaning 
that this strain has a smaller genome than even many artificially reduced streptomycete 
strains. In particular, they noticed that no butenolide synthase or genes associated with the 
production of GBLs/AHFCAs were present in the S. albus genome.(93) However, there is 
still a gene for a predicted GBL-binding TetR family member, that has not been lost during 
chromosomal rearrangements.(93) A BLAST sequence analysis revealed only one significant 
MmfR homologue, identified as SSHG_01258, showing over 40% identity with the S. 
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coelicolor MmfR over 86% of its sequence (Table 7.3 and Figure 7.4). As no gene name was 
given in the Zaburannyi paper it can only be assumed that this is the GBL binding protein that 
they were referring to. No obvious homologue of MmyR could be found. 
Through an analysis of the primary structure of SSHG_01258 compared to MmfR and other 
TFRs, this potential MARE operator-binding protein could be better understood. In particular, 
the ligand and DNA binding domains were of particular interest to try and explain better the 
results collected in Figure 7.1 and Figure 7.2. 
TetR Family DNA Binding Motif of SSHG_01258 
The amino acid sequence analysis in Section 5.3.1 revealed that within the predicted 20 bp 
DNA binding region of MmfR, there was a conserved GAVYFH sequence found in MmfR and 
its orthologues from S. venezuelae and S. avermitilis whereas their paralogues showed an 
alternative conserved GALYGH sequence. Table 7.2 shows a comparison of the DNA binding 
motifs from these proteins with that of the hypothetical S. albus protein. It appears that 
SSHG_01258 shows the conserved GAVYFH sequence found in MmfR and homologues SgnR 
and SAV_2270. It is therefore plausible that SSHG_01258 is indeed binding to the 
methylenomycin cluster operator site contained in the L3 vector and is repressing lux gene 
expression, analogous with the stronger binding to the MARE operator seen for MmfR 
compared to MmyR. 
 
Table 7.2. DNA binding region sequence of SSHG_01258 compared to that of MmfR 
and MmyR and their orthologues 
Protein name p-value Sequence (20 aa) 
SSHG_01258 6e-19 SVNDISARSGRTSGAVYFHY 
MmfR 8e-21 SVKDVAERVGMTKGAVYFHF 
SgnR 4e-20 TLQDVAERAEMTKGAVYFHY 
SAV_2270 3e-18 TIKDIADGAEMTKGAVYFHF 
SAV_2268 1e-19 NLQNIADRIRLTKGALYGHF 
GbnR 3e-18 NLADITARTGLTKGALYGHF 
MmyR 4e-18 NLATVAVRTGMTKGALYGHF 
 
A further analysis of the seven homologues just discussed was carried out, looking at 
percentage identity as well as alignment scores. Results of these findings can be found in 
Table 7.3, Table 7.4 and Table 7.5.1 It can be seen that there is a high level of identity across 
all seven amino acids, where MmfR shares 47% and 54% identity with its orthologues from S. 
venezuelae and avermitilis respectively, across 98% of their sequences. The S. albus 
homologue falls just below this with 41% similarity across 86% of its sequence. The BLAST 
                                                      
1 Sequence similarities can be found in ‘Appendix C. Sequence Analysis of MmfR and 
Homologues’ 
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alignment score for SSHG_01258 (Table 7.5) also indicates that it falls within the same bands 
as SgnR and SAV_2270 when compared to MmfR with all having scores well over 100.  
As may be expected from TetR family members, the regions of highest percentage identity 
between the homologues falls across the DNA binding domain within the TetR type HTH 
motif. This therefore adds further to the possibility of all these homologues binding the same 
MARE operator sequences. 
Table 7.3. Percentage identity of amino acid sequence between MmfR and MmyR 
homologues from S. venezuelae, S. avermitilis and S. albus 
 
MmfR MmyR SgnR GbnR 
SAV_ 
2270 
SAV_ 
2268 
SSHG_ 
01258 
MmfR 100 35 54 28 47 33 41 
MmyR 35 100 36 47 50 39 36 
SgnR 54 36 100 31 53 34 43 
GbnR 28 47 31 100 35 37 56 
SAV_2270 47 50 53 35 100 33 35 
SAV_2268 33 39 34 37 33 100 33 
SSHG_01258 41 36 43 56 35 33 100 
 
Table 7.4 Percentage coverage of analysis of amino acid sequence between MmfR and 
MmyR and their homologues from S. venezuelae, S. avermitilis and S. albus 
Query sequence 
Alignment sequence 
MmfR MmyR SgnR GbnR 
SAV_ 
2270 
SAV_ 
2268 
SSHG_ 
01258 
MmfR 100 51 92 66 85 75 89 
MmyR 54 100 72 58 34 94 53 
SgnR 98 75 100 72 91 81 90 
GbnR 72 61 61 100 68 96 19 
SAV_2270 98 32 83 61 100 74 77 
SAV_2268 75 91 78 68 78 100 72 
SSHG_01258 86 47 86 25 75 71 100 
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Table 7.5. Total score of alignment, according to NCBI BLAST, for the amino acid 
sequences for MmfR and MmyR and their homologues from S. venezuelae, S. avermitilis 
and S. albus 
Red - >= 200, Pink – 80-200, Green – 50-80, Blue – 40-50 
The NCBI BLAST score is based on the standard parameters provided by the BLAST software. 
(31, 142, 143) 
Query sequence 
Alignment sequence 
MmfR MmyR SgnR GbnR 
SAV_ 
2270 
SAV_ 
2268 
SSHG_ 
01258 
MmfR 433 73 210 61 179 88 144 
MmyR 73 413 72 95 62 90 64 
SgnR 197 72 401 68 165 69 140 
GbnR 63 98 73 401 52 79 46 
SAV_2270 177 71 174 58 448 62 85 
SAV_2268 88 105 75 78 59 412 55 
SSHG_01258 132 69 140 46 79 48 410 
 
Ligand Binding Domain of SSHG_01258 
In Figure 7.2, there did not appear to be any pronounced release of lux repression in the 
presence of MMF4. An analysis of the SSHG_01258 sequence compared to MmfR 
specifically looking at the ligand binding pocket, shown in Figure 7.3, reveals that 
SSHG_01258 does not contain the two tyrosine residues predicted to be key to MMF ligand 
binding in MmfR. There are instead two phenylalanine residues. Previous work with the 
bioluminescence assay (Section 4.4.4) showed that although the Y144F mutant appeared to 
improve ligand binding, when working with an MmfR Y84F mutant, a single tyrosine 
replacement with phenylalanine was enough to significantly reduce ligand binding. This and 
the fact that only 56% of the nine residues involved in hydrogen binding the MMFs are 
conserved between MmfR and SSHG_01258 indicates why the addition of MMF4 did not 
release the repression of luxCDABE in S. albus (Figure 7.2 and Table 7.1). The small amount 
of luminescence induction seen in the presence of MMF4 was likely to be due to MmfR 
having bound the MARE operator in some cases whereas the lack of further induction is 
presumed to be an indication of the presence of SSHG_01258 at the MARE operator, which 
is then not released by the MMFs. To confirm this hypothesis, sshg_01258 could be cloned 
into the pCC4 vector and added to the lux system and the effects on repression with and 
without the MMFs observed in S. coelicolor M145. 
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Figure 7.3. Amino acid sequence comparison of MmfR and orthologue SSHG_01258 
from S. albus 
TetR HTH domain shown in red and predicted DNA binding residues are underlined. Y85 and 
Y144 involved in hydrogen binding the MMFs in MmfR have also be underlined. Highlighted 
in yellow are all the residues shown to be involved in ligand binding in MmfR. The equivalents 
in the SSHG_01258 homologue are also highlighted, with yellow indicating a match and blue 
indicating a mismatch. 
 
Following on from this analysis of the DNA and ligand binding domains of SSHG_01258 it 
was of interest to see how this protein fits into the larger picture of TetR phylogeny and 
whether there are any other homologues with similarity of DNA binding motifs to MmfR, 
shedding light on the possible interactions of alternative repressors with the methylenomycin 
cluster operator sites. This was of interest in terms of choosing other possible hosts for the 
MmfR/MMF/MARE operator inducible expression system. 
Sequence Comparison of SSHG_01258 with Other MmfR-Like and 
MmyR-Like Proteins 
A phylogenetic analysis was carried out with a much larger array of TetR family members, 
particularly from streptomycetes, and to include the GBL binding receptors mentioned in the 
introduction. The findings of these analyses can be found as a phylogenetic tree in Figure 7.4 
with the homologies summarised in Table 7.6. 
Following on from this investigation, the 20 bp DNA binding motifs from MmfR and MmyR 
were searched for in each of the 24 homologues analysed in Figure 7.4. The alignments of 
these sequences are presented in Table 7.7. 
 
 
SSHG_01258      ----------------------------------MEAAALLFAEQGYAGTSVNDISARSG 
MmfR            MTSAQQPTPFAVRSNVPRGPHPQQERSIKTRAQILEAASEIFASRGYRGASVKDVAERVG 
                                                  :***: :**.:** *:**:*:: * * 
 
SSHG_01258      RTSGAVYFHYASKEGLALAVVQHRFATWPGLAARYTDRAEPPLEKLVALSFDIAHALAED 
MmfR            MTKGAVYFHFPSKESLAIAVVEEHYARWPAAMEEIRIQGFTPLETVEEMLHRAAQAFRDD 
                 *.******: ***.**:***:.::* **.   .   :.  ***.:  : .  *:*: :* 
 
SSHG_01258      PLARAGARLWAERDTIDAPLPDPFALWTTATTRLLAQARTAGHLTPHIRPAPTARSLVRA 
MmfR            PVMQAGARLQSERAFIDAELPLPYVDWTHLLEVPLQDAREAGQLRAGVDPAAAARSLVAA 
                *: :***** :**  *** ** *:. **      * :** **:*   : ** :***** * 
 
SSHG_01258      FFGLCTLTEALEGPTAVTARLTDWWLLTLGSLQQRPDAAGVLGRVRARGGLLGERMGAAC 
MmfR            FFGMQHVSDNLHQRADIMERWQELRELMFFALRA-------------------------- 
                ***:  ::: *.  : :  *  :   * : :*:                            
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Figure 7.4. Phylogenetic tree (144) showing the relationship between MmfR, 
SSHG_01258 and other TetR family homologues across their amino acid sequences 
 
Table 7.6. Summary of homology between TetR family members across different 
bacterial species 
Protein name Strain Homologue 
MmfR Streptomyces coelicolor A3(2)  
MmyR Streptomyces coelicolor A3(2)  
SgnR Streptomyces venezuelae ATCC 10712 MmfR 
GbnR Streptomyces venezuelae ATCC 10712 MmyR 
SAV_2270 Streptomyces avermitilis MA-4680 MmfR 
SAV_2268 Streptomyces avermitilis MA-4680 MmyR 
SHJG_7318 Streptomyces hygroscopicus MmfR 
SHJG_7322 Streptomyces hygroscopicus MmyR 
SSHG_01258 Streptomyces albus J1074 MmfR 
CprA Streptomyces coelicolor A3(2)  
CprB Streptomyces coelicolor A3(2) CprA 
ScbR Streptomyces coelicolor A3(2)  
ScbR2 Streptomyces coelicolor A3(2)  
TetR Escherichia coli  
ArpA Streptomyces griseus TetR 
AcrR Pantoea ananatis LMG 20103 TetR 
JadR Streptomyces venezuelae ATCC 10712 TetR 
JadR2 Streptomyces venezuelae ATCC 10712 ScbR2 
SabR Streptomyces acidiscabies ScbR 
SabS Streptomyces acidiscabies CprA 
BarA Streptomyces virginiae ScbR 
BarB Streptomyces virginiae ScbR2 
SagR Streptomyces aureofaciens ScbR 
Aur1R Streptomyces aureofaciens ScbR2 
FarA Streptomyces lavendulae ScbR 
FarR2 Streptomyces lavendulae ScbR2 
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Table 7.7. Comparison of 20 amino acid conserved DNA binding motifs in TetR family 
repressors with the motif from MmfR and MmyR 
Name Sequence 
Exact motif match? 
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m
fR
) 
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H
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m
yR
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LYG
H
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YG
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LYF
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N
o M
atch 
MmfR SVKDVAERVGMTKGAVYFHF X      
MmyR NLATVAVRTGMTKGALYGHF  X     
SgnR TLQDVAERAEMTKGAVYFHY X      
GbnR NLADITARTGLTKGALYGHF  X     
SAV_2270 TIKDIADGAEMTKGAVYFHF X      
SAV_2268 NLQNIADRIRLTKGALYGHF  X     
SHJG_7318 TMLDVAELSGMTKGAVYFHF X      
SHJG_7322 NLQRVAAEANLTKGALYAHF      X 
SSHG_01258 SVNDISARSGRTSGAVYFHY X      
CprA SLSEIVAHAGVTKGALYFHF    X   
CprB TLSEIVAHAGVTKGALYFHF    X   
ScbR TITEILKVAGVTKGALYFHF    X   
ScbR2 SLTMISSRAGVSNGALHFHF     X  
TetR No motif match      X 
ArpA No Motif match      X 
AcrR SLADVASAASVTRGAIYWHF      X 
JadR No Motif match      X 
JadR2 KLSAISSGAGVSPGALHFHF     X  
SabR TIAMVLERSAVTKGALYFHF    X   
SabS SLSDIVEHAQVTKGALYFHF    X   
BarA TVAEILSRASVTKGAMYFHF      X 
BarB SLTAISNSAGVSNGALHFHF     X  
SagR TISEILSEAGVTKGALYFHF    X   
Aur1R TLSMISVGAGVSPGALHFHF     X  
FarA TISEILTVAGVTKGALYFHF    X   
FarA2 TLSMISVGAGVSPGALHFHF     X  
 
The most closely related receptors of those analysed to MmfR were SgnR, SAV_2270, 
SHJG_7318 and SSHG_1258 of which SSHG_01258 appears to be the least related to MmfR, 
as shown by the clades on the phylogenetic tree in Figure 7.4. If SSHG_01258 is indeed 
binding to the MARE operator of the L3 vector then it could be expected that possibly SgnR, 
SAV_2270 and SHJG_7318 are also able to bind, due to their even closer sequence similarity 
to MmfR (Table 7.3) and conserved GAVYFH DNA binding domain. It would be interesting 
to clone sav_2270, sgnR or shjg_7318 into the pCC4 vector and see if it can indeed bind the 
S. coelicolor MARE operators using the lux assay.  
MmyR has shown significant binding to some of the MARE operators indicating that the 
conserved GALYGH motif is also viable in interacting with some methylenomycin cluster 
operators. It is therefore possible that SAV_2268 and GbnR are also capable of binding the 
L1 and L3 MARE operators. 
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As well as the MmfR-type GAVYFH and MmyR-type GALYGH DNA binding domain there 
were also commonly found to be GALYGH and GALHFH motifs conserved in the homologues. 
A GAVYGH motif on the other hand was not found, despite its similarities to the other motifs, 
which may reveal more about which residue combinations are key to DNA binding. ScbR, 
ScbR2, CprA and CprB contain either the GALYGH and GALHFH sequences. These four 
proteins come from S. coelicolor and do not appear to have interfered with the earlier 
luminescence assay indicating that they do not bind to the MARE operators. It is seems likely 
therefore that their orthologues, with the same DNA binding motif, will not bind to the 
MARE operators either. However, these interactions are not fully understood yet so these 
possibilities cannot be ruled out. 
SHJG_7322 and BarA do show a motif with some identity to the ones from MmfR and 
MmyR but this is not as conserved as other motifs and so the inference is that they are also 
less likely to bind the MARE operators than some of the other homologues. TetR and its 
orthologues ArpA, AcrR and JadR on the other hand do not have a DNA binding motif 
resembling the ones from MmfR or MmyR and can likely be ruled out as potential interactors 
with the methylenomycin cluster operators.  
Despite the assertions that the TFRs containing the MmfR-type GAVYFH or MmyR-type 
GALYGH motifs are more likely to interact with the MAREs whilst the other proteins are not, 
this has not been shown experimentally and therefore cannot be confirmed. The DNA binding 
region will be influenced by more than the block of 20 amino acids analysed here. For 
example, the amino acids found at the dimer interface of all these homodimers will effect the 
conformation of the DNA binding region. It is therefore possible that some of the proteins 
containing the MmfR or MmyR type motifs may not bind to the MARE operators whereas 
some of the other motifs may sometimes bind the MARE operators. The cut-off for amino 
acid sequence identity resulting in binding to the same DNA operators is not known and, 
without crystal structures of the proteins or an in vivo/in vitro analysis, would be very hard to 
predict. 
7.2.4 Implications of Findings on S. albus 
The findings on SSHG_01258 reveal more about the potential use of MmfR/MMF/MARE 
operator as an inducible system in a variety of hosts. It is likely that the sshg_01258 gene 
from S. albus would need to be inactivated before this strain would be viable as an expression 
host. 
S. venezuelae was also a potential host for the expression system due to its ability to complete 
its life cycle and sporulate in liquid culture. For large-scale protein purification, liquid culture 
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is preferable to solid culture. The findings from working with S. albus indicates that for S. 
venezuelae to be used as an expression host, the sgnR/gbnR/sgnLHP cluster would likely need 
to removed to prevent interference with the MARE operator from SgnR, GbnR or their 
cognate ligands. Even if these MmfR homologues were removed from potential host strains 
however, it is unclear as to whether even more distantly related receptors may also interact 
with the pathway. Therefore, due to time limitations on developing this novel inducible 
expression system, it was decided to continue working with Streptomyces coelicolor as the 
system has already been shown to work in this strain without detectable cross-repression. 
At a later date, there are hopes to further optimise S. coelicolor M145 to create a more 
streamlined host via gene deletion. (Section 8.5.2). There are hopes that a reduced S. 
coelicolor M145 a strain, in addition to being more suitable for gene expression, the 
phenotypic differences sometimes observed in the luminescence assay may also be reduced as 
the cells can focus their resources on the expression of a more select number of genes. 
 
7.3 Development of Vectors for Inducible Expression 
7.3.1 Strategy of Inducible Expression System Mechanism 
Based on all of the findings of the bioluminescence assay it was decided that the 
MmfR/MMF/MARE operator system has potential for development as the control mechanism 
in a novel inducible expression system. Synthetic expression vectors were designed to work 
in a similar way to the luciferase reporter gene assay, relying on two different vectors (Figure 
3.3). One of these vectors was designed to include one of the MARE operators in front of a 
gene of interest (instead of luxCDABE) which was then integrated into the S. coelicolor M145 
genome along with pKMS01; mmfR on the pCC4 vector (a vector derived from pOSV556) 
(120) under the control of ermEp*. A schematic of how this will look once in the 
Streptomyces genome can be found in Figure 7.5. MmfR is expected to be produced 
constitutively, binding to the MARE operator and repressing the expression of the 
downstream gene. The addition of the MMFs to the system should then switch on the 
production of the protein of interest. 
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Figure 7.5. The genetic basis of the novel inducible expression system designed to be 
regulated by MmfR/MMF/MARE operator in the S. coelicolor M145 chromosome 
The intergenic region between mmfR and mmfL (containing the L1 MARE operator and in the 
direction of mmfRp) was selected for the expression system as it showed the strongest MmfR 
binding as well as the easiest release of repression upon the addition of the MMFs. In terms of 
selecting which MMFs to use, both MMF1 and MMF3 (those with branches alkyl chains) 
were shown to have the highest binding potentials to MmfR and so are the logical choice as 
the inducer in the inducible expression system. 
An additional feature that was desirable for this inducible expression system was the 
introduction of a secretion signal for the protein of interest. This signal would allow recovery 
of the protein from the culture supernatant without having to lyse the Streptomyces cells. Not 
only does this reduce the number of proteins present in the initial sample to be purified but 
also streptomycetes are much harder to lyse than E. coli, thus avoiding this potentially tricky 
step in purification is preferential. There are two main bacterial export systems, the Tat (twin 
arginine translocation) system (145) and the Sec system.(146) The Sec system is universally 
conserved across bacteria and archaea and is usually the main route of protein export for cells. 
This pathway exports proteins in their unstructured state and is used to move proteins 
involved in a large number of different processes. The Tat system on the other hand is 
unusual as it exports proteins in their fully folded state (147) and is therefore of particular 
interest in developing this expression system. This system has fewer substrates and is found in 
fewer types bacteria than the Sec system (146) but the Streptomyces genus are the largest 
known users of this Tat pathway, with S. coelicolor having more than 100 Tat substrates.(128, 
148) (Although this means that there are a number of naturally exported proteins that will be 
collected alongside the protein of interest, the number obtained will still be many less than 
would be found from lysing the same cells and collecting intracellular proteins.) 
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Both the Sec and more recently the Tat pathway have shown successes for use in expression 
systems.(149) In particular the Tat pathway was successfully used in Streptomyces lividans 
for the collection of proteins with a Tat signal peptide added.(150, 151) The aim therefore is 
to trial this export pathway alongside regulation by MmfR/MMF/MARE operator in S. 
coelicolor. 
7.3.2 Selecting a Protein for Over Production 
To test out the novel inducible expression system there was a range in choices of genes that 
could be expressed. Our group has been interested in characterising urea synthetases, with 
particular interest in orthologues of S. venezuelae GbnB from Salmonella enterica and 
Streptococcus mutans. For this reason, these two proteins were chosen as the focus of the 
expression system being designed. 
S. venezuelae contains a gene cluster annotated as sgnLHP/sgnR/gbnR, which is homologous 
to mmfLHP/mmfR/mmyR from S. coelicolor. In S. venezuelae these genes are thought to 
regulate the expression of gbnABC, the biosynthetic and export genes for the recently 
discovered gamma-aminobutyrate urea natural products; the gaburedins. GbnA is a glutamate 
decarboxylase which is thought to produce GABA whereas GbnB works as an ATP-
dependent enzyme belonging to the acyl-CoA synthetase family and GbnC as a gaburedin 
exporter protein.(75) 
GbnB shares between 27% and 31% identity with its analogues from S. mutans and S. 
enterica respectively, across 96% of their sequences. Like GbnB, both analogues are 
predicted to be acyl-CoA synthetases (AMP-forming)/AMP-acid ligases. Based on their 
similarities, it can be predicted that possibly both analogues may also be involved in natural 
product biosynthesis, hence the desire to purify and characterise them. Details on the 
properties of the amino acid sequences for all three of these AMP-binding proteins can be 
found in Table 7.8.  
Table 7.8. Details on S. venezuelae GbnB and its analogues 
Details on the predicted pI are from ProtParam(77). Strains: Streptomyces venezuelae ATCC 
10712, Salmonella enterica subsp. enterica serovar Schwarzengrund str. CVM19633 and 
Streptococcus mutans GS-5 
Strain Amino acid length Molecular weight (daltons) Theoretical pI 
S. venezuelae 532 57642 5.17 
S. mutans 487 55627 8.8 
S. enterica 498 56347 6.15 
 
As yet, neither of these GbnB-like proteins from S. enterica and S. mutans have been 
successfully purified from existing commercially available expression systems in E. coli. If 
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they can successfully be over produced and purified from S. coelicolor M145 therefore it 
would certainly be helpful in showing the usefulness of such an expression system. 
Expression vectors were therefore designed to include one or the other of these genes. 
7.3.3 Design of the Expression Vectors 
In addition to the already engineered pKMS01 (containing mmfR under the control of 
ermEp*), two more vectors were created for use in the expression system. These are called 
pKMS05 and pKMS06 for S. mutans and S. enterica gbnB respectively (see Figure 7.6, Table 
2.5 and Table 2.6) and contain the analogues under the control of the mmfL/mmfR intergenic 
region. To make these vectors, the already existing L1 vector was used as a backbone. 
   
Figure 7.6. pKMS05, an expression vector containing the S. mutans gbnB orthologue 
and luxCDABE, both under the control of mmfLp 
This vector contains the mmfL/mmfR intergenic region meaning that the expression of the 
gene insert is under the control of mmfLp and the L1 MARE operator.  
The gbnB-like genes were inserted into the L1 vector downstream of the methylenomycin 
cluster intergenic region. Depending on the restriction enzymes used, the lux genes could 
either be cut out or left downstream of the insert. The lux genes were left in the vectors while 
the system was being optimised as an extra control that could be easily observed. 
Luminescence produced should reflect when the gene of interest was also being expressed. 
Once the system has been shown to be working, the extra luxCDABE genes can then be cut 
out using the NotI restriction sites and the vector re-ligated (Figure 7.6). 
The gbnB analogue insert was created synthetically via the GeneArt service by Thermo Fisher 
and included a number of extra features, which will now be explained. A diagram of the 
layout of the insert can be found in Figure 7.7. 
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Figure 7.7. Layout of synthetic gbnB insert for vectors pKMS05 and pKMS06, for use in 
the novel inducible expression system 
BamHI, MunI, NotI and NdeI all refer to the restriction sites added in these positions. RBS 
indicates the ribosome binding site. 
 
Firstly the insert was designed to include a codon optimised gbnB gene, specific to 
Streptomyces codon usage, producing genes with 65% and 58% GC content for S. enterica 
and S. mutans gbnB respectively, compared to the average genomic GC content of 72% for S. 
coelicolor. Between the start codon and the rest of the gene sequence, a polyhistidine tag was 
added to allow easy nickel Sepharose purification of the protein. A Tat signal was also added 
next to the Histidine tag. The Tat signal was a twin arginine repeat translocation pathway 
signal (Section 7.3.1), with the specific sequence taken from the work carried out by Palmer 
et al. (146) giving the following amino acid sequence; 
TKPVVPSGVSRRGFLGGSLGVAGAVLLAA 
The specific conserved Tat pattern within this sequence has been underlined. This sequence 
was also codon optimised for S. coelicolor expression. 
Also added to the synthetic insert was a synthetic Streptomyces ribosome binding site (5’ 
AAGGAGG 3’) as well as a number of different restriction sites. These restriction sites were 
designed so that different components of the insert could be cut out if needed. For example, 
allowing the choice of leaving the luxCDABE genes in the L1 host vector. The MunI and NotI 
restriction sites can be used to easily swap in and out alternative genes for over expression 
into this vector. The full sequences of the synthetic inserts used are in Appendix A and B. 
Details on the properties of the GbnB-like proteins that are predicted to be purified from 
strains expressing pKMS05 and 06 can be found in Table 7.9. The increased molecular 
weights compared to the earlier Table 7.8 are down to the polyhistidine tag and export signal 
being added to the peptide sequence. 
Table 7.9. Details on synthetic GbnB orthologues predicted to be produced by the new 
constructs; pKMS05 and pKMS06 
Details on the stability and the predicted pI are from ProtParam (77).  
GbnB analogue Amino acid length Molecular weight (daltons) Theoretical pI 
Predicted 
stability 
S. mutans 524 59410 9.03 Stable 
S. enterica 535 60156 6.54 Unstable 
 
BamHI | RBS | ATG | TAT signal | 6 Histidine | MunI | gbnB gene | NotI |NdeI | 
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After the synthetic gene had been synthesised, cloned into the L1 vector and the construct 
checked via sequencing and restriction digests, the new vectors were transferred into S. 
coelicolor M145 by intergeneric conjugation. This new inducible expression system was then 
tested and optimised for purification of the proteins of interest. 
 
7.4 Optimisation of a Novel Inducible Expression System 
7.4.1 Strategy of Protocol Optimisation 
Research into protein over production is streptomycete systems is much more limited than 
that for equivalent E. coli expression systems. For this reason, optimisation of the method had 
to begin with the very basics. First the streptomycete system was trialled to see at which time 
point any exported proteins might be present. It was also necessary to try different types of 
media, for both liquid and solid cultures as well as investigating different carbon sources 
present in the media. In addition to this, different buffers were trialled in the nickel Sepharose 
purification of the protein as well as the addition of protease inhibitors to cultures. An outline 
of the methods used can be found in Section 2.3.11. 
Many of the trials were run initially with only the vector created for the S. mutans GbnB 
orthologue (pKMS05). This protein was predicted by ProtParam to have greater stability than 
the S. enterica equivalent (see Table 7.9). Although this is only a fairly arbitrary value, there 
was a desire to reduce the workload of trialling both vector types and so only one was 
selected for use primarily and there was no other clear reasoning for choosing one over the 
other. Initial trails were also run with no MmfR present (pKMS01 was not added). The 
inducible aspect of the system was only added once optimisation of protein over production 
has yielded some results. The strains containing pKMS05 or 06 are referred to as M145:L1 
and M145:pKMS05 throughout the rest of the chapter. 
Protein samples collected were processed and then checked using SDS-PAGE for the 
presence of a band in the expected position. As can be seen in Table 7.9, a protein of around 
60 kDa is expected for both orthologues. A number of the extracellular protein samples 
collected were also further purified using their poly-histidine tag, based on nickel Sepharose 
affinity (see Section 2.3.11). As many samples were being processed it was not practical for 
high levels of purification to be obtained for each sample. To save both time and resources, a 
packing column was not used, instead the nickel Sepharose protocol was carried out in 
microcentrifuge tubes with the supernatants being collected after each of the elution steps. 
This of course will result in the presence of a larger number of non-specific proteins being 
collected in the elution fractions as well as the protein of interest. This should be taken into 
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consideration when looking at all gels of purified proteins in these preliminary optimisation 
trials. For a higher level of purity to achieve a single band on an SDS-PAGE gel and 
potentially obtain useable proteins, a more thorough purification protocol could later be used, 
for example FPLC (fast protein liquid chromatography). 
Before any protein recovery trials were carried out, the strains were first checked for 
luminescence to determine whether the expression system vectors were integrated into the 
Streptomyces genome and were indeed being expressed. It was found that the cells containing 
pKMS05 and 06 were luminescing at all time points checked. 
7.4.2 Selecting Time points for Protein Purification 
Whereas E. coli will often produce a protein of interest in the first 24 hours of growth, 
Streptomyces have a much slower doubling time of 2.2 hours (51, 152) compared to 20 
minutes for E. coli.(153) The heterologous expression of some antibiotics in Streptomyces 
may take up to two weeks to achieve a good yield (152) and so it is likely that measurable 
heterologous expression in streptomycetes will occur after the 24 hour time point. Based on a 
literary review, it was expected that protein overproduction in the streptomycetes may peak 
anywhere within the first 72 hours of growth, although longer trials were possible for this 
assay if necessary.(101) 
S. coelicolor M145 with pKMS05 (S. mutans gbnB) were grown in 2xYT media in baffled 
flasks. The supernatant was then collected at 24, 48 and 72 hours growth before being 
concentrated in a centrifugal column and run out using SDS-PAGE. Figure 7.8A-D show the 
results of such collections. Expression levels were compared to a control sample of L1 with 
no gnbB insert, which represents the levels of exported proteins normally produced by S. 
coelicolor M145. 
At the 24-hour time point, very few exported proteins were seen so no extra purification 
methods were utilised. At both 48 and 72-hour collections however, the proteins present in 
the supernatant were analysed as well as proteins ‘purified’ on nickel Sepharose1. Both the 
elution and washing stages of the protein purification have been shown on the SDS-PAGE 
gels in Figure 7.8B and D. 
 
 
                                                      
1 During the nickel Sepharose purification, the buffers described in Section 2.2.4 as ‘protein 
purification buffer’ and ‘elution buffer’ with 200 mM imidazole were used. 
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Figure 7.8A-D. Secreted proteins produced at different time points by the M145:L1 
control strain compared to the strain designed to produce S. mutans GbnB 
(M145:pKMS05) 
All samples are collected from concentrated 2xYT growth media supernatant 
A. 24 hours growth 
B. 48 hours growth, purified with nickel Sepharose 
C. 72 hours growth 
D. 72 hours growth, purified with nickel Sepharose 
 
As can be seen in Figure 7.8A, there were very little exported proteins seen at 24 hours. At 48 
hours there are more detectable proteins in the supernatant of the M145:L1 and 
M145:pKMS05 cultures but very few bands were observed after nickel Sepharose purification 
of either samples. The 72-hour time point shows most promise in terms of total protein yield 
but at no time point is there a really distinct band in the position of the expected molecular 
weight, even after nickel Sepharose purification. For example, Figure 7.8C and D show bands 
at the size of the expected product but they are no more distinct that any of the others that can 
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be seen in these samples. It is promising however that there are some bands produced by the 
gbnB strain which are not obviously present in the samples produced by the L1 control, these 
extra bands are all smaller than 60 kDa and therefore may represent the GbnB-like proteins 
degraded into smaller polypeptides. The indication from this data is that an optimisation of 
growth conditions may be needed to obtain the protein of interest.  
Based on observations from Figure 7.8, all optimisation trials from here on were run for at 
least 72 hours before exported proteins were collected and checked via SDS-PAGE. 
7.4.3 Considerations on Further Optimisation of the Protocol 
Cultures from the investigation represented in Figure 7.8A-D were being grown in 2xYT, a 
variant on LB media with increased levels of tryptone and yeast extract. A limitation of this 
media is that it lacks any real carbon source (154), which may be detrimental to protein 
overproduction. For this reason, the following medias and supplements were also trialled; 
2xYT, LB, TSB (0.25% glucose), 2xYT with 3% mannitol, 2xYT with 3% glucose, 2xYT 
with 5% glucose, 2xYT with 3% glycerol, 2xYT with 3% fructose, 2xYT with 3% sucrose. 
The data for this investigation is not shown here but there was no clear impact on the size of 
the band at ~60 kDa in the presence of any of the different media or supplements. One feature 
that was particularly distinct in these results however, was the presence of very large bands at 
the bottom of the SDS-PAGE gel, possibility indicating streptomycete cell lysis in liquid 
media. This cell lysis would cause the internal as well as exported proteins became mixed and 
the release of many proteases, therefore explaining the lack of larger molecular weight bands 
seen elsewhere on the gels. Reducing this cell lysis is therefore of interest when optimising 
this protocol. 
Widdick et al. (128) have reported that in liquid media, energy demanding systems or systems 
that put stress on a cell can result in the lysis of streptomycetes. It is possible that having the 
luxCDABE system in addition to the expression system both working in Streptomyces could 
be causing the cell lysis observed by Widdick et al. (128). The maintenance of the lux genes 
in the L1 vector when creating pKMS05 and 06 was to act as a second marker for gene 
expression, easier and quicker to measure than protein export. The implications this was to 
have on the health of the cell were not known and in the future, when time allows, this extra 
marker should maybe be removed or replaced with something less energy demanding. 
In the paper by Widdick et al., an alternative method of purifying exported proteins from S. 
coelicolor was described, this time using solid media where the streptomycetes appeared to 
grow better even if they had been shown to lyse in liquid media.(128) This approach was 
therefore adopted.  
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7.4.4 Work on Solid Culture and Addition of MmfR and the MMFs 
Using solid culture has the added benefit of not only potentially reducing cell lysis but also 
allowing the S. coelicolor M145 strains to enter the sporulation stage of their life cycle, not 
normally possible in liquid media. It also means that cultures can be grown on smaller scales, 
reducing the demand for high volumes of MMF inducers.  
When using solid media, exported proteins were collected by washing the cell mass that had 
been grown on dialysis tubing. This sterile tubing had been placed on top of the solid soya 
flour mannitol growth media and allowed the passage of nutrients from the medium to the 
bacteria, while keeping proteins produced on top of the tubing for easy harvesting. These 
harvested proteins often did not need to be concentrated further and could either be used 
straight away in nickel Sepharose purification or be precipitated out by lithium 
chloride/trichlororacetic acid precipitation (see Section 2.3.11). Both these sample types could 
then be analysed by SDS-PAGE. The lithium chloride/trichlororacetic acid precipitation 
protocol follows the one specified by the Widdick paper exactly except that they used 
cellophane instead of dialysis tubing (and did not utilise the alternative nickel Sepharose 
purification). 
For the trials with solid media, both the S. mutans and the S. enterica GbnB-like proteins were 
tested and pKMS01 (containing mmfR) was added to the system. MMF51 was then added to 
check the inducible aspect to the expression arrangement and for any changes in protein over 
production. 
Figure 7.9A shows the lithium chloride and trichloroacetic acid precipitation of secreted 
proteins from M145:L1, M145:pKMS05 and M145:pKMS06 in the presence and absence of 
MmfR (from pKMS01) and MMF5 on an SDS-PAGE gel. This gel shows all of the 
precipitated exported proteins collected, with no selection for the histidine-tagged analogues. 
Figure 7.9B shows the nickel Sepharose purification of secreted proteins from M145:L1 and 
M145:pKMS05 (producing S. mutans GbnB) in the presence and absence of MmfR and 
MMF5 and Figure 7.9C shows the same for pKMS06 (S. enterica GbnB). During the nickel 
Sepharose purification, the buffers described in Section 2.2.4 as ‘protein purification buffer’ 
and ‘elution buffer’ with 200 mM imidazole were again used. 
                                                      
1 MMF5 was used rather than one of the MMFs with a higher binding potential due to 
availability of the furans that had been synthesized at the time of this trial. The more efficient 
MMF1 and 3 were then used again when they became available. 
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Figure 7.9A-C. Secreted proteins produced by the M145:L1 control strain compared to 
the strains designed to produce S. mutans or S. enterica GbnB (M145:pKMS05 and 06 
respectively) in the presence and absence of MmfR and MMF5 
All samples collected after 72 hours growth on SFM media. 
UB = unbound proteins E = eluted proteins 
A. S. mutans and S. enterica GbnB - LiCl/TCA precipitation of secreted proteins 
B. S. mutans GbnB - nickel Sepharose purification of secreted proteins 
C. S. enterica GbnB - nickel Sepharose purification of secreted proteins 
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General Observations 
For the gel shown in Figure 7.9A it was possible to see a faint band in the position of ~60 kDa 
in all the pKMS05 and 06 strains (although this is not always apparent on the scans of these 
gels). This band does not appear to be present in exactly the same position for the L1 control 
strain but the band is by no means distinct in any of the pKMS06 or 05 samples. 
The samples in Figure 7.9A contain precipitations of all of the many exported proteins from 
S. coelicolor, without any nickel Sepharose selection for the GbnB analogues, so are expected 
to show multiple bands. However, in a very efficient expression system it would be hoped 
that a bolder band may be seen here at 60 kDa. This therefore does indicate that this system is 
not yet working as desired and more adjustments are necessary. As was mentioned 
previously, it is known that luxCDABE are being expressed in these strains and so it is 
expected that the gbnB-like genes are also being expressed. 
In Figure 7.9B and C, after nickel Sepharose purification the band at ~60 kDa which was seen 
in Figure 7.9A remains (see red arrows) but it is still not any more distinct than the eight or 
nine others also seen. When compared to the L1 control it can be seen that some of these 
bands are also present in the control but a few do seem to be in a slightly different position. 
When considering these gels, it is interesting that all of the bands in the nickel Sepharose 
purified samples appear to be 60 kDa or smaller and, although there isn’t such a distinct band 
at the bottom if the gel like those seen when trialling different carbon sources, there is still an 
indication of protein degradation. If the GbnB-like proteins are being proteolytically cleaved 
there will still be the histidine-tag attached to their N-terminals, resulting in a purified protein 
with a smaller molecular weight. On solid media there does not appear to be the cell lysis 
seen in liquid cultures and so the majority of internal Streptomyces proteases are likely being 
kept separate from the protein of interest. There are however still the proteases that are being 
released by S. coelicolor to assist with aspects of its normal sporulation cycle. Limiting cell 
lysis will not directly reduce the activity of these exported proteases and so the use of 
protease inhibitors was implemented, with the aim that this may result in the production of a 
more distinct 60 kDa band. 
To further understand the nature of the proteins being purified on nickel Sepharose, samples 
from Figure 7.9B were sent for LC-MS analysis. Three of the bands at ~60 kDa, 27 kDa and 
12 kDa were cut out of the gel, digested and processed according to the protocol specified in 
Section 2.3.13. Samples were processed by the Proteomics Facility at the University of 
Warwick. Unfortunately however, the results from this analysis were not conclusive and 
largely showed proteins associated with those native to the Streptomyces genus. 
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It is also of note that the bands on the gel for the S. enterica GbnB (Figure 7.9C) were less 
defined than those for S. mutans GbnB, especially around 60 kDa. As was seen in the earlier 
Table 7.9, the S. enterica GbnB is predicted to be an ‘unstable’ protein whereas the S. mutans 
GbnB classified as being ‘stable’. This is a possible explanation therefore of why S. mutans 
GbnB will give more promising bands on a gel therefore. However, the classification of 
‘stable’ versus ‘stable’ is based on calculations using the ProtParam standard set of 
parameters and therefore is unlikely to directly representative of expression in S. coelicolor. 
There are many other factors that may have also contributed to the differences between the 
gels for these analogues including the level of completion of successful protein folding 
achieved and the possibility that the intracellular pH of Streptomyces is more optimal for one 
protein than the other. 
Inducibility of the System 
Figure 7.9 shows the first results from adding the MMF-inducible MmfR to the expression 
system. A number of the bands in Figure 7.9B and C are very faint so it is not yet possible to 
comment on the effect of adding mmfR to the expression system (via pKMS01). In particular, 
better samples need to be collected from these strains in the presence of the MMFs as these 
gels are particularly indistinct and the total amount of proteins harvested (including wild type 
proteins) was low. The production of gels with proteins from a greater number of culture 
plates may result in the bands on these gels being more distinct due to an increased protein 
yield. 
MmfR binding to the L1 MARE operator has been shown to be leaky (Section 4.3) and so 
some level of the production of the GbnB-like proteins in the repressed mmfR strains was also 
expected to be seen. This does appear to potentially be the case for the gels in Figure 7.9, with 
a number of similar bands being seen when the pKMS01 was added compared when it is not. 
However, the levels of all protein bands produced from these gels appears to be very similar 
indicating that there is little difference in expression the presence of MmfR. The level of 
similarity between the sample types suggests that when under the control of ermEp*, MmfR 
does not result in enough repression for the system to be properly controlled in an inducible 
manner. Whether the current MmfR/MMF/MARE operator system is indeed too leaky for use 
in this system is not clear however or whether the similar bands could be a result of all 
proteins seen being native proteins and therefore unrelated to the expression vectors and the 
desired recombinant proteins. 
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7.4.5 Optimisation with Protease Inhibitors 
A number of the proteins potentially secreted by Streptomyces are proteases, so adding 
protease inhibitors throughout the growth of cultures could increase the yields of the proteins 
of interest.  
When using standard expression systems, such as those using the E. coli host BL21*, protease 
inhibitors are generally only needed to be present in buffers once cells have been lysed. These 
optimised expression hosts often have their genes for secreted proteases knocked out and 
therefore only when intracellular proteases are released is protease inhibition needed. These 
protease inhibitors therefore usually have a short half-life as purification procedures will often 
follow immediately. This standard inhibitor half-life of less than 24 hours at temperatures 
above 4 °C brought some challenges when selecting the right inhibitor cocktail for use in this 
assay. Secreted proteases were likely being released throughout growth of the cells, along 
with the desired GbnB-like protein and so would need constant inhibition over 72 hours. A 
protease inhibitor cocktail specifically designed for tissue cultures and which remains active 
for at least 48 hours at 37 °C was identified and tested, adding it to plates after 24 hours 
growth. This protease inhibitor cocktail was also checked to make sure that at the 
concentration used, none of the components were known to interact with nickel Sepharose. 
No predicted interactions were found. 
Protein samples were prepared for both nickel Sepharose purification and lithium 
chloride/trichloroacetic acid precipitation from M145:L1, M145:pKMS05 and 
M145:pKMS06 in the presence and absence of MmfR and MMF1 from solid cultures as 
before. This time however, the solid culture plates contained 1 mM EDTA (to inhibit 
metalloproteases) and at 24 hours growth were overlaid with the protease inhibitor cocktail 
for tissue culture to a final dilution of 1:500.1 These plates were then allowed to grow for a 
further 48 hours before the secreted proteins were harvested. 
The buffer for nickel Sepharose purification had also been altered for this stage in the trials. 
Not only was the protein purification buffer now used with an extra protease inhibitor cocktail 
but instead of the Tris-HCl buffer, a sodium phosphate buffer with higher sodium chloride 
levels was used.2 This change was made due to concerns over the influence that temperature 
has on the pH of Tris-HCl buffers and whether at 4 °C, the pH of the buffer was too close to 
the theoretical pI of the proteins trying to be purified. Having a pH close to that of the pI of a 
protein has been indicated to have a negative effect on protein purification by other 
                                                      
1 See Section 2.2.4 for more details 
2 See ‘Improved protein purification buffer for Ni Sepharose purification’ in Section 2.2.5. 
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researchers. A corresponding sodium phosphate elution buffer with increased imidazole 
concentration to 500 mM compared to the 200 mM used before was also utilised. The chosen 
optimised sodium phosphate buffers were produced following guidelines that came with the 
nickel Sepharose kit. 
Results from these investigations into the influence of protease inhibition in protein 
purification can be found in Figure 7.10A-C, with results from the lithium 
chloride/trichloroacetic acid precipitation found in Figure 7.10A and the nickel Sepharose 
purification of S. mutans and S. enterica GbnB in Figure 7.10B and C respectively. 
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Figure 7.10A-C. The effects of 
protease inhibitors on 
secreted proteins produced by 
the M145:L1 control strain 
compared to the strains 
designed to produce S. mutans 
or S. enterica GbnB 
(M145:pKMS05 and 06 
respectively) in the presence 
and absence of MmfR and 
MMF1 
All samples collected after 72 
hours growth on SFM media 
containing 1 mM EDTA. Plates 
were overlaid with Sigma Aldrich 
protease inhibitor cocktail for 
tissue culture at 24 hours growth. 
SIGMAFAST protease inhibitor 
cocktail was also added to the 
protein re-suspension buffer. 
 
UB = unbound proteins 
E = eluted proteins 
 
A. S. mutans and S. enterica GbnB 
- LiCl/TCA precipitation of 
secreted proteins 
B. S. mutans GbnB - nickel 
Sepharose purification of secreted 
proteins 
C. S. enterica GbnB - nickel 
Sepharose purification of secreted 
proteins 
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As can be seen in Figure 7.10B in particular (nickel Sepharose purification of S. mutans 
GbnB), there was a marked increase in the boldness of the band at around 60 kDa for all of 
the pKMS05 strains. There are still some other bands present, likely to be due to the level of 
purity achieved from the way the nickel Sepharose samples were processed. The 60 kDa band 
is however now the largest of those seen. The same can also be seen for the strains containing 
pKMS06 (S. enterica gbnB) although this protein is still giving less distinct results. The 
increase in intensity of the band size ~60 kDa might reflect a halting or reduction in protease 
degradation of the protein of interest, increasing its yield. The L1 control also appears to not 
have some of the bands that are present in the samples from the strains containing the 
expression vector on each gel, increasing that prospect that the GbnB-like proteins are 
produced.  
Despite the successes increasing the prominence of the band consistent with the GbnB-like 
protein molecular weight however, there are still concerns as to whether enough MmfR is 
present to efficiently repress and switch off the expression of the gene of interest in the 
absence of the MMFs. In Figure 7.10A, B and C the profiles shown on the gels for both 
expression vectors looked very similar in the presence and absence of MmfR and the MMFs. 
This therefore casts some doubt on the band being seen at 60 kDa being for the GbnB-like 
protein. For this reason, a number of the bands were cut out of the gels shown in Figure 7.10B 
and C and again analysed by LC-MS. The bands at the expected size of around 60 kDa were 
cut out for both the S. mutans and S. enterica samples, as well as a number of prominent 
smaller bands from the S. mutans sample (from ~50, 43, 37 and 26 kDa) to check for protein 
degradation. Most LC-MS samples collected were from the S. mutans GbnB producing strains 
as these bands were more distinct. Samples were also always taken from the positive controls 
containing the expression vectors (pKMS05 or 06) with no MmfR repression due to it not 
being clear how well MmfR was working in the system as a repressor. The contribution of the 
WPH Proteomics RTP, Gibbet Hill Road, University of Warwick, UK should be 
acknowledged for the processing for these samples and help with the analysis of the results. 
As might be expected, the main hits from the LC-MS analysis data returned were again for 
Streptomyces proteins. For none of the samples were there detectable Photorhabdus 
luminescens associated proteins indicating that the luciferase and the enzymes for its substrate 
were remaining inside the streptomycete cells.  
Both S. venezuelae GbnB and its two analogues belong to the acyl-CoA synthetase AMP-
binding family of enzymes. Any AMP binding enzymes found in the bands analysed for LC-
MS would therefore indicate the potential presence of the protein of interest. The six bands 
analysed showed sequence similarity to very few non-actinomycete proteins and the results 
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were largely inconclusive in terms of detecting the presence of the two GbnB-like proteins. 
Some of the bands showed similarity with a sugar ABC transporter substrate-binding protein 
from S. enterica (A0A0W5EVT2_ SALCE), unfortunately this protein does not bear much 
resemblance to the family of proteins that the GbnB analogues come from. There are also at 
least six possible amino acids detected in various bands that are Acyl-CoA binding enzymes 
from the Streptomyces species. These could possibly in fact be the Acyl-CoA synthetases 
being looked for due to the high identity found been the analogues. Unfortunately however, 
no conclusions can be made from this data on the successes of the successful export and 
purification of the GbnB analogues. With further purification of protein samples, the bands 
collected may hopefully yield more relevant results with less interference from exported 
proteins native to S. coelicolor M145. 
Checking Inside Cells for GbnB Orthologues 
As expression vectors were designed to attach a Tat signal to the protein of interest and label 
it for export out of the cell, all trials up until now have been run looking for proteins in the 
supernatant of liquid cultures or by washing the cell mass of solid cultures. To make sure that 
the protein of interest was properly being exported, the cell mass that had been collected for 
the experiments in Figure 7.10 was lysed and the cell contents checked for the GbnB 
orthologues. After cell lysis, the samples were processed in the same way as the exported 
proteins had been previously, using the optimised buffer with protease inhibitor cocktail 
present and purifying via nickel Sepharose purification. These purified proteins were then 
analysed using SDS-PAGE, images of these gels are shown in Figure 7.11A and B. 
As explained before, it is known that some expression of the pKMS05 or 06 inserts is 
occurring, as luminescence is seen when checked for the Photek camera. Assuming the 
upstream gbnB analogues are also being expressed it is therefore a case of finding out whether 
a corresponding protein has been produced and if so, where this may be; whether it is a case 
of successful folding and export but in low amounts, the folded proteins remaining inside the 
cell with failed export or alternatively, incorrect folding and degradation of the protein 
analogues. 
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Figure 7.11A and B. Intercellular proteins produced by the M145:L1 control strain 
compared to strains designed to produce S. mutans or S. enterica GbnB (M145:pKMS05 
and 06 respectively) in the presence and absence or MmfR and MMF1 
A – S. mutans GbnB B – S. enterica GbnB 
All samples collected after 72 hours growth on SFM media containing 1 mM EDTA. Plates 
were overlaid with Thermo Fisher protease inhibitor cocktail for tissue culture at 24 hours 
growth. SIGMAFAST protease inhibitor cocktail was also added to the protein re-suspension 
buffer. Intracellular proteins were collected using the method specified in Section 2.3.11. 
 
Unsurprisingly, there are many more bands seen for internal cell proteins collected than for 
the exported ones studied earlier. Even after nickel Sepharose purification there were no 
distinct bands that would have indicated the accumulation of a particular protein in the 
imidazole elution fraction. This appears therefore to suggest that it is unlikely that there is 
significant accumulation of folded GbnB analogues inside the cell which are not being 
exported. This does leave the possibility of the gbnB genes are not being expressed at all or 
are being expressed but incorrect folding results in protein degradation within the cell. 
However, due to the presence of bands of the correct molecular weight seen in Figure 7.10, 
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low expression levels might explain why the protein of interest was not seen previously, 
something that could be improved with further optimisation of the culture protocol as well as 
a more rigorous purification system to achieve fewer non-specific bands. Whether these 
GbnB analogues can be purified as functional enzymes however, is yet to be seen. 
 
7.5 Discussion and Conclusions on the Work to Develop a 
Novel Inducible Expression System 
Whereas the luminescence data collected on MmfR and MmyR helped draw conclusions and 
offered a fairly complete picture of their regulatory activity, the work creating a novel 
inducible expression system did not reach such completion with much optimisation left to be 
done. This chapter utilises a number of technologies that had not been previously used in this 
project and so learning them took time. Time limitations meant that optimisation could not be 
carried out to a level where the inducible expression system was ready for use by others with 
alternative recombinant proteins. The research did however provide some unexpected insights 
into the regulatory activity of MmfR/MmyR. 
Although the attempt to develop S. albus as an optimised heterologous expression host was 
not successful, these investigations did provide extra information on the regulatory natures of 
MmfR and MmyR and how these relate to the activity of homologues. Specifically, the 
investigation into S. albus as a potential host revealed the possibility of MmfR/MmyR 
homologues interacting with the MARE operator s. From the in silico and reporter gene assay 
analysis carried out in Section 7.2 it is not unreasonable to predict that possible MmfR will be 
able to bind alterative operators in different streptomycete hosts as well as MmfR orthologues 
possibly being able to bind the methylenomycin cluster operators. 
Despite these findings being very interesting however, the cut off point for sequence identity 
in the DNA binding region of MmfR, MmyR and their homologues where they will bind the 
MARE operators and other operators is not known. This therefore casts doubt on the 
MmfR/MMF/MARE operator system being used in strains of streptomycetes which have 
MmfR homologues with particularly high sequence identity, with the possibility of the 
presence of alternative MmfR binding sequences as well as other TetR family members 
interacting with the MARE operators in the inducible system. As a result, a wider analysis of 
MmfR homologues and MARE operator-like sequences is needed to further understand the 
interactions suggested in Section 7.2.  
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The developing inducible expression system shows promise as something that is worthwhile 
continuing to optimise. Results from SDS-PAGE gels indicate that the previously unpurified 
GbnB-like proteins may have been successfully produced by this streptomycete system with 
bands produced at the expected size but this is currently at a fairly low level. The luxCDABE 
operon, located downstream of the gbnB analogues being expressed and successfully resulted 
in luminescence being produced, so it is conceivable that the gbnB analogues are also being 
expressed. However, it is still not entirely clear whether the analogues are successfully being 
exported or folding into their native conformation, with the results from the LC-MS analysis 
not offering any clear indication of the presence of S. enterica or S. mutans peptides. 
Hopefully with the use of a more rigorous purification technique, there will be more distinct 
bands seen for the histidine-tagged proteins. Should more time have been available for this 
project, a more thorough purification protocol, such as FPLC would also have been attempted 
to achieve a reduced number of bands. 
In terms of the inducible nature of the system, this is not something that has yet been shown 
experimentally, with strains containing pKMS01 giving no clear differences to those 
containing only pKMS05 or 6. However, it is known from the luciferase assay in Section 4.4 
that the release of MmfR will be induced upon the addition of any of the five MMFs and so 
this system should hypothetically be adaptable for the regulation of other genes. The 
MmfR/MMF/MARE operator system could be tested further using an alternative reporter 
assay such as gusA or through the use of an antibiotic resistance gene, where the detection of 
repression and its consequent release would validate the inducibility of the system. 
The luminescence trials showed that there was leakage of luxCDABE expression when the 
MmfR repressor was under the control of the ermE* promoter. Since the development of 
ermEp* in 1985 (131) as a strong constitutive promoter, much more research has been carried 
out into stronger promoters that can be used in these GC high bacteria. If ermEp* was 
replaced with another stronger promoter such as kasOp* (134) in pKMS01, a higher level of 
MmfR would likely be produced and therefore more full repression at the methylenomycin 
cluster promoter of the expression vectors may be seen. 
The majority of the work done with optimising the expression system was done using solid 
cultures. For large-scale industrial production of soluble proteins of course, liquid cultures are 
preferable due to their ability to be scaled up to a larger extent. With the removal of the 
energy demanding lux genes and some further fine-tuning, it is hoped that liquid culture 
without the cell lysis will give a useful system. 
Testing the novel inducible expression system on two proteins that had never successfully 
been purified was always going be to challenging and in hindsight, a control vector 
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overexpressing a gene known to be purifyable from streptomycete systems should have also 
been created. This would have made results from optimisation trials easier to interpret. 
The future work required to develop this expression system has been discussed further in 
Section 8.5. 
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8 General Discussion 
8.1 Research Questions and Summary of Findings 
In the introduction the following research questions and hypotheses were laid out: 
Research questions 
Do all five methylenomycin cluster promoters, controlled by MmfR, have the same 
strength? 
Does MmfR bind in the same way to all three MARE operator sequences? 
Is MmfR release by the MMFs the same at all three MARE operators? 
Does MmfR respond to all five furan compounds? 
Do all five MMFs have the same efficacy? 
What are the key residues in ligand binding? 
How does MmyR binding to the MARE operator and the MMFs vary from that of MmfR? 
Are there any other ligands that MmyR may bind to? 
Could MmfR, MMFs and MARE operators be used as a multi-host efficient novel inducible 
expression system for GC rich bacteria? Would this allow the purification of recombinant 
proteins? 
 
Hypothesis 
The promoters that are predicted to be controlled by MmfR have different -35/-10 
sequences so it is possible that they will have varying strengths. 
In vivo, MmfR will bind to DNA at the MARE operator and be released upon the addition 
of a MMF compound. 
The three MARE operators have different semi-palindromic sequences and so are 
likely to show differential binding to MmfR. 
MmfR will respond to all of the MMFs but due to the differing length of alkyl 
chain between the five molecules there is likely to be differences in the binding 
potential of each. 
MmyR is only produced after methylenomycin biosynthesis. It will bind to the 
methylenomycin cluster operators but not be released by the MMFs, thereby repressing 
biosynthesis when methylenomycin has been produced to conserve cell resources and to 
protect the bacterium from the potentially lethal effects of excess methylenomycin. 
Alternatively, an unknown ligand may ‘activate’ MmyR as a repressor. 
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An attempt was made to answer these research questions via the use of a luciferase reporter 
gene assay, in silico amino acid and gene analyses, the creation of repressor mutants and 
optimisation trials of an MmfR/MMF/MARE operator based inducible expression system in 
Streptomyces. 
Findings from the luciferase assay indicated the relative strength of binding at the different 
MARE operators for both MmfR and MmyR as well as their affinities for the five MMFs. It 
should be noted however that the relevance of these findings in the larger picture of the wild 
type system is still not fully understood. The MmfR/MMF/MARE operator system showed 
promise as a component of a novel inducible expression system, the development of which 
was met with varying levels of success. 
In Section 8.2, each individual research question has been presented and a summary of the 
findings made for each question displayed. (An analysis of data collected can also be found 
previously at the end of each individual research chapter.) The impact of this data in then 
discussed in Section 8.3. The methods used to perform the luciferase assay as well as 
developing the novel inducible expression system have also been assessed and comments 
made on possible improvements in Section 8.4.1 and 8.5.1. Following on from this, a 
discussion of suggested future work is also presented in Section 8.4.2 and 8.5.2. A final 
summary of all the findings from this project can then be found in Chapter 9. 
 
8.2 Answers to the Research Questions 
8.2.1 Do all five methylenomycin cluster promoters, controlled by 
MmfR, have the same strength? 
It was shown that the five promoters1 in the three different intergenic regions were of 
different strengths (Figure 3.16). The luminescence assay indicated that the strength of 
promoter goes in the following order; mmyRp > mmfRp > mmyYp > mmyBp > mmfLp. The 
range in levels of luminescence by the unrepressed positive controls was between an average 
of 44.6 and 126.2 times the levels produced by the M145 negative control at 72 hours. This 
represents only a 2.8 fold difference in luminescence between all five promoters, whereas for 
example, Bai et al. saw a 190 fold difference in promoter strength when analysing different 
modular regulatory elements.(134) It is unclear whether this small range in promoters 
strengths is indeed representative of the wild type promoter strength or whether the resource 
demanding nature of the luxCDABE system is a limiting factor on measurable luminescence. 
                                                      
1 See Figure 3.5 and Figure 3.6 for the location of these promoters within the methylenomycin 
BGC 
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It is interesting that mmfR and mmyR have the strongest promoters. For each site that is 
repressed, two MmfR or MmyR monomers are needed. For the enzymes and other regulators 
coded for by other operons, one single protein molecule should be able to exert its effects on 
multiple targets. It therefore appears logical that their promoters are not as strong as those for 
mmfR and mmyR. 
8.2.2 Does MmfR bind in the same way to all three MARE operator 
sequences? 
Research indicated that MmfR binds differently to each of the MARE operators. MmfR was 
shown to bind best at the L1 MARE operator, controlling the expression of its own gene and 
mmfLHP. For the L1+mmfR strain there was shown to be a 10-fold decrease in luminescence 
compared to the positive control L1+pCC4 (Figure 4.2) at 48 hours growth when MmfR was 
under the control of ermEp*. MmfR will also bind and repress at the L2 and L3 MARE 
operators but with less strength. There was seen to be a 6.5 fold decrease in luminescence for 
L3+mmfR compared to L3+pCC4 and a 3.5 fold decrease for L2+mmfR compared to 
L2+pCC4 thereby influencing the expression of mmyR and the mmyBQEDXCAPK and 
mmyYF operons. A similar pattern of results was also seen at 72 hours. 
For all mmfR strains there was always more measureable luminescence than the level 
produced by the M145 negative control, indicating that there was not full repression of the lux 
operon. At 48 hours L1+mmfR produced three times as much luminescence as the M145 
control and for L3+mmfR there was almost nine times as much whereas there was over 24 
times as much luminescence for L2+mmfR compared with the M145 control. This revealed 
varying degrees of apparent leakiness in the system, which will not only be influenced by the 
level of MmfR binding but also the promoter strength at each of the sites. 
As was seen in Chapter 6, the self-regulatory nature of MmfR will also influence the level of 
leakiness seen in the system. When under the regulation of the L1 intergenic region and 
mmfRp instead of ermEp*, MmfR appeared to more tightly regulate the luminescence 
produced. Therefore, the levels of leakiness seen in the earlier luminescence assays (Figure 
4.2) are likely to be greater than that which would be present in the wild type system, where 
mmfR would be naturally under the control of mmfRp. It is likely however that in the wild 
type system, the same pattern will be seen with the L2 MARE operator still being the most 
leaky followed by the L3 MARE operator and then the L1 MARE operator, due to the 
predicted relative strength of MmfR binding at these sites.  
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8.2.3 Is MmfR release by the MMFs the same at all three MARE 
operators? 
As well as variations in promoter strength and strength of MmfR/operator binding, there also 
seems to be variation between the ease of release of MmfR repression from the different 
MARE operator sites. This was seen when MMF4 was trialled at a single concentration of 
100 µM in the L1, L2 or L3 based strains (Figure 4.3). L2+mmfR and L3+mmfR both start 
with already high levels of luminescence and produce an average of three to 3.3 times as 
much luminescence upon addition of MMF4 respectively, compared to nine times more for 
L1+mmfR at 48 hours when compared to the same strains without MMFs. 
When compared to a pCC4 positive control strain (representing no repression) the L1+mmfR 
strain with MMF4 produces 96% of the luminescence that L1+pCC4 produced. On the other 
hand, L3+mmfR with 100 µM MMF4 only achieves around 50% of the luminescence 
produced by its positive control and L2+mmfR achieves around 87%. This indicates that 
compared to the positive control, MmfR is less readily released at the L3 MARE operator, 
followed by L2, with L1 being the most readily release. (By comparing the values for mmfR 
strains with MMF4 with their own individual positive and negative control strains, the effects 
of different promoter strengths should also have been offset in these datasets.) 
8.2.4 Does MmfR respond to all five furan compounds? 
All five MMFs (Figure 4.4) produced a significant increase in luminescence for the L1+mmfR 
strain, containing the mmfL/mmfR intergenic region when analysed using a t-test (Figure 4.6 
and Table 4.2). At a concentration of 100 µM, there was seen to be an increase in 
luminescence of between 7.3 and 11.5 times that of the L1+mmfR in the absence of any 
MMFs. This is between 23.6 and 37.2 times the levels of luminescence produced by the 
M145 negative control. 
8.2.5 Do all five MMFs have the same efficacy? 
The Bmax and Kd values were calculated for each of the MMFs for MmfR at the L1 intergenic 
region, from this it was also possible to calculate the binding potential of each when under the 
particular conditions found in the luminescence assay. It is apparent that the relative binding 
potential for each MMF did vary, with the values ranging from 0.22 to 0.67, a three-fold 
difference. 
This data produce the following order of efficacy: 
MMF1 > MMF3 > MMF5 > MMF4 > MMF2 
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It appears that the MMFs with the branched alkyl chains (Figure 4.4) work the best at 
releasing MmfR from the L1 intergenic region followed by the MMFs with the longest 
straight alkyl chains. 
These calculated binding potentials represents the efficacy of each MMF for MmfR in 
causing its release from the mmfL/mmfR intergenic region. It is therefore possible that it will 
vary at the L2 and L3 intergenic regions. When binding the different operators, MmfR might 
have a slightly different conformation as a result of the interactions with different DNA 
sequences, therefore slightly altering the way the MMFs enter and interact with the binding 
pocket. Unfortunately there was not time to test the full range of concentrations at every 
MARE operator site. 
8.2.6 What are the key residues in ligand binding? 
Based on an in silico analysis of MmfR and observations from its crystal structure with 
MMF2, two tyrosine residues in positions 85 and 144 were selected as being likely to be 
involved in ligand binding in vivo. The mmfR gene had point mutations made to alter these 
amino acids in MmfR to phenylalanine residues (Figure 4.11). These mutants were added to a 
pCC4 vector and which was then put into Streptomyces strains containing luxCDABE under 
the control of mmfLp (L1 strains), allowing the analysis of the ligand-binding activities of 
these mutants via the luciferase assay.  
The Y85F mutant appeared to be released by MMF4 to a significantly lower level than the 
wild type MmfR. Even at a 200 µM concentration of MMF4 this mutant did not result in the 
same levels of luminescence as were induced in the wild type MmfR with 100 µM MMF4 
(Figure 4.17). This indicates that this tyrosine residue is indeed key to ligand binding. 
The Y144F mutant on the other hand was not expected to show any difference in ligand 
binding as it is the amine group that is involved in binding the MMFs, and this remained the 
same in the mutant. Rather unexpectedly however, Y144F with 100 µM MMF4 appeared to 
produce around 125% the luminescence of the wild type strain with the same concentration of 
MMF4. This indicates the possibility that this change to the ligand-binding pocket may have 
optimised furan binding, however more in vitro tests are needed to prove whether this is 
indeed the case. 
It is also of note that both the mutants appeared to produce slightly less repression of 
luxCDABE. Despite being mutants for the ligand binding pocket, the mutations lie close to the 
dimer interface of MmfR and so may influence the overall structure of MmfR and therefore 
also its DNA binding properties. 
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8.2.7 How does MmyR binding to the MARE operators and the 
MMFs vary from that of MmfR? 
Table 8.1 shows a comparison of data collected on MmfR and MmyR in terms of strength of 
binding to the MARE operators. 
Despite MmyR knockouts having been shown to overproduce methylenomycin, the 
luminescence assay showed a much lower level of repression by MmyR compared to MmfR 
(Figure 3.8). MmyR showed the greatest level of luminescence repression at the L3 MARE 
operator followed by the L1 MARE operator. No significant reduction in luminescence was 
detected in L2+mmyR compared to L2+pCC4 however, indicating that MmyR does not bind 
the L2 MARE operator. 
Table 8.1. Summary of data on MmfR and MmyR binding to the MARE operators 
The data in this table summarises the findings from Section 4.3 and 5.3 
MARE 
operator 
site 
Correspo-
nding 
promoter 
Strength of binding (no 
MMFs present) 
MmfR release in the 
presence of MMF4 
compared to a control 
Significant 
change in 
MmyR 
binding upon 
addition of 
MMF4 
Relative 
promoter 
strength (1 
being the 
strongest) MmfR MmyR Negative control 
Positive 
control 
L1 mmfLp Greatest Weakest Greatest Greatest NO 5 
L1F mmfRp - - - - - 2 
L2 mmyRp Weakest No binding  Weakest Middle NO 1 
L3 mmyBp Middle Greatest Middle Weakest 
YES 
(increased 
binding) 
4 
L3F mmyYp - - - - - 3 
 
To compare findings on MmyR relative to the data collected on MmfR; MmfR appears to 
bind the L1 intergenic region with the greatest affinity showing a average of 90% reduction in 
luminescence compared to L1+pCC4, followed by L3 with an 85% reduction and then L2 at 
72% reduction compared to their own pCC4 positive controls. MmyR on the other hand sees 
a 40% reduction in luminescence for L3+mmyR compared to L3+pCC4 and an average 
reduction in luminescence of 32% for the L1+mmyR strain compared to L1+pCC4. It is clear 
therefore than in their apo forms and under the control of the ermEp* promoter, MmfR binds 
more strongly to the MARE operators than MmyR. 
In Table 8.1, it seems clear that the L2 intergenic region has the least regulation by the TFRs; 
MmfR and MmyR. MmfR best regulates the L1 intergenic region, controlling the production 
of itself and MmfLHP whereas MmyR appear to best regulate mmyBQEDXCAPK and 
mmyYF. It was hypothesised in the 2009 paper by O’Rourke et al. (71) that the main role of 
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MmfR may be to regulate MMF production and the main role of MmyR to regulate the 
transcriptional activator MmyB. This premise is therefore in line with what was suggested by 
the data here. 
How MmyR actually carries out its repressive role appears to be complex, with much lower 
levels of repression seen than those produced by MmfR. One theory was that MmyR may 
need to be bound to a ligand for it to be able to bind the MARE operator and repress 
transcription. MmyR lacks both the tyrosine 85 and 144 residues previously associated with 
hydrogen binding with the furan ligand in MmfR (Figure 4.14). Unsurprisingly therefore, 
luminescence in the L1+mmyR strains did not show any significant induction in the presence 
of any of the MMFs at a concentration of 100 µM (Table 5.6). There was however an 
indication that MmyR will work better as a repressor in the presence of the MMFs when 
bound at the L3 MARE operator. The addition of 100 µM MMF5 to L3+mmyR appeared to 
bring the levels of luminescence closer to those seen for mmfR strains, showing 25% of the 
luminescence seen for L3+pCC4 (compared to 15% for L3+mmfR with no MMFs). Future 
trials with MMF1 and 3 will hopefully bring about even greater levels of repression, 
particularly as they had the highest binding potentials when binding MmfR. 
It is not clear why no such difference in luminescence was seen in the presence of the MMFs 
at the L1 MARE operator. However at this MARE operator there was seen to be weaker 
binding of MmyR and it is possible that only with a higher concentration of MMFs that a 
significant change in the levels of repression may be seen. Alternatively, the differences in the 
MARE operator sequences between the L1 and L3 sites may slightly alter the conformation of 
MmyR in a way that adjusts how the MMFs can bind. Again, this is something that would be 
interesting to look at in future trials. 
In summary, MmyR appears to have very different binding affinities for both the MMFs and 
the MARE operators when compared to MmfR. It appears to significantly interact with the 
methylenomycin system, but in a very different way to MmfR. Having two repressors with 
different roles and affinities thereby appears to allow tighter control of methylenomycin 
regulation. 
8.2.8 Are there any other ligands that MmyR may bind to? 
In other GBL binding systems there is often a TetR family GBL receptor as well as a 
paralogous ‘pseudoreceptor’ which has different ligand binding properties as well as a greater 
promiscuity of DNA targets. As MmyR is analogous to some of these ‘pseudoreceptors’ it 
seemed logical that it may bind an alternative ligand than the MMFs. 
Methylenomycin A and its precursor methylenomycin C were trialled to see if they caused a 
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significant change in luminescence in the L1+mmyR strain. Results from this assay were 
inconclusive with the lower concentration of the methylenomycins producing greater changes 
than the higher concentrations. Despite controls being run, it was unclear whether these 
artefacts where a results of the toxicity of the compounds in the cultures or truly 
representative of a change in repressive activity of MmyR. However, when a number of 
different architectures were trialled in mathematical models of the methylenomycin 
regulatory system, models where MmyR was released upon binding methylenomycin did not 
match the phenotypes seen in previously collected experimental data. This therefore indicates 
that it is unlikely that MmyR binds methylenomycin A or C. It would be helpful to analyse 
this further with the luciferase assay however due to the limitations of the mathematical 
modelling performed (Section 6.5). 
The potential of an alternative MmyR ligand cannot be excluded but as yet there are no firm 
hypotheses on what these molecules may be. 
8.2.9 Could MmfR, MMFs and MARE operators be used as a multi-
host efficient novel inducible expression system for GC rich 
bacteria? Would this allow the purification of recombinant 
proteins? 
In terms of developing a novel inducible expression system, the lux vectors have certainly 
shown promise with high levels of expression produced clearly measureable levels of 
luminescence, with up to an 18 times increase in luminescence once the MMF inducer has 
been added (Figure 4.7). The lux genes can easily be replaced with a gene of interest to be 
over expressed, under the control of MmfR/MMF/MARE operator, which should 
hypothetically be able to be controlled in the same way as the lux genes were. Two separate 
GbnB analogues from S. mutans and S. enterica were inserted between the L1 intergenic 
region and luxCDABE in the L1 vector for use as a novel inducible expression system. 
The optimisation of the inducible expression system proved to be challenging however, with 
little known about how to purify proteins from S. coelicolor compared to the better-known E. 
coli systems. In particular there were a number of challenges that were encountered when 
trying to develop a heterologous expression super host meaning that trials were done in S. 
coelicolor M145 instead, a strain which has limitations when trying to grow it in liquid 
culture. While optimising this system there appeared to be a good improvement in protein 
yield of secreted protein of the expected molecular weight when using a selection of protease 
inhibitors, indicating that protein degradation may have a significant impact on protein yield. 
There is hope that with even further optimisation and more extensive purification of the 
proteins of interest that a continued improvement in protein yield may be seen. 
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The presence of a band of the right size for the GbnB analogues does indicate that this 
actinomycete system may allow the purification of recombinant proteins from GC rich 
bacteria. This however still needs to be confirmed with further tests on the purified proteins to 
identify them as the desired GbnB-like proteins, as the LC-MS analysis done was largely 
inconclusive. 
The development of an optimised heterologous expression host was met with very limited 
success. It did however, help to shed some light on the cross-species promiscuity of GBL-like 
receptors, through the in vivo and in silico work done with S. albus. The lux system was 
added to S. albus with the potential of it being used as a host for the novel inducible 
expression system due to its very small, streamlined genome size. It was found however that 
luminescence for the L3+pCC4 positive control was repressed (Figure 7.1). A BLAST search 
for MmfR homologues found the TetR family member SSHG_01258, which shared over 40% 
identity with MmfR (across 86% of its sequence) and was potentially binding to the MARE 
operator and repressing mmyBp. No significant MmyR homologue could be found however. 
This indicates an extra hurdle when developing a multi-host efficient inducible expression 
system. TetR family members share a homologous helix-turn-helix DNA binding region 
which sometimes may share enough sequence identity to bind to one another’s target DNA 
sequences. This poses a limitation when transferring the MmfR/MMF/MARE operator 
expression system between hosts that also contain homologues with high sequence identity to 
MmfR/MmyR. Even weak binding to the MARE operator by native host receptors could be 
enough to considerably interfere with an inducible expression system and its regulation. Of 
course, with the advancing and increasing availability of many bacterial genomes, an 
examination could be run in potential expression hosts for MmfR homologues. However, the 
cut off for sequence identity that would result in these analogues binding the methylenomycin 
cluster MARE operators is as yet unknown. 
In summary, the MmfR/MMF/MARE operator system still shows promise as an inducible 
expression system in streptomycetes. However, much more optimisation is needed before it 
could be widely used. 
 
8.3 Impact of Data Collected 
There is hope that the research presented in this thesis can shed some light on the biosynthesis 
of some other natural products from strains of Streptomyces that contain homologues of the 
MmfLHP/MmfR/MmyR system. For example, tyrosine 85 and 144 (believed be used in 
ligand binding) are conserved in other homologous proteins indicating that other systems may 
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also use furan molecules as ligands. Some of these homologues are from otherwise silent and 
less well understood pathways and so have the potential of revealing otherwise undiscovered 
antibiotics if manipulated in the correct way. 
In particular this research has revealed more about the functioning of TetR family pairs 
analogous to GBL receptors and pseudoreceptors and how they have distinct roles in 
regulating secondary metabolism. It is apparent that whereas the GBL-like receptors often 
have similar and predictable mechanisms of action where they bind a hormonal ligand and 
then are released from a DNA operator, the paralogous ‘pseudoreceptors’ are much hard to 
predict the function of. Despite the knockouts of these pseudoreceptors often bringing about 
the same phenotype of overproduction of the cognate secondary metabolite, the mechanism 
by which they achieve repression appears to vary hugely. Sometimes the pseudoreceptor will 
only be released by a different, non-GBL ligand, possibly the cognate natural product. The 
findings of this thesis on the other hand, indicate that MmyR and MmfR may both bind the 
MMFs but this will bring about a completely different effect on MmyR, that of increased 
repression compared to a release of repression that these ligands bring about for MmfR. There 
are also quite distinct differences in the affinity of MmfR versus MmyR for the DNA 
operators. All this information is helpful when trying to switch on secondary metabolite 
production for silent gene clusters, with a broadened selection of possible alternatives to be 
trialled when trying to manipulate the activity of MmyR analogues. 
The research into the DNA binding domains of MmfR, MmyR and their homologues (Table 
7.7) revealed a number of common motifs, which could also be of relevance when 
manipulating TetR family binding to a chosen DNA operator. This does need further 
investigation but could prove to be very useful when seeking to control other biosynthetic 
clusters as well as engineering the novel inducible expression system. In particular, the work 
on MmfR/MmyR may help to better understand the regulation by SAV_2270 and SAV_2268 
in S. avermitilis and SHJG_7318 and SHJG_7322 in S. hygroscopicus, of which the natural 
product they regulate is unknown. These homologues shared the identical DNA binding 
motifs to those found in MmfR and MmyR and so possibly will reveal similar DNA binding 
profiles to those in the methylenomycin regulatory system studied here. 
 
8.4 Discussion and Improvements of Luciferase Assay 
8.4.1 Discussion of Techniques 
The chosen luminescence assay provided easily detectible results quantitative results which 
were possible to collect in a 30 second reading making this assay quick to obtain data from. 
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The Photek CCD camera was sensitive enough that small changes in luminescence could be 
detected for concentrations of the MMFs as low as 5 µM. A summary of the positive and 
negative aspects of the luxCDABE assay has been presented in Table 8.2. 
Table 8.2. Summary of the positive and negative aspects of the luxCDABE reporter gene 
assay 
Positive aspects Negative aspects 
Allowed the use of solid cultures Energy taxing nature of the luxCDABE operon 
resulted in phenotypic differences of some cells 
Multiple readings over time was possible as this 
was a non-destructive assay 
It was not practical to measure the cell mass from 
solid cultures 
Did not need to add substrates for luciferase, 
everything was made in the system 
Large deviations between results meaning that a 
number of repeats needed to be taken 
Easy manipulation of the system to study 
alternative operators, promoters and repressors via 
the sub-cloning and manipulation of vectors 
The software for the Photek camera was old so 
transfer of data into a readable format for other 
computers could be a lengthy process 
Very sensitive CCD camera  
Quantitative and easily detectable results  
 
In particular, this luciferase assay allowed the use of solid culture, where S. coelicolor grows 
better, completing its complex sporogenic life cycle. The use of solid culture also tends to be 
less susceptible to contamination while manipulating samples to take multiple readings. In 
addition to this, solid cultures were smaller in volume than the liquid ones trialled and so were 
less demanding on the synthesis of purified MMFs, which are not commercially available. 
The measurement of luminescence from solid cultures using the Photek CCD camera was also 
non-destructive, allowing the collection of repeat measurements from the same samples over 
time. 
Liquid cultures proved to be impractical to use for this assay. The large clumps that S. 
coelicolor form in liquid culture meant that there was huge variation between results 
collected. Also, without being able to complete its sporogenic life cycle, it is unclear how 
results collected from liquid cultures may be representative of methylenomycin regulation in 
the wild type system, with unknown interplay from extra transcriptional control such as sigma 
factors and riboswitches possible that may be dependent on different stages in the life cycle. 
The use of baffled flasks needed for Streptomyces growth in liquid culture also meant that 
samples had to be transferred into a different plate for measurements by the Photek camera, 
increasing the chances of contamination. It was also not practical to add the sample back into 
the baffled flask after the luminescence had been measured, meaning that the assay was 
destructive and reduced the volume of the culture each time a reading was taken. Other strains 
of Streptomyces such as S. venezuelae do grow better in liquid culture but as was seen in 
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Section 7.2, analogous TFRs may interfere with the system and so knockouts would need to 
be created. Using an alternative host is therefore not as simple a transition as may be desired. 
A downside of using solid culture was that the exact mass of cells was not known for each 
sample. Methods to measure the mass of solid cultures are often disruptive to the lawn of 
bacteria or be destructive to the sample and result in contamination and so would have 
prevented repeat readings being taken for the same cultures over time. Also, when inoculating 
plates directly from glycerol stocks (which were of a known concentration), luminescence 
production appeared to be effected by storage of the stocks at -80 °C. For this reason, a lawn 
of Streptomyces was grown on selective SFM media for four to five days at 30°C and this 
formed a fresh starter culture for the rest of the study. Picking cells fresh from a selective 
SFM plate ensured that they would be luminescing optimally for data collection but the 
concentration of cell mass was not known. To overcome the problem of not knowing the 
exact cell density, multiple repeats were done for each sample type and luminescence was 
calculated as a ratio, relative to a control sample. This control samples would be under the 
same variations in the inoculation of individual cultures and so should cancel out any effects 
of variation in cell mass and can be used to normalise data. 
It was also found that there is much less variability between readings at the later time points 
likely to be due to the stability brought about by cells were entering the stationary phase of 
growth. These 48 and 72 hour time points were therefore more reliable time points to study in 
detail, using boxplots and t-tests, due to a lower standard deviation and coefficient of 
variance. If these assays were to be done again, it is likely that the decision would also be 
taken to reduce the number of readings taken, removing the 21 and 27 hour time point 
readings and just collecting data at 24, 48 and 72 hours. The earlier time points were initially 
used as there was a lot of change in luminescence earlier on in growth, however the 
deviations in luminescence during this exponential phase make a reliable analysis of results 
difficult. Reducing the number of readings taken around 24 hours would have the benefit of 
decreasing any impact of temperature changes when taking samples out of the 30 °C 
incubator. Although samples are removed from the incubator for less than ten minutes at a 
time, it is unclear what the impact of initially doing this every three hours was. 
Another positive aspect of the luciferase assay was that it was easy to adjust and adapt for the 
study of different operators, promoters and repressors. Through the use of restriction digests 
and sub-cloning, different methylenomycin cluster intergenic regions could be studied and 
MmfR mutants were easily added to the system. This allowed the creation of a large array of 
different lux strains, permitting the analysis of a range of variables, brought together in 
different combinations. 
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Using luxCDABE compared to luxAB is beneficial because nothing needs to be added to the 
system. Both luciferase and its substrate are produced and so there is luminescence generated 
without any external manipulations. Anything extra needed to produce this bioluminescence 
is already present in the lux host strain. The downside of this self-contained system is the 
likelihood that the constitutive expression of luxCDABE is very taxing on the cells resources 
and perhaps for example, the strongest promoters are not revealing the true extent of their 
strength when tested with this assay. This is something that would be helpful to investigate 
further, looking at the different metabolic profiles of cells with phenotypic differences 
compared with those presenting the wild type phenotype of pigments produced. 
In conclusion, the luciferase assay proved to be very useful in the study of methylenomycin 
regulation in S. coelicolor. As with any reporter gene assay there were both positive and 
negative aspects of collecting results in this manner. The main downside of this technique was 
the variation between results. With more information on the cross-species affinity TFRs have 
for each others operator sites, this system could be developed for use in streptomycete strains 
that grow better in liquid culture. This would allow the calculation of cell mass in each 
sample and would hopefully reduce the deviations between data sets. However, until this is 
achieved, the luciferase assay would likely be suitable as it is in future investigations. 
8.4.2 Luciferase Assay Future Work 
The luciferase assay provided a lot of useful data on the regulation of methylenomycin 
biosynthesis and so would be used again to test more variables involving MmfR, MmyR and 
the MMFs. In particular, there is a desire to collect data on a number of other controls to 
produce a better-rounded assessment of biosynthetic regulation. There is hope that some of 
these trials will be completed during a short post-doctorate project to be carried out after the 
conclusion of this report and will be done again using the protocols specified in Section 3.3.7 
and Figure 3.3. These potential trials will now be discussed. 
A control test was run where the five MMFs were tested on the L1+pCC4 strain to look for 
significant changes in luminescence, in the absence of MmfR or MmyR. In the light of 
research indicating that the MMFs may have extra activator roles as well as causing the 
release of MmfR from the MARE operator (Section 4.4.2) it seems apparent that a full set of 
trials should also be run with L2+pCC4 and L3+pCC4 with all five MMFs. Preliminary trials 
were run with these two strains in the presence of a single concentration of some of the 
MMFs but this was not prioritised and a full data set was not collected. It would maybe even 
be useful to trial a range of concentration of the MMFs with these positive control strains to 
assess whether there is a calculable Kd or Bmax value. It is possible that the MMFs may be 
used to recruit other transcriptional regulators, located at different loci to the methylenomycin 
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cluster and so would be able to alter levels of luminescence even in the absence of 
MmfR/MmyR. Alternatively, the MMFs may be involved in the activation of a riboswitch in 
some of the methylenomycin cluster genes. 
Another area that would be interesting to explore with the luciferase assay would be a study 
into the strength of other streptomycete promoters. In this way, the effects of the potentially 
taxing expression of luxCDABE could not only be further explored but also a promoter could 
be selected for the over expression of mmfR. Something that would be particularly useful in 
the development of the novel inducible expression system where more complete repression of 
recombinant genes by MmfR is desired (see Section 8.5). The gfp assay work by Bai et al. 
from 2015 could be used as a benchmark for promoter strength in this particular assay. In 
their work, Bai et al. developed the kasOp* promoter (135) which was found to be ~20 times 
stronger than ermEp* and so is of potential interest as a strong constitutive promoter. As 
before, alternative promoters could be inserted upstream of the luxCDABE genes and the 
relative bioluminescence produced observed in the same manner as was done in Section 3.4. 
This could also then be compared to the work by Bai et al. to see if the same fold difference 
in luminescence for different promoters was seen in their equivalent gfp assay, thus indicating 
any limitations of luxCDABE expression. 
If more time allowed the L1F+mmfR and L3F+mmfR strains would also be further explored 
and compared to their L1 and L3 counterparts to investigate the influence of promoter 
position compared to the MARE operator in the reversed intergenic regions. The strength of 
MmfR/MmyR binding should be the same in either orientation due to the MARE operator 
remaining the same but the proximity of the MARE to the corresponding promoter may have 
an effect on the ‘leakiness’ of the system. 
Investigations into MmfR/MMF/MARE operator interactions were more extensive than those 
done for MmyR. There is interest in further investigating the role of the lesser-understood 
MmyR, in particular looking at the effect of different concentrations of the MMFs on this 
repressor at the different MARE operators. During investigations in Section 5.4 there was a 
lack of evidence of a significant effect on luminescence by 100 µM for L1+mmyR and so no 
trials were run to find out the Kd and Bmax values for mmyR strains, in an attempt to conserve 
MMF stocks. However, since then possible MmyR/MMF interactions have been shown at the 
L3 intergenic region, showing more promise for the production of significant and utilisable 
results if trialled with a full range of MMF concentrations. These trials were not run 
previously due to the finalisation of the lab project but it would be very interesting to carry 
out these tests in the near future. The aim of these further trials would be to investigate 
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whether higher concentrations of the MMFs could be used to achieve ‘full’ repression at the 
L3 intergenic region or possibly a significant change in repression at the L1 intergenic region. 
Another area that would be fascinating to explore using the luciferase assay is the cross-strain 
promiscuity of the DNA binding domain of TetRs analogous to MmfR. Either sav_2268 or 
sgnR could be subcloned downstream of ermEp* in pCC4 and added to the system along with 
the L1, L2 or L3 vectors. The level of repression achieved by these homologous repressors at 
the different intergenic regions, if any, could then be determined. In addition to looking at 
DNA binding properties, these analogues share high sequence identity in their ligand binding 
pockets to MmfR and so this assay set up could also be used to investigate whether 
SAV_2268 and SgnR can bind to and are released by the furan ligands in vivo. 
Finally, the investigation into the auto-regulation of MmfR and possible MmyR was only in 
its preliminary stages before this project concluded. There are many more investigations that 
could be carried out using the sp105 and 11NY strains, including the trial of a gradient of 
MMFs to see if luminescence could be induced at a specific threshold level. It would also be 
interesting to alter the 11NY and sp105 vectors to include alternative intergenic regions in an 
auto-regulatory system. 
 
8.5 Discussion and Improvements of the Novel Inducible 
Expression System 
8.5.1 Discussion of Techniques 
Investigations into the development of a novel inducible expression system were divided into 
two main parts; research into the potential use of S. albus as heterologous super host and the 
optimisation of the MmfR/MMF/MARE operator inducible expression system in a S. 
coelicolor M145 host. This investigation came after a selection of data from the luciferase 
assay had been obtained. For this reason, this section of the investigation was much more 
constrained by time as it came nearer the end of the project. These methods required much 
optimisation and could not be developed as far as a being a useable heterologous expression 
system that could be employed in multiple hosts. However, the data collected did form a good 
basis of preliminary investigations, which can then be developed further in the future. For this 
reason there are large overlaps between technique discussion and improvements and planned 
future experimentation compared to the discussion of the luciferase assay technique. 
Creation of an Optimised Heterologous Expression Host 
The luciferase assay used to investigate the MmfR/MMF/MARE operator system in S. albus 
has already been discussed in Section 8.4.1 but there are some further improvements that 
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would be beneficial with regards to this particular strain. In particular, it was a concern that 
some of the findings of the luciferase assay in Section 7.2.2 were due to problems with 
luxCDABE expression in S. albus, possibly as a result of the genome rearrangements this 
strain undergoes. It would potentially be beneficial therefore to regularly re-check the S. albus 
genome for the presence of the luciferase inserts should the assay be done again, to confirm 
that the results seen were not due to impeded genomic lux maintenance. 
Optimising the Novel Inducible Expression System 
When developing the inducible expression system for S. coelicolor M145 a number of 
different variables were trialled including the use of liquid versus solid media, different 
carbon sources, harvesting proteins at different time points as well as the use of protease 
inhibitors. The use of protease inhibitors showed promise in the optimisation of the technique 
and so is something that should certainly continue to be used over the 72 hours of 
Streptomyces growth in future trials. One major way in which the results of these optimisation 
trials may be improved is through the use of more extensive purification methods. During the 
investigation in Section 7.4, a very basic nickel Sepharose purification technique was used to 
provide a more high throughput system to test assorted variables. However, a more distinct 
band at the expect position on the SDS-PAGE gel may be achieved with a more refined 
method such as fast protein liquid chromatography FPLC. This semi-automated technique 
would hopefully reduce the number of non-specific bands seen in the purified samples and 
make results easier to analyse. 
Also, despite SDS-PAGE bands being analysed using LC-MS, the results from this were at 
times hard to analyse and inconclusive, due to the presence of so many potential polypeptides. 
An additional technique such as Western blotting therefore may be of use when looking for 
the presence of the histidine tagged recombinant GbnB-like proteins. 
Further improvements could also be made to the design of the expression vectors being used, 
with the benefit of hindsight and lessons learnt while optimising the expression system. For 
example, there was no spacer included between the TAT export signal and the 6xhis-tag. It 
became apparent later that the natural cleavage of the TAT signal might also cleave off some 
of the histidine tag, resulting in a potentially lower binding affinity for the nickel Sepharose. 
To remove this possible problem, either a spacer of random DNA could be added between the 
TAT signal and histidine tag or the histidine tag could be made longer so that any cleavage 
would still leave at least six histidine residues. 
In addition to this, there was no cleavage site added for the removal of the histidine tag. 
Although this was not a problem in the optimisation trials, for the expression system to be 
adaptable for a wide range of different proteins and uses it would be helpful to add a cleavage 
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site. Another obvious improvement that will need to be made to the expression vectors is the 
removal of luxCDABE. These genes were left in the vectors created to allow expression to be 
tracked via luminescence measured with the Photek CCD camera as well as via the more 
lengthy process of checking proteins via SDS-PAGE. However, due to the resource 
demanding nature of these lux genes, it is likely that protein expression is not optimal while 
they are still in the system and so will be removed, using the restriction sites included in the 
vector for this very reason, before any future trials. 
8.5.2 Novel Inducible Expression System Future Work 
Creation of an Optimised Heterologous Expression Host 
In addition to S. albus, there are a number of other possible streptomycetes that could be 
developed as heterologous expression super hosts. One of these is the reduced S. coelicolor 
strain, M1152.(123) Like S. coelicolor M145, this strain is lacking the SCP1 and SCP2 
plasmids but also has a number of extra genes removed, making this strain even more 
streamlined and therefore potentially a better host. Due to M1152 being a reduced version of 
M145, there is little chance of any unexpected background interactions not encountered in the 
work done for this project. It is not currently the perfect host however. It was found recently 
that the M1152 host still contains some biosynthetic genes from its gamma butyrolactone 
pathway but lacks repressor ScbR2 and therefore overexpresses these GBLs.(155) It has been 
experimentally shown that SCB1-3 (S. coelicolor butyrolactones 1-3), involved in coelimycin 
regulation, are over produced in the M1152 strain as well as five novel SCBs (SCB4-8).(155) 
This is a drain on the cells resources as well as adding the potential of these unregulated 
signalling molecules interacting with other pathways. In the M145 strain, these SCBs are 
under their normal wild type regulation by both ScbR and ScbR2 and so this overproduction 
has not been shown to be a problem. 
Before M1152 can be used as a heterologous expression host, this problem ideally needs to be 
solved and three genes of interest removed from the genome; scbR, scbA and scbB. ScbA and 
ScbB are involved in the biosynthesis of the SCBs. There are a number of techniques that 
could be used to achieve these gene knockouts. An example of a technique for gene 
manipulation which has recently grown in fame is that of CRISPR/cas9.(156) Unfortunately 
this technique has not shown successes when trialled in S. coelicolor by other lab members at 
Warwick, due to potential toxicity caused by unrepaired double stranded breaks in the 
genome and inefficient transfer of DNA via conjugation. It is unfortunate that such a powerful 
technique cannot be used for this purpose, at least not without some major improvements. 
Mutagenesis techniques in streptomycetes often employ gene targeting, where homologous 
recombination is used to change a plasmid-based endogenous gene, followed by transfer into 
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Streptomyces via conjugation. Problems often come about at the stage of conjugal transfer of 
plasmids from E. coli into Streptomyces. Techniques recently developed by Netzker et al. 
earlier in 2016 (157) may be able to assist with solving these problems. This research group 
developed an optimised conjugation protocol by looking and different media, antibiotic 
concentration, temperature and calcium ion concentration. It is therefore suggested these 
newly optimised conjugal transfer techniques are used to remove scbR, scbA and scbB from S. 
coelicolor M1152, possibly using PCR targeting. PCR targeting is a protocol specified in the 
‘Redirect technology: PCR-targeting system in Streptomyces coelicolor’ manual (158) 
designed by Bertolt Gust, Tobias Kieser and Keith Chater from the John Innes Centre. This 
protocol is based on a well known mutational technique developed by Datsenko and Wanner 
in 2000 for use in E. coli (159) but has been adapted for S. coelicolor. The procedure involves 
the excision of specific genes from a streptomycete cosmid in exchange for a PCR product of 
a selectable marker with added short homologous arms. This is done in a strain of E. coli with 
a high recombination and mutation rate (due to the presence of genes for λ RED 
recombination). These modified cosmids are then transferred to S. coelicolor via conjugation 
and the mutation integrated into the genome via homologous recombination of large stretches 
of native DNA in the cosmid. 
These techniques could also possibly be used for the removal or sgnR/gbnR/sgnLHP from S. 
venezuelae or sshg_01258 from S. albus with the prospect that removing these genes may 
prevent any interference with MmfR/MMF/MARE operator in these alternative hosts, 
hopefully allowing the cross-species adaptability of the inducible expression system. S. 
venezuelae has been shown to sporulate in liquid cultures and liquid cultures have the 
potential to produce larger volumes of biomass and therefore a greater potential protein yield 
meaning that this is a attractive alternative host. 
In addition to work to be done in the laboratory, a more widespread amino acid analysis with 
a detailed look at predicted TetR family protein functions would also be beneficial. Any extra 
information obtained on the cross-species affinity TFRs have for each others operator sites 
would assist in the development of the MmfR/MMF/MARE operator system for use in 
alternative streptomycete strains e.g. S. lividans. DNA binding promiscuity between 
transcriptional repressors could also be investigated in vitro using a gel shift assay or surface 
plasmon resonance (SPR) to test for receptor affinity for specific DNA sequences and cross-
talk with the MmfR/MARE operator system. 
Optimising the Novel Inducible Expression System 
It was seen in Section 7.4.4 that the addition of pKMS01 (mmfR) to strains containing 
pKMS05 or 06 did not result in any obvious reduction in protein synthesis. This is possibly 
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because the bands seen are unrelated to luxCDABE or the GbnB analogues, and are therefore 
not controlled by MmfR repression. Alternatively it could be due to the ‘leakiness’ of 
repression at the L1 intergenic region. The L1 intergenic region was selected for use in the 
inducible expression system as MmfR showed the strongest binding at this site, it appears 
however that even this small amount of leakiness may still result in significant levels of 
recombinant gene expression. To fully optimise the system, it would be preferable that mmfR 
be put under the control of a stronger promoter than ermEp* with the hope that higher levels 
of MmfR will result in more complete repression. There was evidence in Section 6.2 when 
under the control of its own promoter, levels of MmfR repression appeared greater. This 
indicates that it is a problem with the levels of MmfR present rather than its repressive ability 
that allows significant leaky gene expression. Unfortunately the native methylenomycin 
promoters such as mmfLp are unsuitable for controlling mmfR expression due to their self-
regulatory control and lack of observable induction by the MMFs under laboratory conditions. 
Instead there are a variety of strong constitutional promoters that could be trialled, for 
example the kasOp* promoter which was indicated to produce 20 times more gfp 
fluorescence than when the same gene was under the control of ermEp* (See also Section 
8.4.2).(135) Again using the luciferase assay, the promoter that is shown to achieve the best 
levels of MmfR repression could then be used in the novel expression system to make it truly 
inducible. 
An additional adjustment that would also be interesting to explore is the use of a different Tat 
export signals. Li et al. presented research on Tat export in S. coelicolor A(3)2 in 2005 (148) 
where details were given of the signal peptides for 129 possible Tat substrates, as predicted 
by their software; TATscan. It is possible that if a different one of these was used, an 
improvement in protein yield may also be seen. The specific efficiency of different signal 
peptides is not known and so one was picked at random for this assay but it may not be as 
efficient as other signal peptides. A range of alternative Tat signals could be sub-cloned into 
pKMS05 or 06 and expression levels assessed. 
When designing the expression system, the two GbnB analogues were selected due to the 
interest by the research group at Warwick and GSK into their purification. However in 
hindsight, selecting two proteins that had never before been successfully purified was not a 
good place to start with a technique that needed so much optimisation. It would be beneficial 
instead to also try over expressing a gene that is known to be extractable from current systems 
available for GC high bacteria such as the gene for that of streptavidin.(107) This would then 
provide a control for optimisation trials. It is possible that a better indication of the presence 
of the GbnB-like proteins was not achieved because the system was not optimal for protein 
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folding or any other factors involved in the successful collection of a soluble protein for these 
specific polypeptides rather than a flaw in the actual expression system. 
 
8.6 Other Relevant Future Work 
As mentioned in the introduction, the exact mechanism of methylenomycin activity is as yet 
unknown. There are plans to investigate this further in the future. A selection of B. subtilis 
reporter strains have been developed which contain five different promoters attached to the 
firefly luciferase gene.(160),(129) The levels of luminescence produced by each strain in the 
presence of an antibiotic indicate what its biological target is. Once this target has been 
established, further research can be carried out looking for greater depth of understanding on 
interactions with this target. Another researcher within Warwick University is currently 
carrying out this work. 
In addition, work is also being carried out to purify a MmyR orthologue from Streptomyces 
avermitilis; SAV_2270. This orthologue has been indicated to be soluble when purified with 
commonly used E. coli systems, meaning that crystallisation may be possible. This would 
help to shed light on the functionality of these ‘pseudoreceptor’ type proteins. If the crystal 
structure of SAV_2270 could be obtained, the structure of MmyR may also be possible to be 
modelled based on this analogue, allowing a greater understanding of key amino acids in 
DNA and ligand binding including opening the possibility of more accurate docking analyses 
with potential ligands. Previous attempts to model MmyR based on MmfR have as yet proved 
to be unsuccessful, with not enough homology of structure to produce viable docking 
analyses. 
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9 Summary of Results and Conclusions 
To conclude all of the observations made during the experimentation carried out for this 
project, an interesting insight has been developed into the roles of the paralogous pair MmfR 
and MmyR in the regulation of methylenomycin biosynthesis. 
The better-understood MmfR was previously predicted to bind three different intergenic 
regions at a 24 bp methylenomycin auto-regulatory response element site, thereby regulating 
the expression of five different operons. This investigation revealed that these five different 
operons have promoters of differing strengths. The promoters for mmfR and mmyR appeared 
to be the strongest whereas the promoters for other enzymes and regulators were weaker. In 
addition to this, there is a variation in the strength of MmfR binding to the three MARE 
operator sites as well as the level of release of this repressor that can be induced by a single 
concentration of MMF4 ligand. Each of the five MMF ligands were shown to have a different 
efficacy for MmfR when it was repressing at the mmfL/mmfR intergenic region, with the 
furans that have the branched alkyl chains proving to be the most efficient ligands. An in 
silico analysis of the MmfR primary and tertiary structure revealed the presence of two 
tyrosine residues thought to form hydrogen bonds with the furan ligands. A mutational 
analysis of these residues indicated that they are indeed involved in ligand binding and may 
also effect DNA binding due to their close proximity to the dimer interface. 
The activity of MmyR varied from that of MmfR. This paralogue showed significant binding 
to two out of the three MARE operator sites that MmfR was indicated to bind, but showed no 
significant binding to the intergenic region that contains the promoter for its own gene. As 
with MmfR, there was variability in affinity of MmyR for each of the two operator sequences 
it did appear to bind. MmyR showed no significant release in the presence of the MMFs from 
either site, however a level of significant improvement in repression was detected for MmyR 
at the mmyY/mmyB intergenic region in the presence of all the MMFs trialled. No conclusive 
data was collected on the possibility of MmyR binding to methylenomycin A or C but the 
possibility of other alternative ligands cannot be ruled out. 
The MmfR/MMF/MARE operator system shows promise as something that can be developed 
into a novel inducible expression system, although much optimisation is necessary. In 
particular the use of protease inhibition throughout culture growth appeared to be key to the 
recovery of proteins. However, whether this system can be adapted to be efficient in multiple 
hosts is yet to be seen, with affinity for the MARE operators from exogenous proteins 
predicted. 
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Appendices 
Appendix A. Nucleotide Sequences 
Intergenic regions 
MARE operator sequences shown in bold 
 
mmfL_mmfR (194 bp) – L1 
GGCTGCCTTCCTTCGTGTGTGCGGGCCCTGCGGGCGCCATGCTGGTGCGACCCGGGTCGGCACGGAAACCCATTGCATAATACCTT
CCCGCAGGTATATTTCTCTCGGTCAGCTTACCGATCCCGGCTGTCTTGCAGCGCGGCAAGCCAGCCGGTGGTCCCGTACGAGGACA
CACCGGGAGATGTAGCGCCCCT 
 
mmfP_mmyR (150 bp) – L2 
ATCCTGCCGCGCGGTAGCCGTGCTGCCTCCACTTTTGCGCCGATGACTGGGACATCGTCCACGTGCGCCGACCGCCCCCACTAACA
TACCTTCCCGAGGGTATGTTTTCCGGGCCCGTTGGCTCACGACCTTGAGAGGACTCGGGCGTTG 
 
mmyY_mmyB (229 bp) – L3 
GGTGAACTCCTTCGGCGAGTGGTTCGGATCGCTGGCGAGTATCGGCAGGGTCGTGCGAAGGCTGCCAGAGCGAACTTCTGCTAGGG
GCCTCAGACGTGGTGTTCTCAGCACCAGGGCCCCGCCGAGTTGCGGTCCAAACACCGAGGCCCCGCCGCTCTCGTAAGCCCCGGTT
TAACTCTCCGTTACGAGTCATAAAAAACCTTCGGGAAGGTTTGACACTGTGAGGCGCC 
 
ErmE* insert containing promoter 
-35 and -10 sequences shown in bold 
AGCTTGCATGCCGGTCGACTCTAGAGGATCCTACCAACCGGCACGATTGTGCCCACAACAGCATCGCGGTGCCACGTGTGGACCGC
GTCGGTCAGATCCTCCCCGCACCTCTCGCCAGCCGTCAAGATCGACCGCGTGCACCTGCGATCGCCGATCAACCGCGACTAGCATC
GGGCGCAAGCCACCACTCGAACGGACACTCGCACTTAAGACGGATCTTTTCCGCTGCATAACCCTGCTTCGGGGTCATTATAGCGA
TTTTTTCGGTATATCCATCCTTTTTCGCACGATATACAGGATTTTGCCAAAGGGTTCGTGTAGACTTTCCTTGGTGTATCCAACGG
CGTCAGC 
 
GbnB synthetic analogues 
BamHI | RBS | ATG | TAT signal | 6 Histidine | MunI |GbnB  analogue| NotI |NdeI |  
CAC|GGATCC|AAAGGAGG|ATG|ACGAAGCCGGTCGTCCCCTCGGGGGTCTCCCGGCGCGGGTTCCTCGGGGGGTCCCTGGGCGT
CGCGGGCGCGGTCCTGCTCGCCGCC|CACCATCACCATCACCAC|CAATTG|GbnB analogue|GCGGCCGC|CATATG|CAC| 
 
Streptococcus mutans 
CACGGATCCAAAGGAGGATGACGAAGCCGGTCGTCCCCTCGGGGGTCTCCCGGCGCGGGTTCCTCGGGGGGTCCCTGGGCGTCGCG
GGCGCGGTCCTGCTCGCCGCCCACCATCACCATCACCACCAATTGCTGGCCCTGGAGAACCTGATCCAGATCCGCAACCGCAACCC
GGACAAGCTGATCCTGATCTCCGACGAGAAGTCCTTCTCCTGGAAGGAGTACACCAACCTGGTCATCAACAACCTGCGCAACACCA
CCCTGCAGTCCGTCCTGAACAAGACCGACCGCGCCATCATCATCTCCGAGAACACCTGGAAGGTCTTCACCATCTACTCCTGCCTG
TCCACCCAGAAGATCCCGTACTCCGGCATCGACTACTCCATGGAGGACGACAAGAAGGTCGCCGCCATCAACAAGTCCGGCGCCAA
CACCGTCTTCTACTCCAAGGACCAGAAGCCGTCCCAGAACCTGCGCAACTCCCTGAAGGGCGTCTCCTTCATCTCCCTGGACATCC
TGCACGACGACATCGAGGGCTCCGACCTGTCCGACTTCAACATCAAGAAGCACTCCGACTCCATCGTCTCCTTCGGCTTCACCTCC
GGCACCACCGGCCTGCCGAAGTGCATCTACCGCGACTACTCCTTCGCCACCGAGCGCATGAAGGAGCTGACCAAGCTGTACAACTT
CAACGCCACCGACGTCTTCCTGGTCACCATGCCGTTCTACCACGTCTCCGTCAACGGCTGGGTCAAGCTGACCCTGAACAACGGCG
GCTCCGTCGTCCTGGGCGACTTCAACAACCCGATCGACCTGTCCTCCAAGATCAAGCAGTACGACATCACCACCATGCTGATCACC
CCGCCGGTCCTGAAGTCCCTGAACTTCGTCCTGAACCAGCAGGGCTTCATCAACTCCACCGTCCGCTTCATCATGGTCGGCGGCAA
GAACTTCCCGCCGAAGCTGAAGGAGGAGACCCAGAACCTGTTCGGCTCCGTCCTGCACGAGTACTACGGCTCCTCCGAGACCGGCA
TCAACGTCCTGGCCAACTCCTCCGACATGATGCTGTACCCGTCCTCCTCCGGCCGCGTCATGAAGGGCTCCGACGTCATCATCGTC
GACTCCGACAACCGCAAGATCCCGAACAACCACATCGGCCGCATCGCCATCTACTCCTACCAGAACGCCACCGGCTACATCAACCA
GCCGCTGGAGAAGTTCAACTACCGCCAGAAGGAGTACATCCTGACCTCCGACTACGGCTACGTCAACAACGAGGGCTACATCTTCG
TCGTCCAGCGCATCCTGAACCACGAGAACAACAAGATCATCAACGTCTTCCAGATCGAGAACCGCCTGCGCCTGATCAAGGACATC
GACGACGTCGCCATCGTCCAGAAGAACAACCTGCTGCTGGTCAACATCAAGCTGAAGAAGATCTCCGAGATGAAGCGCTCCCTGGT
CAACGACCTGGTCTGCTGGATCTTAGAGAAGACCAAGATCCCGTACGACCTGAAGTACACCGACGAGATCCACTACTCCATGTCCG
GCAAGGTCAAGTACACCGAGGTCATCAACTCCGAGGGCCGCGCGGCCGCCATATGCAC 
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Salmonella enterica 
CACGGATCCAAAGGAGGATGACGAAGCCGGTCGTCCCCTCGGGGGTCTCCCGGCGCGGGTTCCTCGGGGGGTCCCTGGGCGTCGCG
GGCGCGGTCCTGCTCGCCGCCCACCATCACCATCACCACCAATTGATCACCCTGCGCCGCCTGAACGAGATCGCCATCACCCGCGG
CAACGACATCTGCATCATCGACAAGGAGCGCCAGTACACCTGGTACGACATCATCCGCCGCACCGAGTCCCGCATCGTCTTCCTGC
GCCGCGCCTTCAACCCGGAGCAGCTGCGCTCCGTCTGCTACCTGTCCAAGAACTCCGTCGACCTGATCTGCTGGCTGGCCGCCTTC
GCCACCCTGGGCATCCCGGCCAACGGCCTGGACTACTCCCTGCCGATCGAGACCCTGCGCGGCCTGCTGATCAAGATCAACCCGGG
CCTGATGCTGGTCTCCTTCTCCCTGTACTCCCCGGACGAGCTGAACAAGCTGCACGTCCGCACCATCACCATGCTGGCCGTCGACG
CCCCGACCGACCCGGTCATCGGCTCCATCGGCGAGTTCCACCACCCGGAGCTGGAGTCCCTGCTGGCCACCCACATCCCGGCCCCG
TTCCGCTCCGTCTCCCTGACCTCCGGCACCTCCTCCGCCCCGAAGATCGTCCTGCGCTACAACTCCTTCGACGCCCGCCGCTTCGA
CTGGTTCACCCAGCGCTTCAACTTCACCCACCACGACGGCTTCCTGCTGATCCTGCCGCTGTACCACGCCGCCGGCAACGGCTGGG
CCCGCATGTTCATGGGCCTGGGCGCCTCCCTGCACCTGGTCGACCAGGACGACGAGTCCGCCCTGATCCAGGCCCTGTCCCTGAAC
TCCGTCAAGGCCACCGTCATGACCCCGAACCTGGTCTCCCGCCTGACCAAGCTGGCCTCCGAGACCGTCCTGCACCACTACCTGCG
CTGGGTCCTGGTCGGCGGCTCCTACTTCCCGGTCAAGTCCAAGATCGCCGCCTACACCCACCTGGGCCACATCTTCAACGAGTACT
ACGGCTGCACCGAGACCGGCGTCAACGTCCTGTCCGAGTCCTCCGACATGTTCGAGTGCCCGGGCTCCGTCGGCCGCGCCTTCGAC
GGCAACAAGATCCGCATCCTGGACGAGGACAACGTCCCGCTGAAGGCCGGCAACCGCGGCCGTATCGCCGTCGCCTCCTACATGCT
GATGGACGAGTACGGCGACGGCTCCCGCCCGTTCATCGAGATCGACTCCGAGCGCTACTTCCTGATGGCCGACTACGGCTACCTGG
ACGACAACGGCCGCCTGTTCCTGATGAACCGCAACTCCGAGATCAAGTGCGAGCAGGACATCTACCACATCGAGGAGCACCTGCGC
GCCCTGCCGTGCATCACCGACGTCGCCCTGATCCCGATCCGCCAGCAGAACAAGGACCACATCCGCTGCATCTTCTCCGCCAAGTA
CATCAACGAGGACGACGTCTCCTTCATCATGGACGAGATCAAGAACAAGATCAACCACATCGGCGTCACCGACTTCACCGCCCACA
TGGTCGACAAGATCCCGTACTCCCCGTCCGGCAAGGTCCGCTTCTCCGAGATCGTCCAGACCCTGACCGCCGCCGCGGCCGCCATA
TGCAC 
 
Appendix B. Amino Acid Sequences 
> MmfR [Streptomyces coelicolor A3(2)] 
MTSAQQPTPFAVRSNVPRGPHPQQERSIKTRAQILEAASEIFASRGYRGASVKDVAERVGMTKGAVYFHFPSKESLAIAVVEEHYA
RWPAAMEEIRIQGFTPLETVEEMLHRAAQAFRDDPVMQAGARLQSERAFIDAELPLPYVDWTHLLEVPLQDAREAGQLRAGVDPAA
AARSLVAAFFGMQHVSDNLHQRADIMERWQELRELMFFALRA 
>MmyR [Streptomyces coelicolor A3(2)] 
MKQARAMRTRDQVLDAAAEEFALHGYAGTNLATVAVRTGMTKGALYGHFPSKKALADELVSQSTETWNTIGRSIAETACAPETALR
ALVLAVSRQMKHDIRFRAALRLAADCTMPAGGAPDLLDRIRREMAAAARDTQQQQAPYSPLATQPPDVVVHLLLTVAYGLSFAAER
GAPGRSPATTDKVWELLLTALQLEDISTCHN 
> GbnB analogue [Streptococcus mutans synthetic sequence] 
MTKPVVPSGVSRRGFLGGSLGVAGAVLLAAHHHHHHQLLALENLIQIRNRNPDKLILISDEKSFSWKEYTNLVINNLRNTTLQSVL
NKTDRAIIISENTWKVFTIYSCLSTQKIPYSGIDYSMEDDKKVAAINKSGANTVFYSKDQKPSQNLRNSLKGVSFISLDILHDDIE
GSDLSDFNIKKHSDSIVSFGFTSGTTGLPKCIYRDYSFATERMKELTKLYNFNATDVFLVTMPFYHVSVNGWVKLTLNNGGSVVLG
DFNNPIDLSSKIKQYDITTMLITPPVLKSLNFVLNQQGFINSTVRFIMVGGKNFPPKLKEETQNLFGSVLHEYYGSSETGINVLAN
SSDMMLYPSSSGRVMKGSDVIIVDSDNRKIPNNHIGRIAIYSYQNATGNQPLEKFNYRQKEYILTSDYGYVNNEGYIFVVQRILNH
ENNKIINVFQIENRLRLIKDIDDVAIVQKNNLLLVNIKLKKISEMKRSLVNDLVCWILEKTKIPYDLKYTDEIHYSMSGKVKYTEV
INSEGR 
> GbnB analogue [Salmonella enterica GbnB synthetic sequence] 
MTKPVVPSGVSRRGFLGGSLGVAGAVLLAAHHHHHHQLITLRRLNEIAITRGNDICIIDKERQYTWYDIIRRTESRIVFLRRAFNP
EQLRSVCYLSKNSVDLICWLAAFATLGIPANGLDYSLPIETLRGLLIKINPGLMLVSFSLYSPDELNKLHVRTITMLAVDAPTDPV
IGSIGEFHHPELESLLATHIPAPFRSVSLTSGTSSAPKIVLRYNSFDARRFDWFTQRFNFTHHDGFLLILPLYHAAGNGWARMFMG
LGASLHLVDQDDESALIQALSLNSVKATVMTPNLVSRLTKLASETVLHHYLRWVLVGGSYFPVKSKIAAYTHLGHIFNEYYGCTET
GVNVLSESSDMFECPGSVGRAFDGNKIRILDEDNVPLKAGNRGRIAVASYMLMDEYGDGSRPFIEIDSERYFLMADYGYLDDNGRL
FLMNRNSEIKCEQDIYHIEEHLRALPCITDVALIPIRQQNKDHIRCIFSAKYINEDDVSFIMDEIKNKINHIGVTDFTAHMVDKIP
YSPSGKVRFSEIVQTLTAA 
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Appendix C. Sequence Analysis of MmfR and Homologues 
 
Table C.i Percentage similarity between MmfR and MmyR and their homologues from 
S. venezuelae, S. avermitilis and S. albus 
Details on percentage query coverage shown in following table 
Amino acid sequences used: same as Table 7.3 
 
MmfR MmyR SgnR GbnR 
SAV_ 
2270 
SAV_ 
2268 
SSHG_ 
01258 
MmfR 100 56 71 48 64 54 56 
MmyR 56 100 47 54 67 54 53 
SgnR 71 47 100 49 65 49 60 
GbnR 48 54 49 100 50 47 75 
SAV_2270 64 67 65 50 100 49 48 
SAV_2268 54 54 49 47 49 100 44 
SSHG_01258 56 53 60 75 48 44 100 
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